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ABSTRACT 
Thesis Title: Antiplasmodial neolignans from Trema orientalis – Identification, synthesis and      
analogue generation 
Author: Pamisha Pillay 
Date of submission: 30 November 2011  
 
In the continued search for new classes of antimalarial agents that are safe, affordable and 
effective against multi-drug resistant parasites, medicinal plants still provide a useful starting 
point. Trema orientalis, a widely distributed evergreen tree with various medicinal properties 
including the treatment of malaria, was investigated as a potential source of new antimalarial 
lead compounds. Organic extracts of the young growing twigs of T. orientalis were 
reproducibly shown to be active against the chloroquine-sensitive (D10) and chloroquine-
resistant (K1) strains of Plasmodium falciparum. The 8-O-4' oxyneolignans, dadahols A and 
B, were identified as the major active compounds using two bioassay-guided fractionation 
approaches. The new accelerated “HPLC biogram” methodology allowed for early recognition 
of the active compounds in the complex plant extract, requiring considerably less time and 
material compared to the classical reiterative approach.  
 
Although the natural products were shown to have promising antiplasmodial activity (IC50 < 1 
µg/ml) and selectivity (SI > 100) in vitro, they lacked antimalarial activity in vivo. This could be 
attributed to the poor pharmacokinetic (pK) properties of the compounds, which was 
confirmed by an in vivo pK study.  
 
Biomimetic oxidative coupling, ion exchange chromatography and carbonyldiimidazole (CDI) 
coupling were shown to be useful techniques in completing the diastereo-selective synthesis 
of dadahol B. The 8-O-4´ neolignan core of dadahol B, i.e. guaiacyglycerol β-O-4-coniferyl 
alcohol ether (GGCE), lacked antiplasmodial activity identifying the p-coumaroyl moieties as 
key pharmacophores of the natural product. A by-product of the oxidative coupling step, 
dehydrodiconiferyl alcohol (DHCA), showed better initial activity than GGCE and was 
subsequently also used as a scaffold for analogue generation. Using a selection of synthetic 
techniques and approaches, a range of GGCE and DHCA analogues were prepared, 
focusing on optimization of the ester and aromatic ring substituents. None of the precursors, 
by-products or analogues showed improved antiplasmodial activity relative to the natural 
products or chloroquine, and were therefore not considered as potential antimalarial lead 
compounds.   
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CHAPTER 1 
Malaria and antimalarials from plants 
1.1 History of Malaria 
Malaria, a life-threatening disease that is transmitted by Anopheles mosquitoes, is 
probably one of the oldest diseases known to mankind. Mention of this disease can 
be found in ancient Chinese, Indian and Egyptian manuscripts. In the 5th century BCE 
Hippocrates, the Greek physician, was the first to describe the manifestations of the 
disease. In the 7th century CE, the Italians named the disease mal’aria meaning bad 
air, due to its association with ill-smelling vapors from the Roman swamps. 
 
The first recorded treatment of malaria dates back to 1600 when the bark of the 
Cinchona tree was first used by the native Peruvian Indians to treat the intermittent 
fevers associated with this illness (Lee, 2002). It was not until 1889 that Alphonse 
Laveran discovered the protozoal (single celled parasite) cause of malaria and not 
until 1897 that Ronald Ross demonstrated that the Anopheles mosquito was the 
vector for the disease (Robert et al., 2001). His pioneering work on establishing the 
main features of the parasitic life cycle earned Ross the Nobel Prize in Medicine in 
1902. 
 
Over the next century significant advances were made towards attempts to eradicate 
malaria particularly with respect to controlling mosquitoes, understanding the parasite 
and developing drugs to treat the disease (Targett, 1991). But despite this, malaria 
has proven to be one of the biggest killers in the world. Between 300 and 500 million 
people have been infected annually and nine out of ten of these cases have occurred 
in sub-Saharan Africa (World Health Organisation, 2010).  This is due to the majority 
of infections in Africa being caused by Plasmodium falciparum, the most dangerous of 
the human malaria parasites. It is also because the most effective and most difficult to 
control malaria vector - the mosquito Anopheles gambiae - is the most widespread in 
Africa. Climatic conditions over a large part of Africa favor malaria transmission and 
global warming together with changes in land use have extended the areas of 
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transmission. Moreover, many countries in Africa lacked the infrastructures and 
resources necessary to mount sustainable campaigns against malaria and, as a 
result few benefited from historical efforts to eradicate the disease. Also, methods 
aimed at eradicating the disease have been hindered by lack of governmental 
commitment, failure to use existing resources and poor health care facilities. 
 
1.2 Malaria Today 
Today approximately forty percent of the world‟s population, in more than 100 
countries, is at risk to malaria. Malaria is endemic in Africa, much of South and 
Southeast Asia, Central America, and northern South America (Figure1.1). In 2008, 
there were an estimated 243 million cases that led to nearly 863 000 deaths (World 
Health Organisation, 2009). The introduction of long-lasting mosquito nets and 
artemisinin-combination therapy, a revival of support for indoor residual insecticide 
spraying, and increased funding for implementation of control strategies in endemic 
countries have provided evidence that treatment and prevention can alleviate the 
burden of disease. However, the ability of the parasite to quickly adapt and overcome 
eradication efforts remains a constant threat in global malaria control.  
 
  
Figure 1.1 Malaria-endemic regions (Roll Back America, 2010) 
 
 
In South Africa the malaria burden is relatively low. Malaria is mainly transmitted in 
the low altitude areas of the northeastern parts of southern Africa; this includes the 
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lowveld region of Mpumalanga, Limpopo Province and the northeastern parts of 
KwaZulu-Natal. Malaria transmission is seasonal with the greatest number of cases 
occurring between October and May with a significant inter-annual variation in the 
number of malaria cases (Department of Health, South Africa, 2003). In 2006 there 
were 12295 cases while in 2007 there were 3597 recorded cases (Department of 
Health, South Africa, 2008). This variation is mainly attributed to favorable climatic 
conditions, population migration and the emergence of drug resistant parasites.  
 
An increased number of malaria cases were reported in Limpopo Province in 
December 2009 (International Society for Infectious Diseases, 2010). The South 
African government has increased efforts to control the spread of malaria, particularly 
due to its threat to the economy. 
 
Annual economic growth in countries with high malaria transmission has historically 
been lower than in countries without malaria. The direct costs of malaria include a 
combination of personal and public expenditures on both prevention and treatment of 
the disease. The indirect costs of malaria include lost productivity or income 
associated with illness or death. Also, the prevalence of malaria in a country can lead 
to a decline in international trade and tourism and foreign investment, which are vital 
for economic growth. 
 
1.3 The Malaria Parasite 
The malaria parasite, Plasmodium falciparum, is a very small, single-cell blood 
organism, or 'protozoan'. There are three other parasite species (P. malariae, P. vivax 
and P. ovale) that also cause malaria but they are rare in sub-Saharan Africa. The 
parasite is transmitted to humans by a vector, namely the female Anopheles 
mosquito.  
 
Knowledge of the life cycle of the malaria parasite is fundamental to understanding 
the methods of prevention and treatment. Interrupting the life cycle will prevent 
malaria, but this has proven more difficult than anticipated. The Plasmodium parasite 
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spends part of its life cycle in humans and partly in mosquitoes (Caniato and Puricelli, 
2003; Taubes, 2000) (Figure 1.2).  
 
 
 
Figure 1.2 Life cycle of Plasmodium spp. (Jones and Good, 2006) 
 
While ingesting a blood meal, sporozoites are injected into a human host through the 
bite of an infected Anopheles mosquito. After innoculation, sporozoites migrate to the 
liver and infect liver cells to establish the first intracellular replicative stage. 
Sporozoites reproduce by mitosis and develop into schizonts, which rupture and 
release merozoites into the bloodstream. Following the exoerythrocytic phase, the 
merozoites invade erythrocytes (RBCs), where they undergo asexual multiplication 
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(erythrocytic schizogony). The ring stage trophozoites mature into schizonts, which 
rupture releasing merozoites. Two out of every three red blood cells soon become 
infected. The periodic fever and chills associated with malaria occur when the red 
blood cells rupture and release the merozoites. This is the blood stage of the disease. 
A fraction of the merozoites differentiate into gamete producing cells, gametocytes.  
 
The gametocytes, male (microgametocytes) and female (macrogametocytes), are 
ingested by an Anopheles mosquito during a blood meal. The parasites‟ multiplication 
in the mosquito is known as the sporogenic cycle. While in the mosquito‟s stomach, 
the male gametes fertilize the female gametes ultimately generating sporozoites, 
which make their way to the mosquito‟s salivary glands. Inoculation of the sporozoites 
into a new human host occurs and the cycle begins again.  
 
Malaria symptoms appear about 9 to 14 days after the infectious mosquito bite, 
although this varies with different plasmodium species. Typically, malaria produces 
fever, headache, vomiting and other flu-like symptoms. If drugs are not available for 
treatment or the parasites are resistant to them, the infection can progress rapidly to 
become life threatening. Malaria can kill by infecting and destroying red blood cells 
(anemia) and by clogging the capillaries that carry blood to the brain (cerebral 
malaria) or other vital organs. 
 
1.4 Malaria Prevention and Control 
There are a number of approaches towards the prevention and control of malaria and 
the choice of intervention in a country or region is usually most dependant on cost-
effectiveness.  
 
The early diagnosis of malaria and prompt treatment with antimalarial drugs is 
essential in controlling the spread of the disease. By reducing the number of infected 
humans, the number of infected mosquitoes is effectively reduced. This type of 
control is especially important when outbreaks of malaria occur. When humans are 
treated the life cycle of the parasite is essentially interrupted. The malaria parasite 
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invades erythrocytes and feeds off the hemoglobin (oxygen transport protein) during 
growth and development in the red blood cell. Hemoglobin is digested in an acidic 
digestive vacuole of the parasite. Many of the current antimalarial agents, such as 
chloroquine, are thought to disrupt this digestive process one way or another. 
 
Another approach is the use of personal protection. The first objective of this is to 
protect people from being bitten by an infected mosquito. Insecticide-treated mosquito 
nets, door and window screens, wearing protective clothing, using insect repellants, 
coils and vapourizers are all ways of doing this. The other objective of personal 
control is the use of preventative or prophylactic drug treatment. For instance, 
travelers to regions where malaria is present often take prophylactics which help 
prevent the development of the disease but not the initial infection. Cost and 
availability of drugs can be dictating factors in many countries.  
 
A third approach is vector or mosquito control. Spraying of insecticides to kill the adult 
or larval mosquitoes can be quite effective. DDT (dichlorodiphenyltrichloroethane) 
was used successfully for years before environmental campaigns restricting its use 
resulted in a resurgence of malaria related deaths. More recently the WHO has made 
the move to bring back DDT declaring it relatively safe for use in indoor spraying and 
mosquito nets. Managing the environment by reducing mosquito breeding sites has 
also helped to eliminate malaria in some areas. Using natural biological controls such 
as mosquito predators are also promising. In the last few years there has been 
growing interest in bioengineering insects that are unable to transmit the malaria 
parasite (Kotler, 2003). This is referred to as vector manipulation.  
 
The greatest challenge lies in the parasites ability to quickly adapt and overcome 
eradication efforts when these are fragmented and uncoordinated. Malaria quickly 
rebounded from the mass DDT spraying campaigns in the 1950s and 1960s. Since 
the 1980s parasite resistance to chloroquine, then the most commonly available 
antimalarial drug, has emerged as a major challenge. 
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Ideally, a protective vaccine would be the most effective approach to controlling 
malaria. Attempts to develop a vaccine, however, have been hindered by the great 
genetic diversity of the parasite, its multistage life cycle, as well as the complex and 
inefficient human immune response (Newton and White, 1999). Years of vaccine 
research have produced few hopeful candidates and although scientists are 
redoubling the search, an effective vaccine is at best years away.  
 
In addition to destroying the parasite, health care providers are attentive to treating 
the multiple symptoms of malaria. These symptoms include fever, chills, headaches, 
malaise, weakness, hepatomegaly (enlarged liver), splenomegaly (enlarged spleen) 
and dehydration. Malaria can also cause anemia, anorexia, nausea, vomiting, 
abdominal pain and diarrhea. Deaths from malaria are normally caused by cerebral, 
renal or pulmonary fever, or a combination of the three (Strickland and Hunter, 1982). 
 
1.5 Malaria Treatment 
Drugs used for the treatment of malaria do not assist the natural healing processes of 
the body; instead they act chemically on the parasite as a controlled poison. In most 
cases antimalarial drugs target the asexual erythrocytic stage of the parasite. The 
parasite degrades hemoglobin in its acidic food vacuole, producing free heme able to 
react with molecular oxygen and thus generating reactive oxygen species as toxic by-
products. A major pathway of detoxification of heme moieties is polymerization as 
malaria pigment. Most antimalarial drugs act by disturbing the polymerization of 
heme, thus killing the parasite with its own metabolic waste. Antimalarial drugs fall 
into several chemical groups. The first and most commonly used are the quinoline 
based antimalarials, which include quinine (1) and its derivatives chloroquine (2), 
amodiaquine (3) and mefloquine (4) (Figure 1.3).  
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Figure 1.3 Quinoline based antimalarials 
 
Quinine (1) has been used for more than three centuries and until the 1930s was the 
only effective agent for the treatment of malaria. Of the 36 alkaloids found in the bark 
of the Cinchona tree, only four possess antimalarial properties, with quinine being the 
most effective (Lee, 2002). It is able to bind strongly to blood proteins and forms 
complexes that are toxic to the malarial parasite. Due to its undesirable side effects it 
is now only used as an intravenous injection to treat severe malaria.  
 
Chloroquine (2) was introduced in 1944 and soon became the mainstay of therapy 
and prevention, since this drug was cheap, non-toxic and effective against all strains 
of the parasite (Robert et al., 2001). It is capable of blocking the polymerisation of 
heme to hemozoin (malaria pigment) (Zhang et al., 1999). It is a chemically 
synthesized drug. Increased parasite resistance has virtually rendered chloroquine 
useless. Chloroquine‟s reduced efficacy led to the development of the synthetic 
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analogues amodiaquine (3) and mefloquine (4) that are used to treat cases of 
uncomplicated malaria in areas where chloroquine resistance is prevalent.  
 
The second class of common antimalarials is the folate antagonists (Figure 1.4). 
These compounds inhibit the synthesis of parasitic pyrimidines and thus of parasitic 
DNA (Robert et al., 2001). There are two types of antifolates, the dihydrofolate 
reductase (DHFR) inhibitors pyrimethamine (5) and proguanil (6), and the 
dihydropteroate synthetase (DHPS) inhibitors, which include the sulphonamide drugs, 
sulpha-doxine (7) and dapsone (8). Due to a marked synergistic effect, a drug of the 
first group is usually used in combination with a drug of the second one. 
Pyrimethamine-sulfadoxine (SP), or Fansidar®, is the most widely used combination 
and has been used to replace chloroquine as a first line treatment of P. falciparum in 
many parts of Africa (Na-Bangchang and Karbwang, 2009).     
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Figure 1.4 DHPS and DHFR inhibitors 
 
The third class of antimalarials is based on the natural endoperoxide artemisinin (9) 
which was first extracted from the Chinese traditional medicine, Artemisia annua, in 
1972 (Vroman et al., 1999). Artemisinin is not soluble in water or oil and because of 
this poor solubility; the drug absorption and its bioavailability are also poor. However, 
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since the peroxide bridge of the compound is stable under various chemical reaction 
conditions, several oil and water-soluble derivatives of artemisinin have since been 
synthesized (Lee, 2002). These include dihydroartemisinin (DHA) (10), artemether 
(11), arteether (12), artesunate (13) and artelinic acid (14) (Figure 1.5) (Robert et al., 
2001). The semi-synthetic derivatives of artemisinin have improved pharmacokinetic 
properties and are also of current clinical use, artesunate being the most frequently 
used in combination therapy and in cases of resistant and uncomplicated P. 
falciparum.  
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(12) R = Et
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(14) R = CH2(p-C6H4)CO2H
 
 
Figure 1.5 Artemisinin and its semisynthetic derivatives 
 
Artemisinins act against the asexual blood stage of the parasites life cycle. Since an 
artemisinin derivative lacking the endoperoxide bridge (deoxyartemisinin) is devoid of 
antimalarial activity, the possible reactivity of this peroxide function within the parasite 
is the key factor of the pharmacological activity of these molecules (Klayman, 1985). 
This group of antimalarials is the most rapidly acting and is effective against multi-
drug resistant strains of the parasite. Although the precise mode of action of 
artemisinin and its derivatives is not completely understood, it is proposed that the 
endoperoxide bridge is cleaved to generate free radicals. The free radicals are strong 
alkylating agents and form covalent bonds with various parasite proteins.    
 
Artemisinin based combination therapies (ACT‟s) combine one of the derivatives of 
artemisinin with partner drugs (viz. mefloquine, lumefantrine, amodiaquine).  ACT‟s 
have now been adopted as the first line of treatment. The combination of drugs with 
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different modes of action considerably reduces the risk of selecting resistant mutants 
in the parasite population. ACT‟s produce faster clinical recovery, prevent 
deterioration from uncomplicated to severe malaria and reduce the risk of 
transmission.    
 
1.6 Antimalarial Drug Resistance and the Need for New Antimalarials 
For most of the twentieth century, malaria was treated with the readily available, 
inexpensive and effective drugs chloroquine and pyrimethamine-sulphadoxine. But 
from the 1960‟s onwards these drugs succumbed to the rapid emergence and spread 
of drug resistant strains of the parasite (Fidock, 2010).  The reasons for the 
development and spread of drug resistance involve the interaction of drug-use 
patterns, characteristics of the drug itself, human host factors, parasite 
characteristics, and vector and environmental factors (Ridley, 2002). However, only 
gene mutations confer resistance to the parasites in nature.  
 
Early theories on chloroquine resistance were that resistant parasites accumulated 
less chloroquine than sensitive parasites. Thus lethal concentrations of the drug are 
prevented from reaching the parasitic food vacuole. The decrease in chloroquine 
accumulation can be attributed to a higher rate of chloroquine efflux, a lower rate of 
chloroquine uptake, or varying combinations of both these processes (Saliba et al., 
1998). More recent studies have highlighted the role of mutations in the P. falciparum 
chloroquine-resistance transporter (PfCRT) protein in the molecular basis of parasite 
resistance to the quinoline antimalarials (Bray et al., 2005; Sidhu et al., 2002; Zishiri 
et al., 2011). PfCRT is an integral membrane protein of the intra-erythrocytic 
parasite‟s digestive vacuole, the organelle in which chlorquine exerts its antimalarial 
effect by interfering with the formation of hemozoin. It evidently functions as a 
transporter directly mediating the efflux of chloroquine from the digestive vacuole.  
Antifolate resistance is generally due to a combination of mutations in the target 
enzymes and the use of an alternative pathway to recover folate.  
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The artemisinins are currently amongst the most effective and widely used 
antimalarial drugs although recurrence is associated with the monotherapy of 
artemisinin and its derivatives at a high rate. This is not because of resistance in the 
parasite, but because of the drug‟s phamacokinetic properties. ACT‟s are used to 
prevent recrudescence (Bloland, 2001). There is much evidence to support the use of 
combination ACT‟s, however several problems prevent its wide use in the areas 
where its use is most advisable; which include problems identifying the most suitable 
drug for different epidemiological situations, the expense of combined therapy (it is 
over 10 times more expensive than traditional mono-therapy), how soon the 
programmes should be introduced and problems linked with policy implementation 
and issues of compliance. 
Despite the marked success of intense elimination campaigns based on ACT‟s and 
insecticide-treated bednets, the prospect of resistance remains. There is reported 
evidence of reduced clinical response to ACT‟s (Dondorp et al., 2009; Gamo et al., 
2010). P. falciparum from patients in Pailin, western Cambodia, had significantly 
reduced in vivo susceptibility to artesunate compared to parasites from patients in 
Wang Pha, northwestern Thailand. The artesunate resistance was characterized by 
relatively slow parasite clearance, with minimal heterogeneity among patients. The 
reduced parasitological responses could not be explained by pharmacokinetic or 
other host factors.   
No new class of antimalarials has been introduced clinically since 1996, owing to the 
inherent difficulties of antimalarial drug discovery, as well as relative lack of public 
and commercial resource commitment towards antimalarial research (Gamo et al., 
2010). Due to the increased costs of developing and registering new products and the 
prospect of low commercial returns, pharmaceutical companies, particularly the 
multinationals, have little interest in developing a new cure despite the need 
(Ramachandran, 2002).  
 
The sequencing of the Plasmodium genome and increased understanding of the 
parasite‟s biology (Guiguemde et al., 2010) has not yet led to new antimalarials and 
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target-based lead discovery has proved costly and inefficient, generally due to lack of 
whole-cell activity. With no vaccine on the immediate horizon, mosquito control, 
chemotherapy and chemoprophylaxis remain the major methods of keeping malaria 
in check. Malaria control is at a pivotal point.  Continued effectiveness and use of 
ACT‟s and vector control efforts, could lead to a complete eradication of the disease. 
Alternatively, resistance could sabotage the usefulness of artemisinins, and cause 
resurgence in malaria.  
 
Thus there is a real need to continue the search for new classes of antimalarial 
agents that are effective against multi-drug resistant P. falciparum, safe, affordable 
and simple to use. One approach to this is the investigation of medicinal plants, which 
have historically provided useful antimalarials.  
 
1.7 Medicinal Plants 
Although modern medicine is well established in most parts of the world, the World 
Health Organisation (WHO) estimates that 80% of the world‟s population relies solely 
on traditional medicine for their primary health care needs (World Health 
Organisation, 1995). Plants of medicinal value have been used effectively for 
centuries in traditional medicine. Medicinal plants are considered a major source of 
biologically active natural products that may serve as commercially significant entities 
themselves or provide lead structures for the development of modified derivatives 
possessing enhanced activity and/or reduced toxicity. 
 
Traditional medicines include crude plant extracts, or combinations of several 
medicinal plants, which contain numerous components that are thought to contribute 
to the overall therapeutic effect. Because the chemical compounds in the different 
plant components are often quite different, usually only a specified plant part is used 
medicinally (viz. leaves, roots, bark or fruit). The method of preparation is crucial. 
Activities including the addition of appropriate volumes of solvents such as water or 
alcohol to a specified amount of fresh or dry plant material, boiling for a specified 
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length of time or partial burning to achieve a desired colour are important and can 
serve to neutralize certain toxins. Dosage forms (viz. tinctures, extracts, ointments or 
enemas) as well as the method of administration (viz. orally, topically or nasally) are 
also critical and are conveyed by the healer (Van Wyk et al., 2000). 
 
Plant-based traditional medicine systems continue to play an essential role in 
healthcare. Because of the importance of medicinal plants the WHO encourages their 
use not only under an empirical basis, but also under a scientific approach. The 
advantages gained from a scientific approach to traditional plant remedies in 
developing countries, where they have fundamental importance, are numerous.  
 
Firstly it would allow natives to gain some independence from developed countries in 
the preparation of plant-derived medications, and it would promote the establishment 
of sustainable supply and extraction industries, which could prove to be a vital aspect 
for economic development. Proving the efficacy of traditional medicines, would also 
allow the local medium-large scale cultivation of medicinal plants with an obvious 
benefit for the national economy. Finally, from an environmental point of view, the 
proof of therapeutic value of selected medicinal plants would help to conserve 
species that would otherwise be depleted by unsustainable harvesting activities 
(Caniato and Puricelli, 2003).  
 
An estimated 70% of South Africans regularly use traditional medicines, most of 
which are derived from plant species indigenous to the region. South Africa 
represents only 0.04% of the land surface area of the world, yet nearly 10% of all 
known plant species occur here.  There are over 24 000 plants indigenous to South 
Africa. Approximately 3000 species of plants are used as medicines, and some 350 of 
these are the most commonly used and traded medicinal plants. Some South African 
medicinal plant extracts are used worldwide. An extract of Pelargonium sidoides is 
commercially traded as a remedy for bronchitis (“Umckaloabo”) by the Germans.  
Devil‟s claw (Harpagophytum procumbens) products are used to treat rheumatism 
and arthritis, and as a general heath tonic. The bitter yellow juice exuded from just 
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below the surface of the leaves of Cape aloes (Aloe ferox) is dried by an age old 
method to form a dark brown resinous solid which is traded internationally as a 
laxative. (Van Wyk et al., 2000).  
 
1.8 Drugs from Plants 
There are two basic approaches to drug discovery: rational drug design and the 
traditional method of random screening. Rational design-engineering of new drug 
molecules from scratch with the aid of computers and molecular biology requires 
knowledge of the drug target such as a receptor or an enzyme. So far, it has had only 
limited payoffs, although it has promising potential. In random screening many 
synthetic chemicals or natural products are indiscriminately tested for biological 
activity. Because this method is both costly and time-consuming, there has been a 
great need for better efficacy in strategic research and development planning for 
pharmaceutical companies. The strategy of developing new drugs based on 
medicinal plants has an advantage over random screening, since it is guided by 
experience from a long history of clinical practice.  
 
For many centuries plants have been the primary source of crude drugs used to 
alleviate human sickness. The isolation of the analgesic morphine (15) from the 
opium poppy (Papaver somniferum) in 1819 and quinine (1) from Cinchona bark in 
1820, laid the foundation for the purification of pharmacologically active compounds 
from medicinal plants (Butler, 2004). More than 25% of all drugs in clinical use today 
originated from plants or are derivatives of natural products. Well known examples 
include artemesinin (9), extracted from the bark of the Artemisia annua; the 
anticancer drug, taxol (16), from the bark of Taxus brevifolia; and salicylic acid (17) 
which served as a template for aspirin (18), originally isolated from the bark of the 
Salix species. In addition, crude herbal preparations are also popular and some 
examples include  Oenothera biennis (Evening primrose) used in cosmetics, 
Hypericum perforatum (St John‟s Wort) used as an antidepressant, and Panax 
ginseng (Ginseng) taken as a treatment for diabetes and sexual dysfunction. 
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Figure 1.6 Examples of plant-derived drugs 
 
The active ingredients in medicinal plants are chemical compounds that act directly or 
indirectly to prevent or treat a disease or ailment and maintain health. Plants 
investigated for pharmacologically active compounds are usually selected on the 
basis of ethnomedicinal information as there is a correlation between biological 
activity and the traditional use of the plant. In selecting plants that may contain 
biological agents, generally a targeted approach to plant collection is adopted based 
on the belief that plants that have acquired the status of a traditional herbal remedy 
have reasonable proof of safety and efficacy from their history of use and have a 
higher probability of yielding an active substance. 
 
The chemical diversity and stereospecificity of complex natural products are the main 
attractions of working with plants as opposed to synthetic chemistry approaches. In 
developing a drug from a plant-derived lead compound, attempts may be made to 
produce chemical analogues of the active principle with enhanced antiplasmodial 
activity and reduced host toxicity. Guides for conducting this work are often obtained 
from the original plant source since plant constituents often occur as a group of 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
17 
 
structurally related metabolites, making it possible to isolate analogues of the active 
compound and obtain information on structure-activity relations.  
 
There has been a resurgence in natural product drug discovery, as is evident in the 
number of plant-based drugs in clinical trials, mainly for the treatment of cancer, 
immunological and CNS (central nervous system) related diseases (Saklani and 
Kutty, 2008; Newman and Cragg, 2007). Considering that only a small percentage 
(10 – 15%) of higher plant species have been investigated for pharmacological 
activity, it is most likely that plants will continue to offer novel leads for drug 
development.   
 
1.9 Antimalarials from Plants 
Historically the majority of the antimalarial drugs have been derived from medicinal 
plants or from structures modeled on plant lead compounds. Quinine (1), the first 
effective antimalarial drug is still in clinical use today and the more recently 
discovered artemisinin (9) is the template for several semi-synthetic derivatives with 
enhanced animalarial activity. In light of this historic success and the fact that most 
indigenous people living in malaria endemic areas use traditional medicines to fight 
this disease, there is every possibility that ethnopharmacological approaches could 
lead to new antimalarial agents. 
 
The development of continuous culturing of P. falciparum (Trager and Jensen, 1976) 
and subsequent in vitro assays (Desjardins et al., 1979; Makler et al., 1993; Schulze 
et al., 1997) made it possible to screen plant extracts for antiplasmodial activity and 
use bioassay-guided fractionation to isolate active principles. The investigation of a 
range of plants used in traditional medicine for the treatment of malaria in various 
countries has led to the discovery of a large number of antimalarial compounds with 
significant structural variety (Schwikkard and Heerden, 2002). Table 1.1 lists some of 
these compounds, which belong to different secondary metabolite classes, and the 
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traditional medicines from which they were isolated (Caniato and Puricelli, 2003; Kaur 
et al., 2009).  
 
South Africa‟s rich biodiversity and long history of traditional medicinal plant use has 
also prompted several studies to evaluate local indigenous plants for antimalarial 
properties (Clarkson et al., 2004; Nundkumar and Ojewale, 2002; Prozesky et al., 
2001). A recent review (Pillay et al., 2008) concluded that the identification of 
compounds from South African plants implicated in the treatment of malaria suggests 
that these compounds may play a role in the medicinal properties of the plant, but 
their potential for the development of antimalarial drugs was limited by inherent 
toxicity and lack of selectivity.  This is often the case with antimalarial compounds 
identified from plants, and together with low bioavailability and/or poor solubility, 
accounts for the limited number that reach drug candidate status.   
 
Table 1.1 Examples of classes of compounds with antimalarial activity isolated from 
medicinal plants 
Class of compound Compound  Plant Plant  
part 
Country of 
plant origin 
Quinones  
 
1-hydroxybenzoiso-
chromanquinone 
 
Psychotria 
camponutans 
 
Stem & 
roots 
 
Panama 
 
Triterpenes Lupeol 
 
Vernonia 
brasiliana 
 
Leaves 
 
Brazil 
 
Diterpenes Ferruginol Harpagophytum 
procumbens 
Roots South Africa 
Sesquiterpenoids 16,17-Dihydrobrachy-
calyxolide 
 
Vernonia 
brachycalyx 
 
Leaves 
 
Kenya 
 
Quassinoides Bruceolide 
 
Brucea javanica 
 
Fruits 
 
China 
 
Limonoids Fissinolide 
 
Khaya 
senegalensis 
 
Bark 
 
Sudan 
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Class of compound Compound  Plant Plant  
part 
Country of 
plant origin 
Alkaloids Ancistroheynine A 
 
Ancistrocladus 
heyneanus 
Roots 
 
India 
Lignans Justicidin B Phyllanthus 
piscatorum 
Aerial 
parts 
Venezuela 
Flavanoids Exiguaflavanone A Artemesia indica Stems Thailand 
Chalcones (+)-Nyasol 
 
Asparagus 
africanus 
 
Roots Kenya 
Xanthones Cowaxanthone Garcinia cowa Bark Thailand 
Coumarins O-Methylexostemin Exostema 
mexicanum 
Stem bark Latin 
America 
 
1.10 Antimalarial Drug Discovery 
Biological testing for antimalarial activity in plants has progressed over the years. In 
the 1950s, the screening of crude plant extracts was based on avian malarias using in 
vivo tests against P. gallinaceum in chicks and against P. cathemerium and P. 
lophurae in ducklings. In the 1970s, in vitro procedures were developed utilizing P. 
falciparum cultures in human red blood cells, a technique that enabled the 
development of a microdilution assay. This technique, compared to previous ones 
active on human malarias, is useful to assess in vitro antimalarial activity of crude 
extracts prior to the isolation of active principles (Caniato and Puricelli, 2003).  
 
One such in vitro assay is the parasite lactate dehydrogenase (pLDH) assay. pLDH is 
a terminal enzyme in the glycolytic pathway of Plasmodium spp. and plays an 
important role in the parasites anaerobic carbohydrate metabolism. As malaria 
parasites principally rely on anaerobic glycolysis, they require the regeneration of 
nicotinamide adenine dinucleotide (NAD) for the continuous flux of glucose through 
this pathway (Noedl et al., 2003). On the basis of the discovery that pLDH is 
distinguishable from host LDH using the 3-acetylpyridine dinucleotide analogue of 
NAD (ADAP), Makler et al.(1993) developed a drug-sensitivity assay that determines 
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inhibition profiles by measuring the enzymatic activity of pLDH. Other in vitro 
antiplasmodial assays include those based on flow cytometric activity (Prozesky et 
al., 2001) and the titrated hypoxanthine incorporation method (Kaur et al., 2009).    
 
An in vivo screening assay is possible in mice using a natural infection with P. 
berghei. These methods allow the development of strains resistant to chloroquine or 
to other antimalarials by a passage in the presence of increasing concentrations of 
the drug. In vitro tests are considered more practical, quicker and less expensive than 
in vivo cultures and not all antimalarial drugs are active in the P. berghei mouse 
model. In addition, the in vivo model requires significantly higher amounts of drugs (at 
least 1 g of extract) when compared to the in vitro assays which require a few mg of 
extract. The advantage of the in vivo model is that at the same time it gives a 
measure of toxicity.  
 
Detailed evaluation of antimalarial drugs is done in the Aotus monkey (Aotus 
trivirgatus) using P. falciparum infection or in the Rhesus monkey (Macaca mulata) 
with P. cynomolgi B infection (Caniato and Puricelli, 2003). Of the numerous extracts 
and compounds studied in primary screens in vitro, very few reach this stage of 
investigation.  
 
In researching plants which are frequently mentioned as antimalarials in literature it is 
often found that these do not necessarily show high activity in in vitro tests. This can 
partly be explained by the fact that many plants are used in the treatment of malaria, 
not for their antiparasitic effects but because of other therapeutic activities. These 
include reducing fever, calming convulsions and headache, and possibly even 
immuno-stimulatory effects. Another problem is that some plants are given in a 
mixture and are possibly only active in this combination due to synergistic effects. 
Also, an in vitro assay cannot precisely reproduce the in vivo situation. Certain plant 
extract components might only become active after specific metabolic processes in 
vivo (Gessler et al., 1994).     
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Other problems commonly encountered when investigating medicinal plants as a 
source of antimalarial drugs is that crude extracts or compounds show in vitro activity 
but are extremely toxic or those which are active in vitro fail to display in vivo activity. 
If a compound destroys parasites, it is logical to screen for toxicity in vitro using 
human cells in culture. When a compound is found to destroy human cells at similar 
concentrations, its potential as a useful drug is limited as the safety margins will be 
too slender. The difficulty arises from the fact that protozoa share many biochemical 
pathways with the human host thereby limiting the antimalarial drug‟s selectivity to kill 
the parasite without harming mammalian cells. The pharmacokinetic and 
pharmacodynamic properties of the extract or compound determine whether it will 
display in vivo activity.  This includes absorption, distribution to the action site and 
whether the compound is metabolized too rapidly or to a less active form (Kirby, 
1996).  
 
The current productivity crisis in drug discovery and development may be overcome 
by adopting a multidisciplinary approach and combining the novel molecular diversity 
of natural products with total and combinatorial synthetic methodologies, and 
including the manipulation of biosynthetic pathways (combinatorial biosynthesis). 
Despite their inherent limitations (viz. toxicity, bioavailability, solubility), antimalarial 
compounds discovered from plant sources provide useful bioactive synthons, which 
may be synthetically modified to improve their drug-like properties.  
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CHAPTER 2 
Antiplasmodial Activity of Trema orientalis 
 
 2.1 Background and Aims of this study 
 South Africa boasts remarkable biodiversity and a rich cultural heritage of medicinal 
plant use. A number of extracts from South African plants have been evaluated for in 
vitro antimalarial activity but little is known about their active constituents (Pillay et al., 
2008). In light of this and the pressing need for new antimalarial drugs, the South 
African Department of Science and Technology awarded an innovation fund to a 
national multidisciplinary consortium to further evaluate South African medicinal 
plants for the treatment of malaria.  
 
A survey of relevant literature (30 books) on medicinal plant use in East and Southern 
Africa revealed approximately 700 taxa associated with malaria and/or fever. All 623 
taxa, occurring indigenously or naturalised within the Flora of Southern Africa (FSA) 
region, were ranked using weighted criteria (primarily ethnobotanical and 
chemotaxanomic). From the ranked list, over 134 species representing 54 families, 
were collected throughout South Africa and extracts thereof were tested for in vitro 
activity against a chloroquine-sensitive (D10) strain of P. falciparum using the pLDH 
assay. Sixty-six species (49%) were reported to show promising antiplasmodial 
activity (IC50  10 g/ml), of which 17% (23 species) were considered highly active 
(IC50  5 g/ml) (Clarkson et al., 2004).  
 
One of the “highly active” plant extracts originating from this screening programme, 
was from Trema orientalis, and further investigation of this hit by the Council for 
Scientific and Industrial Research (CSIR) formed the basis of this study. The research 
undertaken was aimed at:  
1. Investigating the in vitro and in vivo antiplasmodial properties of the plant 
extract/s 
2. Comparison of a classical and accelerated approach to bioassay-guided 
fractionation to identify the active ingredient/s 
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3. Isolation and characterization of the active compounds  
4. Total synthesis of the active natural product/s 
5. Analogue generation based on identified pharmacophore/s  
 
2.2 Trema orientalis 
2.2.1  Botanical Description and Distribution 
Trema belongs to the botanical family Ulmaceae and is a genus of about 30 species 
of evergreen trees, occurring in subtropical and tropical regions of southern Asia, 
northern Australasia, Africa, South and Central America, and parts of North America 
(Wikipedia, 2010). They are fast growing pioneer trees or shrubs, reaching 10 – 20 m 
in height. In South Africa only one species, i.e. T. orientalis, occurs naturally.  
 
T. orientalis (Linn.) Blume is more commonly known as the pigeon wood tree. The 
name „Trema‟ is based on the Greek word for a hole and alludes to the trees pitted 
seed and „orientalis‟ is Latin for eastern or „of the orient‟. The common name pigeon 
wood is derived from the fact that pigeons are frequently seen nesting in these trees 
(World Agroforestry Centre, 2010).  
 
T. orientalis is fast growing shade tree with soft foliage that may be evergreen or 
deciduous depending on climatic conditions. The species is very variable in growth 
habit, ranging from a shrub to a slender, spreading tree 10 - 18 m in height. Its height 
is proportional to the amount of water it receives. It resembles the White Stinkwood 
(Celtis africana) superficially, but can be distinguished by certain leaf and fruit 
characteristics (University of Pretoria Botanical Garden, 2006). 
 
The bark of T. orientails is smooth and light grey with longitudinal lines and corky 
spots. The leaves are simple, alternate and stipulate. Flowers are inconspicuous, 
greenish, usually unisexual and appear from late winter to autumn. Fruit are small, 
round, fleshy and green, turning glossy black when ripe (Malan and Notten, 2005). 
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Figure 2.1 Trema orientalis growing in Pinetown, Kwazulu-Natal  
 
The trees are found in the higher rainfall areas of eastern and northern South Africa; 
the Eastern Cape, KwaZulu-Natal, Swaziland, Mpumalanga, Gauteng and the 
Northern Province. It does not occur south of the Kei River.  
 
2.2.2 Medicinal Usage  
The young leaves are eaten as spinach by the Zulus, who also use the roots and bark 
medicinally (Hutchings, 1996). Various plant parts are also used in traditional 
medicine in West Africa, Tanzania, east Africa and Madagascar.  
  
Fruit and leaf infusions or tonics are used to treat bronchitis, pneumonia and pleurisy 
and coughs. Bark is used for dysentery, as an inhalant for chest diseases and as a 
vermifuge. Stems and twigs are used for coughs and other respiratory ailments, 
fevers, toothache and venereal diseases. Pods and seeds are used for tired muscles 
and aching bones (Hutchings, 1996; Watt and Breyer-Brandwijk, 1962).  
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A decoction of the aerial parts of the plant is reportedly used to treat malaria in 
Madagascar (Jenkins, 1987; Rasoanaivo et al., 1992). 
 
2.2.3 Chemical Constituents 
Phytochemical investigations of T. orientalis growing in various parts of the world 
have led to the identification of several classes of compounds including triterpenoids, 
sterols, fatty acids, xanthones, coumarins, and glucosides.  
 
The Nigerians, Ogunkoya et al., isolated simiarenol (19), simiarenone (20), trematol 
(21), a long chain hydrocarbon and -sitosterol from the light petroleum extract of T. 
orientalis stem-bark (Ogunkoya et al., 1972a; Ogunkoya et al., 1972b; Ogunkoya et 
al., 1973; Ogunkoya et al., 1977).           
 
Tchamo et al. studied the trunk and root barks of T. orientalis, which grows as a shrub 
in Cameroon, and reported xanthone; secoiridoid and ursane skeletons in the 
Ulmaceae for the first time (Tchamo et al., 2001). Methylswertianin (22), decussatin 
(23), 1-O-glucosyldecussatin (24), 1-O-primeverosyl-decussatin (25), sweroside (26), 
2 , 3 , 23-trihydroxyurs-12-en-28-oic acid (27), 2 , 3 -dihydroxyurs-12-en-28-oic 
acid (28), lupeol (29), simiarenone (20), -sitosterol, 3-O- -glucopyranosyl- -
sitosterol, scopoletin, (-)-epicatechin, p-hydroxybenzoic acid and hexacosanoic acid 
were identified. They later reported on the isolation of two novel dihydrophenanthrene 
constituents (30) and (31), and orientoside A (32), a novel phenyldihydroisocoumarin 
(Dijoux-Franca et al., 2001). 
  
The Taiwanese reported the isolation of (+)-syringaresinol (33), (-)-ampelopsin F (34), 
N-(trans-p-coumaroyl)tyramine (35), N-(trans-p-coumaryl) octopamin (36), 3,5-
dimethoxy-4-hydroxyphenyl-1-O- -D-glucoside, (-)-epicatechin, (+)-catechin, and 
trans-4-hydroxy-cinnamic-acid from the stem of T. orientalis (Kuo et al., 2007). 
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2.2.4 Biological Properties 
The cytotoxic, antitumour and antimicrobial activity of extracts of the T. orientalis have 
been studied (Akinyemi et al., 2005; Chowdhury and Islam, 2004). An aqueous stem 
bark extract of the plant was also reported to significantly reduce blood glucose in 
STZ-induced diabetic rats by a mechanism different from that of sulphonylurea agents 
(Dimo et al., 2006). A flavanoidal mixture from T. orientalis was shown to possess 
strong CNS depressant properties, protecting 50% of experimental animals against 
electroshock convulsions (Chauhan et al., 1988). 
  
Extracts of T. guineense, reported to be a synonym of T. orientalis (Hutchings, 1996), 
showed significant analgesic, anti-inflammatory and antiarthritic activity in rodents. 
These pharmacological effects were evaluated using the acetic acid induced writhing 
test and hot plate method, the carrageenin-induced Oedema assay and Newbould‟s 
adjuvant arthritis test, respectively (Barbera et al., 1992). An ethanolic extract of T. 
guineense leaves was evaluated for its neuropharmacological properties in rodents 
and was found to induce hypothermia, significantly shorten the latency to sleep and 
prolong the duration of chemically induced sleeping time and significantly delay the 
onset of chemically induced clonic seizures; suggesting that the plant may contain 
compounds with a tranquilizing and/or sedative action (N'Gouemo et al., 1994). 
 
There are no reports on the investigation of the antimalarial properties of T. orientalis. 
However, extracts of the stem bark of a related species, Trema micrantha, was found 
to be weakly active in vitro (62% inhibition at 100 µg/ml) against a chloroquine 
resistant strain (Indo), but showed good activity in vivo (81% inhibition at 100 mg/kg) 
using a classical 4-day suppressive test against P. vinckei petteri 279BY (Muñoz et 
al., 2000).     
 
2.3 In vitro Antiplasmodial Activity of T. orientalis Extracts 
T. orientalis was selected for a national antimalarial screening programme (Clarkson 
et al., 2004) based on its ethnobotanical links to malaria (Jenkins, 1987; Rasoanaivo 
et al., 1992). The sequentially prepared 1:1 dichloromethane/methanol (DCM/MeOH) 
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and aqueous extracts of T. orientalis twigs, part of CSIR‟s historical extract repository, 
were tested in vitro against a chloroquine-sensitive (D10) strain of P. falciparum in 
duplicate in the pLDH assay (Table 2.1). 
 
Table 2.1 In vitro antiplasmodial activity of T. orientalis extracts 
Extract 
D10 
(Experiment 1) 
IC50 ( g/ml) 
D10 (Experiment 
2) 
IC50 ( g/ml) 
K1 
IC50 ( g/ml) 
P05644B 
(1:1 DCM/MeOH) 3.0 2.2 1.7 
P05644C 
(Aqueous) >10 >10 - 
 
The active component in the twigs of T. orientalis, responsible for the observed 
antiplasmodial activity, was concentrated in the organic extract, P05644B. It was 
found to be significantly active against the D10 strain of the parasite, having a 50% 
inhibitory concentration (IC50) value of less than 5 g/ml. The aqueous extract 
(P05644C) was relatively inactive; only an IC50 less than 10 g/ml was considered 
active at the extract level (Clarkson et al., 2004).  
 
The organic extract was subsequently tested against the K1 strain of P. falciparum 
and was found to have similar activity (IC50 1.7 µg/ml) against this chloroquine-
resistant strain. It was therefore prioritized for bioassay-guided fractionation to isolate 
and identify the active compounds.  
 
2.4 Bioassay-guided Fractionation of the T. orientalis Organic Extract 
Bioassay-guided fractionation, based on in vitro antiplasmodial activity against the 
D10 P. falciparum strain, was conducted on the 1:1 DCM/MeOH extract of the twigs 
of T. orientalis.  
 
Figure 2.2 outlines the stepwise fractionation of the organic extract, P05644B, guided 
by observed antiplasmodial activity against the D10 P. falciparum strain. As the 
extract showed activity against both the chloroquine-sensitive (D10) and resistant 
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(K1) strains, the D10 strain was selected as the primary indicator for activity as it is 
generally easier to culture than the K1 strain. The crude extract was subjected to a 
liquid/liquid partitioning process, separating the components into three fractions of 
varying polarity  to yield a hexane- (1A), dichloromethane- (1B) and aqueous- (1C) 
soluble fraction. The choice of partitioning between these three solvents is based on a 
standard method to remove fatty acids (concentrated in the hexane fraction) and 
tannins (concentrated in the aqueous fraction) from the more biologically attractive 
secondary metabolites (concentrated in the dichloromethane fraction).  
 
Enhanced antiplasmodial activity was observed for the dichloromethane-soluble 
fraction 1B (IC50 1.6 g/ml) while the hexane-soluble fraction 1A showed moderate 
activity (IC50 6.4 g/ml). Both these fractions were further purified by silica gel column 
chromatography to yield 16 fractions each. Further fractionation of 1A did not improve 
the antiplasmodial activity as none of the sub-fractions showed any significant activity. 
The further fractionation of 1B yielded sub-fraction 3G, with an improved IC50 of 0.8 
g/ml.  
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Figure 2.2 Bioassay-guided fractionation of P05644B. IC50 values are in g/ml 
 
 
Fraction 3G was also bioassayed against a Chinese Hamster Ovarian (CHO) cell line 
as a measure of cytotoxicity (Table 2.2). It was found to have a promising selectivity 
index (SI > 100), which is a ratio of cytotoxicity versus bioactivity. TLC and HPLC 
analysis of 3G revealed that it was a mixture of at least 5 compounds. However; due 
to the low yield of fraction 3G (3.2 mg), further fractionation was not practical. A 
recollection of plant material was required to further pursue the bioassay-guided 
fractionation. 
 
 
Liquid / liquid partitioning 
P05644B 
DCM/MeOH (1:1)  extract 
Ave IC50 2.6 µg/ml 
1A (Hexane fraction) 
IC50 6.4 µg/ml 1C (Aqueous fraction) 
IC50 > 100 µg/ml 
1B (Dichloromethane fraction) 
IC50 1.6 µg/ml 
Sub-fraction IC50 
3A 64.3 
3B 21.6 
3C 7.6 
3D 4.6 
3E 3.3 
3F 3.0 
3G 0.8 
3H 2.0 
3I 13.8 
3J 12.1 
3K >100 
3L 12.0 
3M 13.3 
3N 19.0 
3O 11.6 
3P >100 
 
Sub-fraction IC50 
2A >100 
2B >100 
2C 21.5 
2D 63.4 
2E 50.0 
2F 46.2 
2G 51.2 
2H 30.5 
2I 33.9 
2J 34.8 
2K 26.5 
2L 34.4 
2M 31.5 
2N 19.2 
2O 12.6 
2P 68.9 
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Table 2.2 In vitro antiplasmodial activity and cytotoxicity of fraction 3G 
Fraction 
D10  
IC50 ( g/ml) 
 
CHO 
IC50 ( g/ml) 
SI
a
 
3G 0.8 81.5 101.9 
 
a 
Selectivity index (SI) = cytotoxicity CHO IC50 / antiplasmodial D10 IC50 
 
2.5 Recollections of T. orientalis Twigs 
Following the first observation of antiplasmodial activity and bioassay-guided 
fractionation attempt, several recollections of T. orientalis were undertaken. Plant 
material from various regions of the KwaZulu-Natal North coast was collected at 
different times of the year.  Extracts of other plant parts (viz. the stem bark and 
leaves) were also prepared and bioassayed. However, the activity was found to be 
restricted to the young growing twigs of the trees and this was shown to be 
reproducible between the 1:1 DCM/MeOH twig extracts from various collections 
(Table 2.3). An in vivo evaluation of the organic twig extract from the fourth 
recollection (P05644-4B) was subsequently conducted.  
 
Table 2.3 In vitro antiplasmodial data of recollected T. orientalis twig extracts  
Extract 
Date of 
collection 
Collection 
area 
D10 
IC50 ( g/ml) 
K1 
IC50 ( g/ml) 
P05644B 
(Original organic extract) 
October 2001 Darnall 2.0 2.8 
P05644-1B 
(1
st
 recollection) 
April 2003 Mtunzini 9 - 
P05644-2B 
(2
nd
 recollection) 
July 2003 Darnall 2.0 - 
P05644-3B 
(3
rd
 recollection) 
January 2004 
Darnall / 
Zinkwazi 
1.4 3 
P05644-4B 
(4
th
 recollection) 
December 
2005 
Mtunzini 2.8 - 
P05644-5B 
(5
th
 recollection) 
March 2006 Darnall 2.8 - 
 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
32 
 
2.6 In vivo evaluation of T. orientalis semi-purified extract 
The semi-purified dichloromethane fraction, produced through liquid/liquid partitioning 
of the crude extract, showed improved potency in vitro (cf Figure 2.2). Analysis of this 
semi- purified fraction from the 4th recollection (P05644-4B) by HPLC (UV/MS) 
revealed that it was still a complex mixture of 10-15 major compounds and more than 
70 minor compounds (Appendix I). P05644-4B was evaluated for in vivo 
antiplasmodial activity against P. berghei using a 4-day suppressive test (Raw data in 
Appendix II). The extract was administered by subcutaneous injection at a dose of 
500 mg/kg.  
 
The survival rate of the mice is summarized in Figure 2.3. Of the four mice in the 
control (untreated) group, two died on day 6 and all were dead on day 7. The 
experimental group (treated with extract P05644-4B) showed a high survival rate, with 
60% survival up to day 20. The mice in this group did not die from malaria but were 
sacrificed on day 20 following the ethics protocol. The survival results of the 
experimental group were comparable to that of the chloroquine control group.  
 
 
Figure 2.3 The survival rate of mice in each group after infection with P. bergei ANKA 
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The parasitemia percentages, summarized in Figure 2.4, were more indicative of the 
parasite suppression effect in the infected mice. Over the first four days the extract 
showed ~40% parasite suppression compared to the control group. The untreated 
group (control) had parasitemia of 28.4% on day 6 which led to the death of the entire 
group on day 7; whereas 60% of the mice in the experimental group survived with 
parasitemia levels above 47% on day 13 and continued to survive with significantly 
high parasitemia levels until they were sacrificed on day 20. 
 
 
 
 
Figure 2.4 The average percentage parasitemia in each group at any given day after 
infection 
 
The gradual weight loss observed amongst all the animals in the experimental group 
(Figure 2.5) confirmed that the mice were sick. 
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Figure 2.5 The weight loss of infected mice over time 
 
Overall, the extract did not show good antimalarial activity due to the high parasitemia 
levels observed compared to chloroquine treatment. The efficacy of chloroquine is 
characterized by an almost immediate effect and a rapid reduction of parasitaemia. 
However, the semi-purified extract clearly prolonged the survival period of treated 
mice. The increased tolerance of high percentages of parasitemia in the blood 
indicates that the semi-purified extract could have either immune modulatory 
properties or some other kind of antimalarial effect (viz. parasite growth inhibition).  
 
 
2.7 Bioassay-guided fractionation of P05644-5B 
The first four recollections of T. orientalis twigs (Table 2.3) were relatively small scale 
(5 – 20 kg) and due to their low yields, bioassay-guided fractionation of extracts from 
these historical collections proved unsuccessful in identifying the active compounds. 
 
A bulk recollection was subsequently undertaken in March 2006, followed by large 
scale extraction (to yield extract P05644-5B) and bioassay-guided fractionation 
(summarized in Figure 2.6). The purification, guided by results of previous 
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fractionation attempts, was based primarily on size-exclusion and reverse-phase 
chromatography to avoid considerable mass loss observed through silica gel 
chromatography.  
 
The dichloromethane fraction 4B, prepared by liquid/liquid partitioning (i) of the 
DCM/MeOH (1:1) extract, served to concentrate the actives in a less complex matrix. 
Purification of the dichloromethane fraction 4B was initiated using vacuum liquid 
chromatography (VLC) (ii). Of the ten pooled fractions generated (5A - 5J) only two 
(5D and 5E) were found to retain biological activity and were combined and further 
purified by size-exclusion gel chromatography (iii). Four of the five fractions (6A – 6E) 
subsequently generated showed improved biological activity but based on the results 
and yields only fraction 6D was selected for further purification.  Fraction 6D was 
separated by reverse-phase solid phase extraction (SPE) (iv) and yielded 6 pooled 
fractions (7A – 7F). Only fraction 7D showed significant retention of biological activity 
and was further purified by reverse-phase semi-preparative HPLC (v).  
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Figure 2.6 Bioassay-guided fractionation of PO5644-5B. IC50 values are in g/ml. IA 
= Inactive at the maximum concentration tested (100 µg/ml) 
 
Four fractions (8A, 8B, 8Ci and 8Cii) were generated and all of these showed 
significant biological activity (< 1 µg/ml). 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5A - 5C 
IA 
5D 
IC50 0.8 
5E 
IC50 0.9 
i) Liquid / liquid partitioning 
P05644-5B 
Dichloromethane/ MeOH (1:1)  extract 
IC50 2.8  
 
4A (Hexane fraction) 
IA 4C (Aqueous fraction) 
IA 
4B (Dichloromethane fraction) 
IC50 1.3 
ii) VLC 
5F - 5J 
IA 
iii) Gel chromatography 
6A 
IC50 0.33 
6B 
IC50 1.10 
6C 
IC50 0.37 
6D 
IC50 0.26 
6E 
IC50 0.68 
iv) SPE 
7A 
IA 
7B 
IC50 2.7 
 
7F 
IA 
 
7C 
IC50 0.8 
 
7D 
IC50 0.48 
 
7E 
IC50 1.0 
 
v) Semi-prep purification 
8A  
IC50 0.8 
 
8B 
IC50 0.6 
 
8Ci  
IC50 0.4 
 
8Cii 
IC50 0.5 
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Preliminary TLC, 1H NMR and MS analysis revealed that 8A was a mixture of 
diastereomers; 8B was a mixture of 3 – 4 compounds, while 8Ci and 8Cii were the 
partially separated diastereomers of a single compound. The HPLC separation of 7D 
to give the diastereomers 8Ci and 8Cii was not optimal as the NMR‟s of each showed 
traces of the other diastereomer. However; the NMR data of each diastereomer could 
be amply discerned for characterization. 
 
2.8 Identification and Characterization of Compounds (8A), (8Ci) and (8Cii) 
 
The mixture of the pair of diastereomeric compounds 8A, and the partially separated 
diastereomers 8Ci and 8Cii, were identified and characterized by mass spectrometry 
(HR QTOF ESI-MS) and NMR experiments. The structural assignments of the 
compounds are based on detailed studies of the high-field 1H and 13C NMR spectral 
data (chemical shifts and coupling constants) and standard two-dimensional (2D) 
NMR techniques (Croasmun and Carlson, 1987; Sanders and Hunter, 1987). 
 
The proton-proton connectivity patterns were established by 2D (1H,1H) correlation 
spectroscopy (COSY) experiments. The multiplicities of the different resonances in 
the 13C spectra were deduced from the proton-decoupled CH, CH2 and CH3 
subspectra obtained using the DEPT (distortionless enhancement by polarisation 
transfer) pulse sequence. The 13C resonances were partly assigned by correlation of 
the proton-bearing carbon atoms with specific proton resonances in 2D (13C,1H) 
heteronuclear single quantum correlation (HSQC) experiments. The assignment of 
the quaternary carbon atoms and the deduction of the long-range (more than one 
bond) connectivity pattern was facilitated by 2D (13C,1H) heteronuclear multiple bond 
coherence (HMBC) experiments. Correlations observed in nuclear Overhauser 
enhanced spectroscopy (NOESY) experiments provided information on the relative 
stereochemistry of the compounds.   
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2.8.1 Structural Elucidation of Compound 8Cii 
 
 
8Cii 
 
Compound 8Cii was isolated as a colorless gum. The ESI-MS showed a molecular 
ion with an m/z 697.2288 [M-H]- corresponding to an accurate mass of 698.2367 and 
allowing the molecular formula of 8Cii to be deduced as C39H38O12.  
 
Resonances were concentrated in the downfield oxygenated (δH 3.7 – 5.0 ppm) and 
the olefinic regions (δH 6.2 – 7.7 ppm) of the 
1H NMR spectrum. Characteristic 
chemical shifts , splitting patterns and coupling constants identified two para 
substituted aromatic rings at δH 7.48 (2H, d, J = 8.8 Hz, H-2'' and H-6''), δH 7.55 (2H, 
d, J = 8.8 Hz, H-2''' and H-6''') and δH 6.73 – 6.90 (H-3'', H-5'', H-3''' and H-5'''). Each 
ring was found to correlate to a trans double bond at δH 6.25 (H-8'') and δH 6.38 (1H, 
H-8'''). The olefinic protons H-7'' (δH 7.37) and H-7''' (δH 7.64) correlated to α,β-
unsaturated carbonyls at δC 167.1 (C-9'') and δC 167.3 (C-9'''); respectively. Also, two 
aromatic oxygenated carbons δC 160.9 (C-4'' and C-4''') and δC 167.3 (C-9''') 
correlating to H-2'' (and H-6'') and H-2''' (and H-6'''); repectively, suggested that 8Cii 
contained two 4-hydroxycinnamoyl groups.  
 
Figure 2.7 Major HMBC correlations categorizing 4-hydroxycinnamoyl fragment 
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Three methoxy groups ( C 56.1, 3-OCH3 and C 56.5, 3'-OCH3 and 5'-OCH3), two 
oxygenated methylenes ( C 65.1, C-9 and C 65.0, C-9') and two oxygenated 
methines ( C 74.5, C-7 and C  86.7, C-8) were found in the more upfield region of the 
13C NMR and DEPT spectra of 8Cii. An additional two aromatic rings were also 
identified. Chemical shifts, splitting patterns and coupling constants of ring A were 
consistent with a 1,3,4-trisubstituted aromatic pattern. The methoxy groups were 
assigned on the basis of the HMBC correlations. The methoxyl at δH 3.79 (3H, s, 3-
OCH3) was found to correlate to C-3 ( C 148.0) while ring B was found to possess two 
methoxy groups (δH 3.86, 6H) attached to C-3' and C-5' ( C 153.9) in a symmetrical 
manner.  
 
Further analysis of the 1H, HSQC and 1H-1H COSY NMR spectra identified a third 
trans double bond at δH 6.68 (1H, br d, J = 15.9 Hz, H-7') and δH 6.39 (1H, dt, J = 
15.9 Hz, 6.2 Hz, H-8') correlating to H-9' (δH 4.81). HMBC and COSY correlations 
were also observed between H-7 (δH 4.99), H-8 (δH 4.31) and the methylene protons 
H-9a (δH 4.44) and H-9b (δH 4.02). Based on this information and further HMBC 
correlations between H-7 and the aromatic carbon C-2 ( C 104.7) and between H-7' 
and the C-2' and C-6' ( C 111.4) aromatic carbons, it was evident that compound 8Cii 
contained two C6-C3 units, linked by an ether bond between the oxygenated carbon, 
C-8 and the phenolic carbon, C-4' ( C 133.3), identifying it as a 8-O-4' neolignan 
derivative (Figure 2.8) (Agrawal and Thakur, 1985; Gellerstedt et al., 1995).  
 
Figure 2.8 Major HMBC correlations identifying 8-O-4' neolignan core 
 
Key HMBC correlations from H-9' to C-9''' ( C 167.3) and H-9 to C-9'' ( C 167.1) 
revealed that the two 4-hydroxycinnamoyl groups were attached to C-9 and C-9' as 
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esters.  The coupling constant between H-7 and H-8 was 7.1 Hz, which suggested 
that the relative configuration between these two protons is threo (Zhong and Xian, 
2003). Thus compound 8Cii was structurally elucidated as threo-1-(4-hydroxy-3-
methoxyphenyl)-2-[2,6-dimethoxy-4-{(1E)-3-(4-hydroxycinnamoyl)-1-
propenyl}phenoxy]-3-(4-hydroxycinnamoyl)propan-1-ol. 
 
2.8.2 Structural Elucidation of Compound 8Ci 
 
 
8Ci 
Compound 8Ci was also a colorless gum with essentially the same accurate mass 
(698.2384) and corresponding formula (C39H38O12) as 8Cii. The 
1H NMR spectrum of 
compound 8Ci closely resembled that of 8Cii. The most obvious difference was the 
chemical shift of H-8 (δH 4.58) and splitting pattern of H-7 (δH 4.97, 1H, br d, J = 3.3 
Hz). The smaller coupling constant suggested that the relative configuration between 
H-7 and H-8 was erythro (Zhong and Xian, 2003). A thorough investigation of the 1H, 
13C, HSQC, HMBC, COSY and NOESY experiments performed on this compound 
confirmed that 8Ci was the erythro diastereomer of 8Cii i.e. erythro-1-(4-hydroxy-3-
methoxyphenyl)-2-[2,6-dimethoxy-4-{(1E)-3-(4-hydroxycinnamoyl)-1-
propenyl}phenoxy]-3-(4-hydroxycinnamoyl)propan-1-ol.     
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2.8.3  Structural Elucidation of Compound 8A 
 
 
8A 
 
Compound 8A, also a colorless gum, showed a molecular ion peak with an m/z 
667.2197 [M-H]- corresponding to an accurate mass of 668.2276 allowing the 
molecular formula to be deduced as C38H36O11, one methoxy group less than that of 
8C. This was supported by the 1H and 13C NMR data of 8A which revealed that this 
compound was also a 8-O-4' neolignan analogue, differing from 8C only in the 
substituent pattern of ring B. NMR data of ring B in 8A was consistent with a 1,3,4-
trisubstituted aromatic ring, confirming that only one methoxy group was attached to 
C-3'.  
 
The undisputed doubling of resonances in the 1H and 13 C NMR spectra of 8A, 
especially the well resolved characteristic signals of C-7 ( C 73.3 and 73.8) and C-8 
( C 83.4 and 84.1), confirmed that 8A was a mixture of threo and erythro isomers (in 
approximate 1:1 ratio).  
 
Therefore, compound 8A was identified as a mixture of threo- and erythro -1-(4-
hydroxy-3-methoxyphenyl)-2-[2-methoxy-4-{(1E)-3-(4-hydroxycinnamoyl)-1-
propenyl}phenoxy]-3-(4-hydroxycinnamoyl)propan-1-ol.       
 
The natural product could not be further resolved and NMR assignments of the two 
diastereomers was deferred till the compound could be diastereoselectively 
synthesized (Chapter 3).     
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2.9 Characterization of Compounds 8A and 8C 
A literature search revealed that compounds 8C and 8A were previously isolated from 
the twigs of the Indonesian tree, Artocarpus dadah and were subsequently named 
dadahol A and B; respectively (Su et al., 2002). In this previous report, the authors 
had transposed the NMR signals of the 9- and 9′-coumaroyl groups. These were 
unambiguously assigned here due to access to 2D NMR data, as well as NMR data 
of the respective monoesters synthesized in Chapter 3. 
 
 
 
Although this is the first report of their isolation from T. orientalis twigs it is not an 
unexpected result as lignans and neolignans are the structural units of lignoid 
polymers (lignin) which occur in woody plants. They are characterized by the common 
constitutional feature of two C6-C3 (n-propylbenzene) residues (Figure 2.9) (Haworth, 
1942). For nomenclature purposes, the C6-C3 is numbered from 1 to 6 in the ring, 
starting from the propyl group, and the propyl group numbered from 7 (or α) to 9 (or 
γ), starting from the benzene ring. The numbers are primed in the second C6-C3 unit.  
 
 
Figure 2.8 Two common ways of labeling the carbon atoms in n-propylbenzene 
residue of lignans 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
43 
 
When the two units are linked by a bond between the central (8 and 8´) carbon 
atoms, the compound is referred to as a lignin. The lignans can be divided into six 
subgroups, based on general structures (Figure 2.9).  
 
 
Figure 2.9 Lignin types 
 
The term neolignans is used in the absence of the C-8 and C-8´ (β-β) bond, where 
the C6-C3 units are linked by another carbon-carbon bond. And when there are no 
direct carbon-carbon bonds between the C6-C3 units and they are instead linked by 
an ether oxygen atom, as in dadahols A and B, the term oxyneolignan is used (Moss, 
2000). There are more that fifteen subgroups of neolignans; these are most readily 
designated by specifying the points of union between the C6-C3 units (Whiting, 1985). 
The two phenylpropanoid units of dadahols A and B are linked via C-8 of the first unit 
and the oxygen of the hydroxyl substituent at C-4´ in the second unit, therefore further 
characterizing them as 8-O-4´ (or β-O-4) oxyneolignans (Agrawal and Thakur, 1985; 
Gellerstedt et al., 1995).     
 
Lignans and neolignans show enormous structural diversity, varying substantially in 
oxidation level, substitution pattern and the chemical structure of their basic carbon 
framework. The aryl moieties of these phenylpropane dimers are primarily substituted 
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with hydroxyl (phenolic) or their corresponding methyl ethers and methylene dioxy 
functionalities (Jensen et al., 1993). 3-Methoxy-4-hydroxyphenyl (guaiacyl), 3,4-
dimethoxyphenyl (veratryl), 3,5-dimethoxy-4-hydroxyphenyl (syringyl) 3,4,5-
trimethoxyphenyl and 3,4-methylenedioxyphenyl (piperonyl) (Figure 2.10) are the 
most commonly occurring aromatic rings found in lignans (Umezawa, 2003). The 
neolignan core of dadahol B is composed of two guaiacyl rings while in dadahol A the 
B ring is syringyl.   
 
 
Figure 2.10 Principal aromatic structures of lignans 
 
Two cinnamic acid residues are attached to the terminal hydroxyls of the 
oxyneolignan core of dadahols A and B as 4-hydroxycinnamoyl (p-coumaroyl) groups. 
p-Coumaric acid is a precursor in the lignan biosynthetic pathway.  
The presence of two chiral carbons (C-7 and C-8) in dadahols A and B implies that 
two possible diastereomers, erythro and threo, can be present. With the possibility of 
free rotation around the C-7 and C-8 bond, it is difficult to determine the 
stereochemistry of such units and there appears to be no straightforward guideline. 
According to Zhong and Xian (2003) the relative stereochemistry between C-7 and C-
8 should be in the erythro form if the coupling constant between them measured by 
1H NMR is small (J = 2.7 – 5.0 Hz). If the coupling constant measured is larger (J = 
6.0 – 8.6 Hz), the configuration is in the threo form. Although there appears to be 
some confusion and contradicting reports in literature regarding the determination of 
threo and erythro stereochemistry, published data for erythro dadahol A (Su et al., 
2002) and similar 8-O-4´oxyneolignans (Seca et al., 2001; Paula et al., 1995) 
substantiated the observations of Zhong and Xian (2003), therefore this guideline was 
used to determine the relative stereochemistry of the dadahol A diastereomers (8Ci 
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and 8Cii). Ideally, X-ray crystallography would have been the best approach to 
confirming the relative stereochemistry of the natural products but unfortunately 
crystallization attempts were unsuccessful.    
  
As plant metabolites often exist as part of a family of related compounds it is likely 
that other less active neolignan analogues were also present in the T. orientalis 
extract. Several other fractions (viz. 6A, 6D, 6E and 7C in Figure 2.6) showed 
considerable activity but the further fractionation of these were not pursued as the 
bioassay-guided fractionation process employed focused on the identification of the 
major active compounds. These fractions could contain analogues of dadahols A and 
B, which contribute to the activity of the crude extract. Fraction 8B (Figure 2.6) 
provided evidence of this. It was found to be an inseparable mixture of at least 3 
minor compounds with similar Rf‟s, NMR and MS profiles to 8A and 8C. Dadahols A 
and B were subsequently recognized as major components of the semi-purified 
extract, P05644-4B (Appendix I), which increased tolerance of P. berghei infected 
mice to high percentages of parasitemia (Section 2.6).     
 
2.10 Classical versus Accelerated Bioassay-guided Fractionation Approach 
The bioassay-guided fractionation approach that was used to identify the active 
compounds, 8A and 8C, is regarded as classical bioassay-guided fractionation. 
Basically, this entailed the bioassaying of the crude plant extract in a primary screen, 
followed by a purification process whereby the active extract underwent iterative 
steps of activity-guided fractionation to identify the active compounds. For T. 
orientalis, this entire process spanned over 2-3 years, requiring numerous 
recollections, bulk extractions and fractionation steps (Figure 2.1 and Figure 2.6).     
The classical approach of bioassay-guided fractionation to target the active 
constituents is not only time consuming, but often leads to the re-discovery of known 
compounds, and loss of activity in the course of the purification is not uncommon as 
the process may neglect interesting compounds with minor biological activity. These 
secondary active compounds discarded during the traditional approach may 
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contribute to the overall activity of the extracts and present interesting chemical 
scaffolds that could make them preferential candidates for their chemical optimisation 
(hit-to-lead and lead-optimisation) into therapeutic candidates. 
 
Transformations in the drug discovery process over the last decade have stimulated 
new requirements for natural product research and more targeted approaches are 
being adopted in order to identify promising candidate molecules upfront and 
accelerate the development process (Fura et al., 2004; Potterat and Hamburger, 
2006). An accelerated natural product drug discovery process, based on the “HPLC 
biogram” approach (Shu et al., 2002), was recently implemented at CSIR 
Biosciences.  The approach is based on rapid bioassay-guided plant metabolite 
detection and characterization - a schematic illustration of the “HPLC biogram” 
method is shown in Figure 2.11.  
 
Plant extracts are separated by semi-preparative HPLC and fractions are collected 
into 96-well plates. The fractions are subjected to one or more relevant bioassays 
(on-line or off-line). Fraction collection is time based, resulting in a direct relationship 
between the well‟s position in the plate and a corresponding region on the HPLC 
chromatogram. This allows assignment of activity to a particular component or range 
of components of the mixture. The active peaks are correlated back to HPLC/UV/MS 
profiles and followed up with UV/MS spectral analysis for structure characterization.   
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Figure 2.11 “HPLC biogram” approach 
 
When applied to the discovery of bioactive natural products, the “biogram” 
methodology allows for early recognition of active compounds in complex plant 
extracts in a rapid and efficient manner while minimizing time and effort spent on 
inactive, known or otherwise uninteresting compounds. It therefore facilitates 
decision-making in initiating re-isolation or scale-up of active compounds for full 
structural and biological evaluation. If the bioassay employed is robust and as 
sensitive as the analytical method, both with a good “signal/noise” ratio, the “biogram” 
method can provide rapid and efficient detection and characterization of very minor 
bioactive compounds, previously undetected by other physical methods.  
 
T. orientalis was included as part of the validation process, in order to compare the 
time frame and actives identified via the “HPLC biogram” approach to that of the 
historical approach. The dichloromethane fraction (4B; Figure 2.6) obtained through 
liquid-liquid partitioning of the T. orientalis crude extract (P05644-5B) was fractionated 
into a 96-well microtitre plate using semi-preparative HPLC. The selection of the 
dichloromethane fraction (4B) for the 96-well plate fractionation was based on the 
enriched antiplasmodial activity (cf. Section 2.7) and lack of fatty acids and tannins 
(cf. Section 2.4) in this semi-purified extract relative to the crude extract.  
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The semi-purified extract, 4B, and 96-well plate were subjected to in vitro bioassays 
at the Swiss Tropical and Public Health Institute (Swiss TPH) against the various 
micro-organisms responsible for the so-called „neglected‟ diseases i.e. Trypanosoma 
brucei rhodesiense, Trypanosoma cruzi, P. falciparum and Leishmania donovani. 
Cytotoxicity was also evaluated using rat skeletal myoblast (L-6) cells. In a pre-
screen, the extract showed selective activity against a chloroquine-resistant (K1) P. 
falciparum strain (Table 2.4).  
 
Table 2.4 Activity and cytotoxicity of T. orientalis extract (IC50‟s in µg/ml) 
Organism/ Cell line 
T.b. 
rhodesiense 
T. 
cruzi 
L. 
donovani 
P. falciparum 
K1 
Cytotoxicity 
L6 
Melarsoprol 0.004     
Benznidazole  0.314    
Miltefosine   0.175   
Chloroquine    0.07  
Podophyllotoxin     0.004 
T. orientalis  
semi-purified  
extract (4B) 10.24 18.72 8.32 1.54 29.41 
 
           
The 96-well plate fractions were subsequently bioassayed against P. falciparum K1 at 
two concentrations, 4.8 and 0.8 µg/ml (See Appendix III) using the 3H-hypoxanthine 
incorporation assay. Wells which showed more than 50% inhibition of the parasite at 
the lower concentration were considered active. The activity profile at 0.8 µg/ml is 
depicted in Figure 2.12 and shows that there were three active regions, wells A1 – 
A4, wells C6 – E4 and well G7.   
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Figure 2.12 Activity profile of 96-well plate fractions at 0.8 µg/ml 
 
IC50 values were determined for these wells (Figure 2.13).  They were also evaluated 
for toxicity to L6 cells (Appendix III).  
 
 
Figure 2.13 Plot of IC50 values in µg/ml 
 
Based on the serial dilution assay eight wells showed IC50 values less than 0.5 µg/ml 
with selectivity indices (SI, ratio of cytotoxicity to antiplasmodial activity) greater than 
10 (Table 2.5).  
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Table 2.5 Summary of activity and cytotoxicity of most active fractions 
 
The corresponding wells of a duplicate plate were analysed by UPLC-TOF-MS and 
bioactivity was correlated with the spectral data of the well components. In order to 
determine if the active wells contained the same or a common region/compound their 
Base Peak Intensity (BPI) (negative mode) chromatograms were compared 
(Appendix IV). The chromatograms showed that wells D4-D7 and D9-D11 were 
identical. Well G7, which had the lowest IC50, was found to be an unresolved mixture 
of weakly UV-active apolar compounds that eluted during the column wash, and was 
subsequently not further analysed. One representative well from each of the other 
regions was analyzed in more detail and major peaks occurring in both the BPI (ES-) 
and UV chromatograms were identified (Figure 2.14). 
 
Accurate mass and UV maxima data for each of these peaks were then used to 
search the Dictionary of Natural Products (DNP) database (Chapman & Hall, 2010) 
for possible structures (Appendix V).   
 
Fraction/ Well P. falciparum K1 
IC50 (ug/ml) 
Cytotoxicity L6 
IC50 (ug/ml) 
SI 
A1 0.459 5.19 11.3 
D4 0.403 4.83 12.0 
D6 0.324 3.32 10.2 
D7 0.374 9.1 24.3 
D9 0.296 10.7 36.1 
D10 0.381 8.9 23.4 
D11 0.286 9.1 31.8 
G7 0.256 8.5 33.2 
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Figure 2.14 ES- BPI chromatograms of representative active wells 
 
Peak 1, with a retention time (rt) of 2.93 min, showed a molecular ion with an m/z 
328.1166 [M-H]- corresponding to an accurate mass of 329.12454 and UV maxima 
peaks at 220 and 318 nm. A search on DNP based on the accurate MS and UV data 
of this compound identified the possible structure of this compound as N-trans-
feruloyl-S-octopamine, a close analogue of N-(trans-p-coumaryl)-octopamin (36) 
which has been previously isolated from T. orientalis (Kuo et al., 2007).   
 
 
A DNP search based on the accurate mass (313.1284) and UV maxima (219 and 318 
nm) of peak 2 (rt 6.42 min) resulted in two possible alkaloid structures; Cassiarine B 
Well A1 
Well D5 
Well D11 
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or N-trans-Caffeoyl-O-methyltyramine; the latter compound being the more obvious 
choice due to its structural relation to alkaloids previously isolated from T. orientalis 
(Kuo et al., 2007).  
 
 
Peak 4 (rt 16.74), showing a molecular ion with an m/z 667.2184 [M-H]- 
corresponding to an accurate mass of 668.22634 and UV maxima peaks at 222 and 
310 nm, resulted in just one hit in the DNP search i.e. dadahol B. Peaks 6 and 7 had 
almost identical accurate mass (697.23944 and 697.23844; respectively) and UV 
maxima (222, 310 and 223, 310 nm; respectively) and searches using this data 
revealed that these two peaks most likely corresponded to the two diastereomers of 
dadahol A. The tentative identification of peaks 4, 6 and 7 was confirmed by 
comparison of their retention times with those of dadahol A and B standards using the 
same UPLC analytical method. 
 
No possible hit structures were obtained based on the accurate mass and UV 
maxima of peak 3 (rt 12.73 min) and peak 5 (rt 17.38 min). However, based on their 
similar rt‟s, MS and UV maxima profiles to peaks 4, 6 and 7 it is likely that these 
compounds are closely related to dadahols A and B. Peak 3 with an accurate mass of 
728.25004 correlates to a possible analogue of dadahol A, which has an additional 
methoxy substituent (Exact mass calculated for C40H40O13: 728.25). Similarly, the 
accurate mass of peak 5 (654.24754) suggests that it could be an analogue of 
dadahol B, where one of the methoxy substituents is replaced with a hydroxyl (Exact 
mass calculated for C37H34O11: 654.21). There are several other minor peaks with 
similar MS and UV profiles in the regions of peaks 3 – 7 that are also likely to be 
analogues of dadahols A and B with different substituent patterns. 
 
Peaks 4 -7 were relatively major compounds common to all the active wells and the 
spread of this over the 96 well plate suggests that the separation was not ideal due to 
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column overload and that there might have been some carry-over of the actives 
between successive runs due to insufficient washing of the column between runs. 
However, the 96-well microtiter fractionation approach not only confirmed dadahol A 
and B as the major bioactives, but also served to identify other possible compounds 
which might be contributing to the overall activity of the extract. This physio-chemical 
process was achieved with a few hundred mg of extract over a couple of months as 
opposed to the classical bioassay-guided fractionation approach which required bulk 
recollections and took at least two years to identify the actives. 
 
The accelerated approach therefore represents a highly suitable tool for the 
identification of biologically attractive molecules and the profiling of extracts with 
pharmacological potential. The limitations of this approach lies in the facts that it is 
more suited to the dereplication of known compounds with published accurate mass 
and UV maxima data and is dependent on access to regularly updated electronic 
databases. In that respect, the “HPLC biogram” approach cannot fully replace the 
traditional bioassay-guided fractionation approach.  
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CHAPTER 3 
Diastereoselective Synthesis of Dadahol B 
 
3.1 Monolignol Biosynthesis 
Monolignols are monomeric phenolic compounds with a phenylpropane carbon 
skeleton, derived from the aromatic amino acid phenylalanine. The aromatic amino 
acids (L-phenylalanine, L-tyrosine and L-tryptophan) are synthesized from the 
carbohydrate precursors D-erythrose-4-phosphate (derived from the pentose 
phosphate pathway) and phosphoenolpyruvate (from glycolysis) via shikimic acid 
(Ganem, 1978; Haslam, 1974).  
 
Several other major classes of plant metabolites are derived from phenylalanine, 
including flavanoids, coumarins, stilbenes and benzoic acid derivatives (Dixon and 
Paiva, 1995). The initial steps in the biosynthesis of all these compounds are shared 
through the phenylpropanoid pathway.    
 
Lignin biosynthesis begins in the cytos l with the synthesis of monolignols from the 
amino acid phenylalanine as outlined in Scheme 3.1 (Boudet and Grima-Pettenati, 
1996; Campbell and Sederoff, 1996; Whetten and Sederoff, 1995). As the first step, 
phenylalanine (a) is deaminated to yield cinnamic acid (b) by the action of 
phenylalanine ammonia-lyase (PAL) (1). Cinnamic acid is hydroxylated to p-coumaric 
acid (c) by cinnamate-4-hydroxylase (C4H) (2), a cytochrome P-450-linked 
monooxygenase. p-Coumaric acid is in turn activated to p-coumaroyl-coenzyme A 
(CoA) (d) by p-coumarate-CoA ligase (4CL) (6). The activated thioester is the 
precursor for the synthesis of flavanoids, stilbenes and other phenylpropanoids as 
well as the monlignol p-coumaryl alcohol (f).      
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Scheme 3.1 Overview of the monolignol biosynthetic pathway 
 
p-Coumaric acid and p-coumaroyl-CoA can both be hydroxylated at the 3 position to 
yield caffeic acid (g) and caffeoyl-CoA (h), respectively, but the responsible enzymes 
(3a and 3b) are not well studied. The newly added hydroxyl group can be methylated 
by O-methyltransferase (OMT) (4a or 4b) to  
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give ferulic acid (i) or feruloyl-CoA (j) Caffeic acid and ferulic acid can be activated to 
their corresponding CoA thioesters by 4CL (6).    
 
Ferulic acid can be hydroxylated by ferulate 5-hydroxylase (F5H) (5), another P-450-
linked monooxygenase, to yield 5-hydroxyferulic acid (m), which is also a substrate 
for 4CL. The 5-hydroxyferulic acid can be methylated by OMT (4a) to produce sinapic 
acid (p). The corresponding methylation of 5-hydroxyferuloyl-CoA to sinapoyl-CoA 
has also been described and is most likely catalysed by caffeoyl-CoA 3-O-
methyltransferase (CCoA-OMT) (4b). Activation of sinapic acid to sinapoyl-CoA is 
possible but occurs ineffectively in most plants tested.   
 
Reduction of the CoA thioesters to the corresponding aldehydes is catalysed by 
cinnamoyl-CoA reductase (CCR) (7). Caffeoyl aldehyde is not shown as it has no 
known physiological role. Further reduction of the aldehydes by cinnamyl alcohol 
dehydrogenase (CAD) (8) yields the three monolignol monomers: p-coumaryl alcohol 
(f), coniferyl alcohol (l) and sinapyl alcohol (s).   
 
The order in which hydroxylation, methylation, thioactivation and reduction reactions 
occur during monolignol synthesis may vary at one or more levels, although the 
extent and physiological significance of this variation are unclear. 
 
The monolignols p-coumaryl alcohol, coniferyl alcohol and sinapyl alcohol are 
relatively toxic and unstable. Glycosylation on the phenolic hydroxyl group yields the 
monolignol glucosides 4-hydroxycinnamyl alcohol glucoside, coniferin and syringin, 
respectively. The attached glucose renders them water soluble and less toxic. Once 
transported through the cell membrane to the apoplast, β-glucosidase releases the 
three alcohols from their glucosides and makes them available for further processing 
by phenol dehydrogenases (oxidative enzymes) (Freudenberg, 1965).    
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3.2 Oxidative Coupling of Monolignols: Dehydrodimerisation 
The dimeric lignans (homodimers), dilignols (heterodimers) and the structural units in 
polymeric lignin are formed by the so-called oxidative coupling reaction of 
monolignols. There are three modes of coupling mechanisms in pteridophytes and 
woody gymnosperms/angiosperms, each having evolutionary significance (Lewis and 
Davin, 1994). The first involves monolignol oxidations catalysed by H2O2-dependent 
peroxidases to yield lignan dimers. Woody plants also contain laccases, O2-
dependent oxidases containing four copper atoms, which catalyse the coupling of 
coniferyl/sinapyl alcohols to give racemic (neo)lignans. In contrast, optically active 
lignans are formed by stereoselective coupling catalysed by more specific weakly 
characterized O2-requiring oxidases.  
 
Dehydrodimerisation is based on the oxidative coupling of monolignols where two 
phenoxy radicals are first generated in a one-electron oxidation reaction by an oxidant 
system such as peroxidases/H2O2, where peroxidase is a catalyzing enzyme and 
H2O2 is an oxidant (Setälä, 2008). The oxidant penetrates into the active site of the 
enzyme forming an activated enzyme which is capable of oxidising a substrate. The 
monolignol penetrates into the active site of the enzyme to form a monolignol-enzyme 
complex. The ratio and availability of monolignols in the reaction side of the cell wall 
together with oxidizing enzymes are important factors. The relative reactivities (redox 
potentials) of the monolignols are important in cross-coupling reactions 
(heterodimerisation) (Syrjänen and Brunow, 1998). 
 
The postulated dehydrogenation and one-electron oxidation of the monolignol 
monomer generates phenoxyradicals. Delocalization of the unpaired electron spin 
density over the aromatic and double bond ring system of the phenoxy radical, gives 
several resonance forms and positions that can react with each other (Scheme 3.2).  
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 Scheme 3.2 Resonance forms (A-E) of a phenoxy radical 
 
3.2.1 Regioselectivity in Phenoxy Radical Coupling 
Two phenoxy radicals subsequently couple to form quinone methide intermediates. 
How the radicals are initially coupled, which reaction route is selected and the ratio of 
possible dimeric products are primarily dependent on the stereoelectronic effects 
related to the structure of the phenoxy radical, but the catalyst/oxidant system and 
reaction conditions can also have significant effects.   
 
The different kinds of C-C or C-O bonds formed when one phenoxyradical couples to 
another are represented in Scheme 3.3. The β-β, β-5 and β-O-4 couplings are the 
most common in lignan and lignin structures. The 4-O-5' (A + C) and 5-5' (C + C) 
couplings are only possible if there are no substituents in the C-5 (and/or C3) position 
of the aromatic ring and are most likely to occur if there is no β-radical coupling 
possibility. β-1 (8-1') (B + E) coupling is possible if there is no β-radical coupling 
possibility in another phenoxy radical forming compound and more likely if the C-3 
and/or C-5 positions in the aromatic ring are blocked. Other coupling products have 
not been observed most likely due to instability or steric hindrance.    
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Scheme 3.3 Possible coupling of resonance stabilized phenoxy radicals generated 
from 4-hydroxy monolignols 
 
Factors which control the formation of various dimeric products have been studied 
using molecular dynamic calculations (Elder and Ede, 1995), semi-empirical 
molecular orbital calculations (Shigematsu et al., 2006, Elder and Worley, 1984), 
density functional theory (Durbeej and Eriksson, 2003b, Durbeej and Eriksson, 
2003a) and computational and simulation methods (Houtman, 1999, Russell et al., 
1996).  
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Kinetic arguments were used to explain the product distribution in the case of 
coniferyl alcohol. Tereshima and Atalla (1995) studied pH effects and measured the 
product distribution of coniferyl alcohol dimers and oligomers in various water/diglyme 
mixtures. Based on this and molecular dynamic (MD) calculations Houtman (1999) 
proposed a mechanism by which the solvent environment determines the product 
distribution of dimers. In water the coniferyl alcohol radicals are not free to adopt all 
possible orientations, resulting in a modified product distribution ratio since the 
outcome is most likely determined by the relative orientations of the molecules at the 
moment the orbitals of two centers of unpaired spin density overlap. In contrast, the 
relative orientations of the molecules seem to be freer in glycerol, and thus the 
product distribution is more comparable to that predicted from a statistical analysis of 
the probability of forming each product, assuming an equal likelihood of each relative 
orientation.  
 
Phenoxy radicals are assumed to initially form π-complexes that have to be 
superimposed in a way that enables the maximum overlapping of single-occupied 
molecular orbitals (SOMO) while the stereoelectronic repulsions of substituents on 
the aromatic ring and C3-side chain have to be minimized (Setälä, 2008). The 
different configurations of the intermediate π-complexes may also play a significant 
role in the regioselectivity of phenol oxidative coupling reactions. The π-complexes 
(sandwich model) lead to the σ-complexes (quinone methide intermediates) resulting 
in transition states (Chioccara et al., 1993). The quinone methides may be in 
equilibrium with the π-complexes or each other (Scheme 3.4). 
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Scheme 3.4 Possible phenoxy radical coupling routes and mechanisms to different 
structures 
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The stabilisation of the α-carbon in quinone methide intermediates by the addition of 
nucleophiles (Rx-OH) is essentially also a reversible reaction, and competes with the 
intramolecular nucleophilic attack. It depends on the nature and availability of 
nucleophiles in the reaction matrix, on the structure of the quinone methide, on the 
solvent system (solvolysis, H-bonding, and bulk effects) as well as the type of 
catalysis (viz. acid or base catalysed, pH dependence, solvent catalysis) (Setälä, 
2008).  
 
The quinone methides are electrophilic in nature and good Michael acceptors 
allowing nucleophiles to be readily added under mild conditions to the quinone 
methide exocyclic methylene group to form benzylic adducts. The formation and 
subsequent reactions of quinone methides are highly dependent on the presence of 
electron-withdrawing and –donating groups in the aromatic ring: electron-donating 
groups promote initial quinone methide generation and electron-rich groups lead to 
slower but more selective reaction with nucleophiles (Weinert et al., 2006). 
Nucleophilic addition to a quinone methide can be an intramolecular attack of a 
substituent on the dimeric intermediate (such as in the formation of β- dimers), or an 
attack by other nucleophiles existing in the reaction matrix (viz. stabilization of β-O-4 
dimers).             
 
3.2.2 Stereoselectivity in Phenoxy Radical Coupling 
The coupling of two phenoxy radicals leads to new stereogenic centers. If 
stereocontrol is exerted due to a catalyst and/or environment and/or chiral auxiliaries 
in the monolignol, the reaction can lead to pure enantiomers. Natural lignans often 
exist in enantiopure forms. The regio- and stereospecificity of bimolecular phenoxy 
radical coupling in lignan and lignin biosynthesis are clearly controlled in some 
manner in vivo. In contrast, in vitro coupling reactions using oxidases, such as 
laccases, have lacked strict regio- and stereospecific control. That is, if chiral centers 
are generated during in vitro coupling, the products are racemic, and different 
regiochemistries can result if more than one potential coupling site is present. Thus 
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the ability to generate a particular coupling product in vitro, is not under explicit 
control (Davin et al., 1997).   
 
For instance, one-electron oxidation of the monolignol, E-coniferyl alcohol (37), 
results in “random” bimolecular coupling to initially afford three possible quinone 
methide intermediates, which ultimately undergo inter- or intra-molecular nucleophilic 
attack to yield the dimeric products, (±)-dehydrodiconiferyl alcohols (38), (±)-
pinoresinols (39) and (±)-guaiacyglycerol β-O-4-coniferyl alcohol ethers (40) (Scheme 
3.5).        
 
Scheme 3.5 Bimolecular phenoxy radical coupling intermediates and products from 
E-coniferyl alcohol 
 
β-O-4 coupling can give rise to erythro and threo isomers while β-5 type coupling 
nearly always results in pure trans isomers (Scheme 3.6). The erythro/threo ratio of β-
O-4-structures is an important structural characteristic of lignin (Akiyama et al., 2003). 
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The stereochemistry in forming these isomers is believed to be kinetically controlled 
(Ralph et al., 2004). In vitro experimental results are lacking, unreliable, non-
systematic and have varied quite significantly making it difficult to draw fundamental 
conclusions on the correlations between the erythro/threo ratio and the reacting 
species (quinone methides and nucleophiles), the effect of the monolignol structure, 
and the reaction conditions.    
 
 
 
Scheme 3.6 Schematic diagram showing the acid catalysed addition of a nucleophile 
to a quinone methide intermediate and formation of erythro and threo isomers of β-O-
4 dimers and Cα-Cβ
 
 trans β-5 dimer 
 
Soluble and insoluble enzymes prepared from Eucommia ulmoides, incubated with 30 
mM coniferyl alcohol for 60 min, were shown to enantioselectively form (-)-erythro, 
(+)-erythro and (+)-threo, (-)-threo-GGCE‟s respectively (Alam et al., 2008).  
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A 78-kilodalton protein, isolated from Forsythia species, has been shown to affect 
stereoselective bimolecular phenoxy radical coupling in vitro in the presence of an 
oxidase or one electron oxidant. Lacking a catalytically active (oxidative) center itself, 
its mechanism of action is presumed to involve capture of coniferyl alcohol-derived 
free radical intermediates, with consequent stereoselective coupling to yield (+)-
pinoresinol (Scheme 3.7). The directing protein (DP) therefore acts as a chiral 
inducer.  
OH
OCH3
OH
O
OCH3
OH
DP
O
H3CO
HH
HO
O
OCH3
H
H
OH
HO OCH3
O
O
OH
H3CO
-H, -e re si si re
Putative enzyme-
bound intermediate
(+)-pinoresinol  
 
Scheme 3.7 The formation of (+)-pinoresinol by directing protein (DP) mediated 
coupling of coniferyl alcohol 
 
 
3.3 Retrosynthesis: Dadahol B 
Retrosynthetic analysis of dadahol B (Scheme 3.8) revealed that disconnections at 
the ester groups leads to p-coumaric acid (41) and a guaiacyglycerol β-O-4-coniferyl 
alcohol ether (GGCE) (40) moieties. GGCE contains two guaiacyl rings with two 
methoxy groups and is recognised as the biomimetic bimolecular oxidative coupling 
product of coniferyl alcohol (37) - the radical species of coniferyl alcohol bears one 
guaiacyl ring with one methoxy group. The monolignol (4-hydroxycinnamyl alcohol) 
(37) is the reduction product of the corresponding p- hydroxycinnamyl ester (42), 
which is ultimately prepared from the readily available benzaldehyde, vanillin (43), via 
a classical Wittig reaction.    
 
Other retrosynthetic routes were considered but were deemed less practical as these 
required synthetic routes with several more steps and specialized reagents.       
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Scheme 3.8 Retrosynthesis of dadahol B 
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3.4 Total Diastereoselective Synthesis of Dadahol B 
Scheme 3.9 summarises the synthetic route adopted to synthesise the two 
diastereomers of dadahol B using readily available starting materials.   
 
 
 
 
 
Scheme 3.9 Diastereoselective synthesis of dadahol B  
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3.4.1 Synthesis of the Monolignol: Coniferyl Alcohol 
Ethyl bromoacetate (44) was reacted with triphenylphosphine to produce the 
triphenylethoxycarbonylmethylphosphonium bromide salt (45). The phosponium ylide, 
or Wittig reagent (46), was prepared by reaction of the phosphonium salt with a base 
(sodium hydroxide). The Wittig reaction between vanillin (43) and the Wittig reagent 
(46) proceeds at room temperature but is slow and low yielding due to the anion-
stabilizing/electron withdrawing nature of the -CO2Et substituent.  
 
Stabilized ylides such as (46) tend to be less reactive than other ylides and 
predominately give E-alkenes. This selectivity has been attributed to the fact that 
stabilized ylides react with aldehydes under thermodynamic control (Vedejs and 
Peterson, 1994). Therefore, the less crowded trans-oxaphosphetane intermediate is 
favoured (Scheme 3.10). The major product 4-hydroxy-trans-cinnamyl ester (ethyl 
ferulate) (42) (~ 50 % yield) was separated from minor (> 5 % yield) corresponding cis 
ester by silica gel column chromatography.   
 
 
Scheme 3.10 Wittig reaction mechanism 
 
 
Diisobutylaluminum hydride (DIBAL) was used to reduce ethyl ferulate (42) to the 
monolignol, E-coniferyl alcohol (37). DIBAL is a versatile reducing agent useful in 
achieving stereo- and chemoselective reductions, particularly in the case of 
unsaturated carbonyl compounds. Alternative reducing agents, such as lithium 
aluminum hydride, yield varying amounts of saturated alcohol due to competing 1,4- 
vs 1,2-attack by the hydride (Quideau and Ralph, 1992).     
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3.4.2  Oxidative Coupling of E-coniferyl Alcohol 
Biomimetic oxidative coupling of E-coniferyl (37) alcohol provided a straightforward 
and reproducible method for the preparation of the core neolignan structure (GGCE) 
(40). Oxidant systems and reaction conditions which favoured the formation of the β-
O-4 (8-O-4') dimer were investigated. Enzymatic systems such as peroxidase/H2O2 
and laccase/O2 were more successful than inorganic oxidants such as Ag2O.   
 
The best yields of β-O-4 dimer (40) (25 – 35%) were obtained using horseradish 
peroxidase (HRP) as a catalyst with hydrogen peroxide (H2O2) as an oxidant, in a 2:3 
(v/v) dioxane/water mixture at pH 4 - 4.5  (Houtman, 1999; Terashima and Atalla, 
1995).  
 
HRP is a heme-containing enzyme from horseradish (Armoracia rusticana P. Gaertn., 
B.Mey. & Scherb.; Cruciferae) roots. The stability and activity of HRP is dependent on 
the concentration of H2O2, which can inhibit the enzyme at too high a concentration. 
The molar ratio of coniferyl alcohol / oxidant was generally 1:0.5 because one H2O2 
can generate two phenoxy radicals.    
 
Terashima and Atalla (1995) measured the product distributions from the dimerization 
of coniferyl alcohol in various water/diglyme mixtures and observed that a small 
addition of diglyme (20%) dramatically increased the production of β-O-4 dimers at 
the expense of the β-5 and β-β dimers (Scheme 3.5). Similar effects were observed 
for water/dioxane and water/glycerol mixtures.  
 
The amount of organic solvent is generally kept as low as possible to prevent 
denaturing of the enzyme. HRP has been found to be fairly active even at high 
concentrations of organic solvents (Ryu and Dordick, 1989). According to kinetic 
studies, the apparent Km values (enzyme-substrate interactions) in dioxane/water 
mixtures increases as the substrate hydrophobicity increased, whereas in aqueous 
buffer, the apparent Km values remained relatively constant. Values of Vmax (catalytic 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
70 
 
turnover), i.e. Vmax/Km, were reduced because of a stronger binding of substrates to 
HRP (Ryu and Dordick, 1992; Ryu and Dordick, 1989).      
 
pH also affects the dimerization of coniferyl alcohol. Among the contributing 
structures to the resonance hybrid of the coniferyl alcohol radical, the phenoxy radical 
(resonance form A in Scheme 3.2) is greater under acidic than neutral conditions, and 
will therefore give more β-O-4 dimer (Terashima and Atalla, 1995). The formation of 
β-O-4 dimer differs from the other two coniferyl alcohol dimers (β-β and β-5; Scheme 
3.5) in that it requires the addition of water to the intermediate quinone methide; this 
is an acid catalysed reaction which is very slow at neutral pH.  
 
A dioxane/water mixture at pH 4 – 4.5 was established as the most suitable matrix for 
scale-up of the oxidative coupling reaction since it allowed for optimal yields and 
easier recovery of β-O-4 dimer (40). No significant change in pH occurs during the 
reaction. Due to reduced peroxidase activity, the reaction slowed after one hour and 
addition of more peroxidase and H2O2 usually completed the dimerisation process.  
 
In all experiments, trace quantities (< 5%) of β-β dimers (pinoresinol) (39) and 
variable amounts of oligomeric products, that were not further characterized, were 
obtained. However, the major products were GGCE (40) (25-35% yield) and DHCA 
(38) (10-15%) (Scheme 3.11), even after an excess of H2O2 was added; while the 
relative ratio of the two was fairly constant regardless of the reaction time. This 
indicates that the reactivity of the monomers is greater than that of the dimers, and 
coupling between monomer and dimers and two dimers does not occur readily as 
long as they are in dilute solution. This may be due to steric hindrance factors or 
substrate specificity of peroxidase between monomer and dimer.   
 
Oxidative coupling results in carbon-carbon and carbon-oxygen bond formation. 
Subsequently, new chiral centers are formed. Peroxidases have not been observed to 
catalyse the oxidative coupling of phenols in an enantioselective way without the help 
of so-called dirigent proteins (Davin et al., 1997). No diastereoselection between 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
71 
 
threo (40i) and erythro (40ii) forms of GGCE was observed in the HRP-catalysed 
oxidative coupling of E-coniferyl alcohol. The 1H NMR of the synthesized GGCE (40) 
revealed that the diastereomeric ratio was ~1:1.   
 
 
Scheme 3.11 Major products of oxidative coupling of E-coniferyl alcohol  
 
 
3.4.3 GGCE Esterification 
To complete the synthesis of dadahol B, GGCE (40) needed to be coupled with two 
p-coumaric acid (41) molecules at the C-9 and C-9' positions (Scheme 3.12).  
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Scheme 3.12 Coupling of GGCE with 2 x p-coumaric acid to yield dadahol B  
 
Phenolic alcohols and phenolic acids are not easily amenable to esterification 
reactions. Varying degrees of chemoselectivity have been achieved with strong protic 
acids (Fischer esterification), Lewis acid-catalysed acylations, enzymes, condensing 
agents (viz. N, N'-dicyclohexylcarbodiimide, DCC) and catalytic quantities of 
promoters (viz. 4-dimethyaminopyridine, DMAP). However, harsh reaction conditions, 
the requirement of a large excess of one of the reagents, long reaction times and 
modest yields limit the scope and versatility of these esterification techniques to more 
hydroxylated and sensitive substrates (Appendino et al., 2002; Nahmany and 
Melman, 2004).  
 
Several methods for the acylation of vanilinol (47) (Scheme 3.13) were investigated 
(Appendino et al., 2002). Reactions of symmetric and mixed anhydrides and acyl 
chlorides in the presence of pyridine or triethylamine/DMAP were found to give 
comparable rates for the acylation of the phenolic and alcohol hydroxyls. Even 
reactions of a carboxylic acid/carbodiimide/DMAP system showed similar rates for the 
formation of alkyl and aryl esters.   
 
 
Scheme 3.13 Acylation of vanilinol 
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The esterification of phenolic alcohols and phenolic acids via acyl nucleophilic 
substitution under nucleophilic catalysis requires protection of the phenolic hydroxyls, 
since acids activated in situ or ex situ show poor discrimination between hydroxyls 
bound to aliphatic and aromatic carbons. Since deprotection of polyphenolic esters is 
often not a trivial operation, the more rational alternative would be to switch from 
carbonyl to hydroxyl activation - phenolic carbons are not substrates for SN2-type 
reactions. For instance, the cesium salts of phenolic acids have been reported to 
chemoselectively react with alkyl halides, but with modest yield and with an excess of 
halides (Stüwe et al., 1989). But this approach cannot be directly extended to 
multifunctional substrates such as phenolic alcohols.        
 
More specialised techniques like the Mitsunobu esterificati n, using the diisopropyl 
azodicarboxylate (DIAD) and triphenylphosphine (TPP) complex as a condensing 
agent, has been successfully applied to the chemoselective esterification of 
polyphenolic acids with polyphenolic alcohols. This is demonstrated by the 
condensation of hydroxytyrosol (48), a major antioxidant of olive oil, with gallic acid 
(49) (Appendino et al., 2002) (Scheme 3.15). Ester (50) was previously prepared in 
five steps with a 5% overall yield (Tillekeratne et al., 2001). The SN2-mechanism of 
the Mitsunobu reaction rules out aromatic carbons as electrophilic substrates, while 
generation of the nucleophilic species by deprotonation with a stabilized azaenolate, 
a relatively weak base (Hughes et al., 1988), ensures that carboxylates rather than 
phenolates are formed, provided that stoichiometric amounts of reagents are used.  
 
 
Scheme 3.15 Mitsunobu esterification of hydroxytyrosol 
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In theory, the difference in electronic properties and acidity between alcohols and 
phenols could be manipulated to control the chemoselectivity of esterification. The 
oxygen atoms in phenols generally have lower basicity and nucleophilicity - Kb of 
phenol is about 106 times lower than that of methanol. 
 
However, the challenge in selectively esterifying a substrate like GGCE (40), lies in 
the fact that it contains four potential reaction sites with varying properties i.e. an 
allylic hydroxyl (at C-9'), a primary hydroxyl (at C-9), a secondary hydroxyl (at C-7) 
and a phenolic hydroxyl (at C-4).  
 
 
 
3.4.3.1  Acid Chloride Esterification 
To assess the reactivity of the different GGCE hydroxyls, a simple acid chloride 
esterification (Scheme 3.16) was conducted. 2.5 Equivalents of cinnamic acid (51) 
were treated with oxalyl chloride to yield the corresponding acid chloride (52). In the 
presence of triethylamine, the acid chloride reacts with unresolved GGCE (40) to give 
two primary products, the erythro 4,9-diester (53) and the 4-monoester (54) as a 
diastereomeric mixture.     
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Scheme 3.16 Acid chloride esterification of GGCE 
 
The phenolic hydroxyl was the most reactive, followed by the primary hydroxyl at C-9. 
As expected, the tertiary hydroxyl at C-7 was completely unreactive, but surprisingly, 
so was the allylic hydroxyl (at C-9').        
 
This selectivity can be attributed to the alkaline reaction conditions. In the presence of 
even weak bases, deprotonation of the phenolic moiety tends to be the main factor 
controlling the chemoselectivity of acylation (Nahmany and Melman, 2004). In the 
presence of triethylamine, the phenolic hydroxyl of GGCE deprotonates producing 
phenolate anions that is acylated in preference to the less acidic hydroxyl groups.  
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3.4.3.2 Protection and Alternative Esterification Methods 
To circumvent the selectivity issue observed in the acid chloride esterification, 
phenolic protection as well as alternative esterification techniques, were investigated. 
In several instances, the β-5 dimer, DHCA (38), was used as an alternative substrate 
(cf. Chapter 5) since the relative hydroxyls of DHCA (38) were found to have similar 
properties and reactivities to those of GGCE (40) (Figure 3.1).  
 
 
Figure 3.1 Comparison of DHCA and GGCE hydroxyls 
 
Table 3.1. summarises the reactivities of the different DHCA/GGCE hydroxyls to 
various protection and esterification methods attempted (based on literature 
precedence and available reagents). The rationale and results of these are discussed 
further in Chapter 5.   
 
Table 3.1 Summary of results of protection and esterification reactions on DHCA 
and/or GGCE 
Reaction/Conditions 
Reaction at position/s: 
4 9 9' 4,9 4,9' 9,9' 7,9 4,9,9' 
TBS-Cl (1.1 equiv.), Imidazole, 
DMAP, THF, rt.  
- - X - - X - - 
TBS-Cl (1.1 equiv.), Imidazole, 
DMAP, THF, 0°C 
- - X - - - - - 
TBS-Cl (1.1 equiv.), Et3N, DMAP, 
THF, 0°C 
- - X - - - - - 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
77 
 
Reaction/Conditions 
Reaction at position/s: 
4 9 9' 4,9 4,9' 9,9' 7,9 4,9,9' 
TBS-Cl (1.1 equiv.), 2,6-lutidine, 
CH3CN, 0°C 
- - X - - - - - 
DHP (1.5 equiv.), PPTS, DCM, rt. - - X - - - - - 
TrCl (1.05 equiv.), Et3N, DMAP, 
DCM, 0°C 
X - - - - - - - 
Acetone/DMP (1:1), PPTS, rt. - - - - - - X - 
Acid chloride (2.5 equiv.), Et3N, 
THF, rt. 
X - - X - - - - 
Acid chloride (1.1 equiv.), Et3N, 
THF, 0°C 
X - - - - - - - 
Acid (2 equiv.), DCC, DMAP, 
DCM/THF (1:1), 0°C → rt  
X - - X - - - - 
Acid (2 equiv.), DCC, DMAP, 
DCM/THF (1:1), rt → 60°C 
X - - X - - - - 
Acid (1 equiv.), (CF3CO)2O, THF, 
60°C 
- - - - - - - - 
Acid (2.5 equiv.), DIAD, PPh3, 
THF, 0°C 
- - - - - - - - 
Acid (2 equiv.), CDI, DMAP, 70°C - X X - X X - X 
 
 
Both DHCA (38) and GGCE (40) proved fairly fragile, showing a tendency to 
decompose or polymerise even under mildly acidic or basic conditions. Reaction 
yields were modest, even simple silylation was not resoundingly successful, with 
more than half the substrate not yielding any recoverable product and favouring the 
9'-position. The specialized Mitsunobu esterification which is reported to distinguish 
between alcohol and phenol hydroxyls in esterification reactions (Appendino et al., 
2002) also proved unsuccessful with no reaction occurring between the substrates. In 
other cases, desirable products were difficult to separate from each other as well as 
unreacted starting materials and degradation/polymerization products; acetonidation 
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of the 7,9-positions of GGCE (40) yielded a complex mixture of several inseparable 
unstable products.  
 
In terms of selectivity, of the various approaches attempted, only CDI (N,N'–
carbonyldiimidazole) coupling proved successful in obtaining the desired 9,9'-diester. 
CDI coupling of GGCE (40) with 2 equivalents of cinnamic acid (51) resulted in a 
mixture of products, the major products being the triester (55), and the diesters (56) 
and (57) (Scheme 3.17). Although the reaction was slow and low yielding, it was 
possible to separate and individually characterise the threo (56) and erythro (57) 
forms of the 9,9'-diester.  
 
 
Scheme 3.17 CDI coupling of GGCE with cinnamic acid  
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However, in attempting the same reaction between GGCE and silylated p-coumaric 
acid (41), an inseparable diastereomeric mixture of the threo and erythro forms of 
dadahol B 8A2 was recovered (Scheme 3.18) in modest yield (8.2%). The 
diastereomeric forms of GGCE (40) would therefore need to be resolved before 
esterification.       
 
 
 
Scheme 3.18 CDI coupling of GGCE with p-coumaric acid 
 
3.4.4  GGCE Diastereomer Separation 
The threo (40i) and erythro (40ii) forms of GGCE were inseparable by conventional 
column chromatography and semi-preparative HPLC methods. The separation of 
diastereomers of lignin-related diol compounds based on ion exchange 
chromatography on an anion exchanger using a borate solution as the eluent was first 
introduced by Berndtsson and Lundquist (1977). This method and modifications 
thereof has since been applied in various studies (Ibrahim and Lundquist, 1994; 
Karlsson et al., 1990; Kristersson et al., 1980; von Unge et al., 1988).   
 
The preparative separation of the diastereomers of GGCE (40) was achieved on an 
ion exchanger with polysaccharide matrix (QAE Sephadex A-25), using 0.06 M 
potassium tetraborate (K2B4O7) in EtOH/water (1:4) as the eluent. QAE (Quaternary 
aminoethyl) Sephadex is a strong anion exchanger. The ion exchange group is 
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diethyl-(2-hydroxy-propy)aminoethyl which remains charged and maintains 
consistently high capacity over a wide pH range.  
 
The threo isomer (40i) eluted from the column in advance of the erythro isomer (40ii). 
The elution volumes of both diastereomers were large (400 – 500 ml) and the 
symmetrical elution peaks and difference in elution volume (~ 60 ml) allowed for the 
complete separation of the GGCE diastereomers.  
 
The erythro form gives the stronger borate complex and elutes after the threo form. 
This is expected from a conformational analysis of the borate complexes; in the 
borate complex of the threo form (Figure 3.2), the bulky aryl substituents are cis 
orientated and energetically unfavourable interactions between these groups cannot 
be avoided (Ibrahim and Lundquist, 1994).  
 
 
Figure 3.2 Boric acid complex of threo GGCE 
 
Work-up of the fractions containing the threo or erythro forms of GGCE gave mixtures 
of the compounds, their boric acid complexes and some degradation products. The 
boric acid was removed by repeated addition and evaporation of methanol. The pure 
diastereomers were then separated from their degradation products by silica gel 
column chromatography.  
 
Most of the degradation products were found to be oligomeric in nature and were not 
further characterized. The 1H NMR of one of the by-products that was recovered 
showed a triplet at δH 1.58 coupled to a quartet at δH 3.50 (J = 7.0 Hz), which 
correlated to C-9' in the HMBC. The ESI-MS data of this compound [m/z 404.179; 
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C22H28O7] supported the addition of an ethyl group to GGCE (40). Thus, it was 
confirmed that the allylic alcohol of GGCE (40) was ethylated during the ion-exchange 
chromatography, even though the nucleophilic double bond is more likely to react with 
acid.  
 
A possible mechanism for this is that the allylic alcohol was preferentially protonated 
during the acidic conditions of ion exchange chromatography and the generated 
protonated intermediate undergoes dehydration to yield two possible resonance-
stabilized carbocation intermediates (58) and (59). Presumably, nucleophilic attack 
via the more stable (disubstituted double bond-containing) carbocation (59) by 
ethanol yielded the observed product, the 9'-ethoxy boric acid complex of GGCE (61) 
(Scheme 3.19). Once the boric acid was removed, the ethylated analogue of GGCE 
(62) was recovered by silica gel column chromatography.  
 
 
Scheme 3.19 Proposed mechanism of GGCE ethylation 
     
3.4.5. Diastereoselective CDI coupling 
Each resolved GGCE diastereomer, (40i) and (40ii), was subsequently coupled with 
p-coumaric acid (41) using CDI (63) as the activating agent. CDI is a highly active 
carbonylating agent which contains two acylimidazole groups that can activate 
carboxylic acid groups by forming N-acylimidazoles (64) (Scheme 3.20). The reaction 
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is usually driven forward by the liberation of carbon dioxide and imidazole (65). The 
active carboxylate reacts with hydroxyl groups to form ester linkages.   
 
 
Scheme 3.20 Esterification via CDI activation of carboxylic acids 
 
Methods of improving yields in CDI activated esterification reactions were 
investigated. Since purity of CDI may be variable due to its water sensitivity, an 
excess was used to ensure complete conversion of the carboxylic acid to the 
acylimidazole. It has been suggested that the alcohol might react faster with the 
residual CDI than the acylimidazole, contributing to overall low yields of the ester. The 
activation step was conducted in anhydrous DMF, known to drive the reaction forward 
(Bode et al., 1994).    
 
The p-coumaric acid (41) was silylated (66) to limit homogenous coupling of the 
phenolic acid. Since alcoholysis of the intermediate acylimidazole is slow (Wipf, 
2005), the reaction mixture had to be heated for several hours at 70ºC. Catalytic 
amounts of base (viz. Na2CO3, NaH) were added to convert the alcohol to the 
alkoxide, which is reported to drive the esterification reaction forward (Wipf, 2005). 
The base catalyst was added after formation of the N-acylimidazoles (64) from the 
acid as indicated by the cessation of evolution of carbon dioxide.  The subsequent 
alkaline reaction conditions resulted in the loss of the silyl protective groups, thus 
eliminating the need for an additional deprotection step. Consequently, overall yields 
were low but sufficient for the isolation and characterisation of each dadahol B 
diastereomer, 8Ai and 8Aii, as well as the some of the 9- and 9'-monoesters, (67) – 
(69) and one of the other possible diesters, (70) (Schemes 3.21 and 3.22). Traces of 
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the 4,9,9'-triesters were also recovered but low quantities and complexity of NMR‟s 
did not allow for full characterisation. 
 
 
Scheme 3.21 CDI esterification of threo GGCE 
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Scheme 3.22 CDI esterification of erythro GGCE 
 
The 1H NMR of the natural product 8A (~1:1 diastereomeric mixture) was 
subsequently resolved by comparison with the spectroscopic data of the synthesised 
threo 8Ai and erythro 8Aii forms of dadahol B (Appendix VI). NMR data of the 
monoesters were also useful in resolving ambiguous resonances of dadahols A (cf 
Chapter 2) and B.  
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CHAPTER 4 
Biological Properties of Dadahols A and B 
4.1 Biological Properties of Lignans and Neolignans  
Many lignans and neolignans from plants display important physiological functions in 
plants and human health. Because they have been shown to display potent 
antimicrobial, antifungal, antiviral, antioxidant, insecticidal and antifeeding properties, 
lignans probably play an important role in plant defense against various biological 
pathogens and pests. They may also participate in plant growth and development. In 
addition to their purpose in nature, lignans and neolignans also possess significant 
pharmacological activities which include antitumor, anti-inflammatory, 
immunosuppressive, cardiovascular, antiviral and antioxidant actions (Saleem et al., 
2005).  
 
Many naturally-derived lignans and neolignans have served as lead compounds for 
organic synthesis of derivatives to optimize activity and to study structure-activity 
relationships (Apers et al., 2003). Although their molecular backbone consists only of 
two phenylpropane units, lignans and neolignans show enormous structural diversity, 
offering a huge library of natural compounds, unsurpassable by modern combinatorial 
chemistry techniques. The exploration of the chemical diversity of naturally occurring 
lignans and neolignans has already resulted in the characterization of many 
interesting lead compounds in various therapeutic areas, some of which are 
highlighted here.   
 
4.1.1 Antitumoural Activity 
Podophyllotoxin (71), a cytotoxic arytetralin lactone originally isolated from 
Podophyllum peltatum L., is the first and best known example (Canel et al., 2000). Its 
antimitotic activity is due to reversible binding to tubulin, which inhibits microtubule 
assembly and interrupts the cell cycle. A wide range of analogues and derivatives 
continue to be investigated in an effort to improve upon the antitumour activities and 
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properties of the clinical drug etoposide (72) (Ward, 1999).  The antitumoural activity 
of etoposide (72) and teniposide (73), despite being podophyllotoxin analogues, is 
due to inhibition of DNA topoisomerase II. Combination of both pharmacophores has 
led to compounds with a dual mechanism of action, such as azotoxin (74).  
 
 
 
In addition to podophyllotoxin, other types of lignans and neolignans have also been 
identified as inhibitors of tubulin polymerization. Dihydrobenzofuran neolignans, 
based on the natural lead 3‟-4-di-O-methylcedrusin (75) have also been investigated 
as potential antitumoural agents. The dimerisation product of caffeic acid methyl 
ester, dihydrobenzofuran (76), showed the best activity against leukemia and breast 
cancer cell lines. Dihydrobenzofuran (76) appeared to inhibit mitosis at µM 
concentrations in vitro, but it lacked activity in a hollow fiber in vivo assay, most likely 
due to enzymatic hydrolysis of the methyl esters or instability and ring opening of the 
dihydrobenzofuran ring (Apers et al., 2003).    
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Antitumor activities of other classes of lignans have been studied and reviewed over 
the years (Apers et al., 2003; Hahm et al., 2005; Kong et al., 2005; Konuklugil, 1994).  
These studies suggest that lignans might be valuable as antitumor compounds in 
chemical carcinogenesis – they can be sedative non-toxic agents for the inhibition of 
apoptotic agents. Lignans that inhibit Phospholipase Cγl (PLCγl), that plays a key role 
in the proliferation and progression of human cancer, are also suggested as worthy 
candidates for chemopreventative and chemotherapeutic agents (Saleem et al., 
2005).   
 
There is also growing evidence that the consumption of foods rich in lignans (viz. 
wheat, oats, beans, lentils, garlic, broccoli and carrots) can decrease the risk of 
developing certain forms of cancer. For instance, the lignans may contribute towards 
the prevention of breast cancer as a result of their antiestrogenic properties whereby 
they interact with the estrogen receptor and modulate the action of estrogen. 
Alternatively they may act as antioxidants and prevent the production of carcinogens 
from estrogen, or they may inhibit aromatase enzyme activity and thereby contribute 
to the prevention of hormone dependent cancers (Ward, 1999).  
   
4.1.2 Antiviral Activity 
Several modes of antiviral activity are associated with lignans: tubulin binding 
(inhibition of tubulin polymerization interferes with the formation of the cellular 
cytoskeleton and with some critical viral processes), reverse transcriptase inhibition, 
intergrase inhibition, and topoisomerase inhibition. While podophyllotoxin and its 
derivatives were the most prominent representatives of the tubulin binding lignans, 
inhibition of reverse transcriptase was observed for various classes of lignans, such 
as dibenzylbutyrolactones, dibenzylbutanes, dibenzocyclooctadienes and arylteralins 
(Charlton, 1998). Dibenzylbutyrolactones derived from arctigenin (77) were active 
inhibitors of viral integrase.   
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The Na and K salts of (78) and (79), which are known tetramers of caffeic acid, have 
been isolated from Arnebia euchroma and shown to possess potent anti-HIV activity 
(Kashiwada et al., 1995).  
 
 
 
 A number of lignans isolated from Larrea tridentata including nordihydroguaiaretic 
acid (80), were found to suppress HIV-I replication in infected cells. A series of 
methylated derivates were prepared and the tetramethyl nordihydroguariaretic acid 
(81) was more active than the original lead (Hwu et al., 1998). This derivative, as well 
as the tetraacetyl nordihydroguariaretic acid (82), was found to be useful in the 
treatment of papillomavirus infections and their associated induced human cancers 
(Craigo et al., 2000).     
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4.1.3 Antiparasitic Activity 
As antiparasitics, lignans and neolignans have mostly been tested against 
Trypanosoma cruzi, the causative agent of Chagas‟ disease (Bastos et al., 1999; 
Cabral et al., 1999; Cabral et al., 2010; Cherigo et al., 2005; da Silva Filho et al., 
2004; Lopes et al., 1998; Luize et al., 2006; Martins et al., 2003; Nocito et al., 2007).  
 
Lopes et al (1998) demonstrated the potential of the tetrahydrofuran lignans, grandsin 
(83) and veraguensin (84), from Virola surinamensis twigs to prevent the transmission 
of T. cruzi by blood transfusion. The compound (-)-methylpluviatolide (85), isolated 
from the hexane extract of the leaves of Zanthoxyllum naranjillo, was highly effective 
against T. cruzi in vitro and against the bloodstream forms of the two strains in vivo. 
Healthy animals injected with (-)-methylpluviatolide did not develop infection pointing 
to potential use in chemoprevention (Bastos et al., 1999). In an in vitro evaluation of a 
series of 8-O-4‟-neolignans based on those isolated from the Myristicaceae family, 
Nicoto et al ( 2007) identified compound (86) (3,4-methylenedioxi-7-oxo-1‟-allyl-3‟,5‟-
dimethoxy-8-O-4'-neolignan) as having promising trypanocidal activity.  
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8-O-4‟-Neolignans were also shown to have effects against Leishmania donovani, 
one of the causative agents of leishmaniasis. Based on the active principles isolated 
from Virola surinamensis, surinamensin (87) and virolin (88), a series of compounds 
with ether linkages and their corresponding C-8 sulfur and nitrogen analogues were 
synthesized and evaluated in vitro. The highest selective activity against amastigotes 
was found in those compounds with sulfur bridges, suggesting that the C-8 sulfur 
bond may be a key pharmacophore in their antileishmanial activity. Of these, only 
compound (89), (3,4-dimethoxy)-8-(4'-methyl-thiophenoxy)-propiophenone), was 
significantly active in vivo, resulting in 42% inhibition of L. donovani amastigotes in 
the liver of infected mice at  a dose of 100 mg/kg orally once a day over 5 consecutive 
days (Barata et al., 2000).        
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A norlignan isolated from Asparagus africanus, (+)-Nyasol (90), was shown to 
potently inhibit the growth of Leishmania major promastigotes (IC50 12 μM) and 
moderately inhibit Plasmodium falciparum schizonts (IC50 49 μM) (Oketch-Rabah et 
al., 1997). Moderate antiplasmodial activities have also been reported for the 8,5‟-
linked lignan dehydrodiconiferyl dibenzoate (91) (IC50 12 μM; D6) isolated from the 
roots of Euterpene precatoria (Jensen et al., 2002), and an arylnaphthalide lignan, 
justicidin B (92) (IC50 > 5.0 µg/ml; 3D7), obtained from Phyllanthus piscatorum 
(Gertsch et al., 2003). 
 
 
 
8-O-4'-Neolignans which have shown antiplasmodial activity include polysyphorin (93) 
(IC50 0.4 µg/ml; D6) isolated from Rhaphidophora decursiva (Zhang et al., 2001) and 
rourinoside (94) (IC50 3.7 µM; D6) from Rourea minor (He et al., 2006). Antimalarial 
properties have also been reported for sesquilignans (Kraft et al., 2002), aryltetralone 
lignans (de Andrade-Neto et al., 2007) and tetrahydrofuran lignans (da Silva Filho et 
al., 2004).  
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4.2 In vitro Antiplasmodial Activity of Dadahol A and B 
Although dadahols A and B were originally isolated from an A. dadah twig extract by 
activity-guided fractionation using a cyclooxygenase-1 (COX-1) inhibition assay, they 
were found to be inactive (IC50 > 100 µg/ml) against both COX-1 and COX-2 (Su et 
al., 2002). Therefore, this is the first report of the compounds having any biological 
activity. Dadahol B, 8A, and the two diastereomers of dadahol A (8Ci and 8Cii) were 
isolated from T. orientalis via bioassay-guided fractionation using antiplasmodial 
activity against a chloroquine-sensitive (D10) strain of P. falciparum as the biological 
indicator (Figure 2.6). These compounds were subsequently bioassayed against the 
K1 strain to determine relative activity in a drug resistant strain, and against a 
Chinese Hamster Ovarian (CHO) cell line, as a measure of cytotoxicity and selectivity 
(Table 4.1).  
 
Natural products 8A, 8Ci and 8Cii were significantly active against the chloroquine-
sensitive strain of the parasite with IC50‟s of 0.8 µg/ml (1.2 µM), 0.4 µg/ml (0.5 µM) 
and 0.5 µg/ml (0.7 µM); respectively. The resistance index (RI) gives an indication of 
the relative activity of the compounds in a drug resistant and sensitive strain of P. 
falciparum. The lower the RI value, the greater the likelihood that the compound will 
be effective against the resistant strain. The RI values of all three compounds were 
significantly lower than that of the chloroquine control.  
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Table 4.1 In vitro antiplasmodial activity of natural compounds against the D10 and 
K1 strains of P. falciparum and cytotoxicity against CHO cells 
Compound 
D10: IC50 
(µg/ml) 
K1: IC50 
(µg/ml) 
CHO: IC50 
(µg/ml) 
RI SI 
(D10) 
8A 
Dadahol B 0.8 1.1 71.8 1.4 90 
8Ci 
Dadahol A 
(erythro) 0.4 0.6 88.3 1.5 221 
8Cii 
Dadahol A 
(threo) 0.5 0.8 74.3 1.6 149 
Emetine     0.05     
Chloroquine 0.015 0.13 18.5 9  1233 
 
Selective index (SI) = IC50 CHO / IC50 D10 
Resistance index (RI) = IC50 K1 / IC50 D10 
 
The selectivity index (SI) is a ratio of cytotoxicity to antiplasmodial activity and gives a 
general indication of the specific activity. The greater the SI value, the greater the 
potential therapeutic window. The erythro and threo forms of dadahol A (8Ci and 8Cii; 
respectively) showed limited cytotoxicity at the active concentrations (SI > 100). 
Dadahol B (8A), which was a mixture of the two diastereomeric forms, was shown to 
be relatively less active and selective than the dadahol A diastereomers despite 
differing from them by just one less methoxy group in the B ring. This observation and 
the fact that polysyphorin (93) and rourinoside (94), which both have reported 
antiplasmodial properties (He et al., 2006; Zhang et al., 2001), also possess methoxy 
groups in the C-3' and C-5' positions of the B ring suggesting that this di-methoxy 
substitution is a key pharmacophore for antiplasmodial activity of 8-O-4 neoligans.  
 
In considering basic criteria for antiparasitic drug discovery (Pink et al., 2005), a 
compound can be considered a hit if it is: 
 Active in vitro against whole protozoa with an IC50 of ≤1 µg/ml  
 Selective (at least tenfold more active against the parasite than against a 
mammalian cell line)  
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Based on this, dadahols A and B can be considered antiplasmodial hit compounds. 
The identification of antiplasmodial 8-O-4 neolignans from T. orientalis suggests that 
these molecules may play a role in the medicinal properties of the plant. Although 
their activity does not compare to chloroquine (IC50 0.03 µM), the basic dadahol 
structure does provide an attractive scaffold for chemical modification with the aim of 
exploring structure-activity relationships and possibly improving overall activity and 
selectivity.      
 
4.3 In vitro Antiplasmodial Activity of Synthetic Precursors and Analogues of 
Dadahol B 
The diastereoselective synthesis of dadahol B (Chapter 3) resulted in several 
synthetic precursors and related compounds that were subjected to biological 
assaying, to provide some insight into structure activity relationships (Figure 4.1). The 
natural product 8A was rescreened with the synthesised dadahol B diastereomers 
and analogues to compensate for batch to batch variation. Bioactivity was measured 
against the chloroquine-sensitive D10 strain of P. falciparum 
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Figure 4.1 In vitro antiplasmodial activity of synthetic precursors and analogues of 
dadahol B against the D10 strain of P. falciparum. Average IC50 of chloroquine = 
0.016 µg/ml.  
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The monolignol, coniferyl alcohol (37), did not show any activity (IC50 >100 µg/ml); 
and of the three oxidative coupling products (DHCA, pinoresinol and GGCE), the β-5 
coupling product (38) showed the best antiplasmodial activity (IC50 5.97 µg/ml). 
GGCE (40), which forms the core of the natural product, did not show any significant 
activity in either of its diastereomeric forms. This suggests that the p-coumaryl groups 
are essential components for the antiplasmodial properties of dadahol B. However p-
coumaric acid (41) itself was shown to be inactive (IC50 >100 µg/ml).    
 
Cinnamic acid derivatives (CAD‟s) have been reported to arrest growth of all stages 
of intraerythrocytic P. falciparum in culture, in direct correlation with their hydrophobic 
character. But their application as antimalarial agents has been limited by their 
inherent toxicity – it has been observed that CAD‟s may inhibit some process in the 
host cell whose function is vital for parasite growth (Kanaani and Ginsburg, 1992). 
CAD‟s may inhibit ATP production in the parasite and its utilization by the host cell.  
 
Rescreening of the natural product, dadahol B 8A, resulted in a much higher IC50 
(3.39 µg/ml) compared to its original bioassay result (IC50 0.8 µg/ml). The pLDH assay 
generally gives reproducible results (Makler et al., 1993; Persson et al., 2006) and 
besides inter-assay variation based on different technicians conducting the assay and 
standard human error; this marked difference in activity can only be attributable to 
chemical instability or insolubility of the natural product in the culture medium. Due to 
the hydrophobic properties of dadahol B, it is likely to precipitate out of solution in the 
bioassay culture medium and the effective concentration will therefore vary with 
different rates of precipitation. In order to validate the original activity of the natural 
products, they were screened in an independent laboratory at the London School of 
Hygiene and Tropical Medicine and activity of both natural products was confirmed to 
be < 1 µg/ml against a chloroquine-sensitive (3D7) and chloroquine-resistant (K1) 
strain of P. falciparum.    
 
The threo form of dadahol B, 8Ai, was found to be relatively more active (IC50 1.96 
µg/ml) than the erythro form (8Aii) (IC50 3.36 µg/ml). Of the various synthesized 
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monoesters, only the threo 9'-monoester (68) showed antiplasmodial activity (IC50 
3.28 µg/ml) comparable to the natural product (IC50 3.39 µg/ml). Activity is lacking if 
just the 9-OH position is esterified, as in (67) and (69), suggesting that this p-
coumaryl group might not be a key pharmacophore of dadahol B. But if the phenolic 
or allylic position is also esterified, as in (70) and dadahol B 8A, the antiplasmodial 
activity is more significant.  
 
4.4 In vivo Antiplasmodial Activity of Dadahols A and B 
In order to isolate sufficient quantities of dadahols A and B for in vivo biological 
evaluation, a targeted purification based primarily on liquid/liquid partitioning and flash 
silica gel chromatography was undertaken on the 1:1 DCM/MeOH extract (P05644-
5B) of the twigs of T. orientalis. This yielded 80 mg (0.38% w/w of dry plant material) 
of dadahol B and 50 mg (0.25% w/w of dry plant material) of dadahol A. The 
compounds were isolated and evaluated as mixtures of the threo and erythro isomers 
due to challenges in completely resolving or stereoselectively synthesizing sufficient 
quantities of the individual diastereomers.     
 
Dadahols A and B were evaluated for in vivo antiplasmodial activity against P. 
berghei using a 4-day suppressive test. The compounds were administered by 
subcutaneous injection at a dose of 100 mg/kg. The survival rate of the mice is 
summarized in Figure 4.2.  
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Figure 4.2 The survival rate of mice in each group after infection with P. bergei ANKA  
 
In the control group, mortality was first observed on day 8. All the animals were dead 
on day 9. The two groups treated with dadahols A and B showed poor survival rate, 
with only 60% survival rate on day 8 and 100% mortality by day 10. All mice in 
chloroquine group survived for the duration of the experiment. There is no difference 
in the survival pattern between the treated groups and the control group, which shows 
that samples exhibited no antimalarial activity. Mice in the treated group also lost 
weight at more or less the same rate as the control group (Appendix VII), indicating 
that the treated mice were still sick.  
 
The chloroquine group had an unusually high parasitemia of 3.7% on day 4 and even 
higher on day 6, reaching 5.1% (Figure 4.3). The parasitemia in the chloroquine 
treated group is usually maintained below 2% up to day 8-10. Nonetheless, the 
average percentage parasitemia in each treated group on day 6 was significantly high 
and more comparable to the control (untreated) group than the chloroquine treated 
group.  
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Figure 4.3 The average percentage parasitemia in each group at any given day after 
infection  
 
The parasitemia reduction by each test compound is compared with that of 
chloroquine (Table 4.2). On day 4, the average percentage parasitemia reduction in 
the treated groups was comparable to the chloroquine group, but by day 6 the 
parasitemia reduction was significantly lower in the experimental groups compared to 
the choloroquine control group. This suggests that the antiplasmodial effect of the 
compounds does not last past the 4 days that the mice are treated. Dadahol B 
showed better parasite reduction than dadahol A on day 6, but overall the natural 
products showed poor antimalarial properties in vivo compared to chloroquine.   
 
Table 4.2 The average % parasitemia and % reduction on Days 4 and 6 
Group 
Day 4 Day 6 
Parasitemia (%) Parasitemia 
percentage 
reduction (%) 
Parasitemia (%) Parasitemia 
percentage   
reduction (%) 
Control 8.8  25.5  
Dadahol A 3.9 56.7 23.6 8.1 
Dadahol B 5.0 42.2 17.5 31.6 
Chloroquine  3.7 57.9 5.1 80.0 
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The in vivo results for dadahol A and B do not compare with that of the semi-purified 
T. orientalis extract (P05644-4B) previously evaluated (Chapter 2). The extract 
prolonged the survival period of treated mice and increased their tolerance to high 
parasitemia levels, indicative of a possible immune stimulant effect. Although 
dadahols A and B were relatively major components of this semi-purified extract 
(Appendix I), they were isolated through bioassay-guided fractionation based on in 
vitro antiplasmodial activity (which is not related to any possible immune stimulating 
effect), and it is possible that these were not the compounds responsible for the in 
vivo properties of the extract.  As is often the case with medicinal plant extracts, the 
observed result could have been due to a synergistic effect of several components in 
the extract or more importantly the components of the extract could have been 
metabolized in vivo into metabolites with immune stimulating properties.      
 
4.5 Pharmacokinetic Properties of Dadahols A and B 
Pharmacokinetics (pK) describes the time course of a drug on entry into the body to 
its eventual excretion. It includes the study of the mechanisms of absorption and 
distribution of an administered drug/substance, the rate at which drug action begins 
and the duration of the effect, the chemical changes of the substance in the body 
(e.g. by CYP or UGT enzymes) and the effects of excretion of the metabolites of the 
drug/substance (Benet, 1984).    
 
Pharmacokinetics is subsequently divided into several areas including the extent and 
rate of absorption, distribution, metabolism and excretion. This is commonly referred 
to as the ADME scheme. Since up or down regulation of these processes has been 
associated with the toxicity of many drugs, the study of ADME has been strongly 
connected to that of toxicology, hence the acronym, ADMET.  
 
Most drugs are administered orally for the sake of convenience and compliance. 
Typically, a drug dissolves in the gastro-intestinal tract, is absorbed through the gut 
wall and then passes the liver to get into the blood. The percentage of the dose 
reaching blood circulation is called the bioavailablity. From there, the drug is 
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distributed to various tissues and organs in the body. The extent of distribution will 
depend on the structural and physiochemical properties of the compound. Some 
drugs can enter the brain and central nervous system by crossing the blood-brain 
barrier. Ultimately the drug will bind to its molecular target (viz. a receptor or ion 
channel) and exert its desired action.  
 
Dadahols A and B had significant in vitro antiplasmodial activity but showed poor 
overall efficacy in a mouse model, suggesting that the compounds may have poor 
pharmacokinetic properties. In order to confirm this, the compounds were 
administered subcutaneously at a dose of 10mg/kg to healthy mice and blood 
samples were collected at relevant time intervals. Test compounds were 
subsequently extracted and levels were determined by LC-MS/MS. The test 
compound levels in mice were erratic and below the limit of quantification at several 
of the measured time points (Tables 4.3 and 4.4).  
 
Table 4.3 Levels of Dadahol A in mice blood samples  
Time (hour) M1 (ng/ml) M2 (ng/ml) M3 (ng/ml) 
0 0 0 0 
0.5 21.1 BLQ 15.7 
1.0 17.2 8.44 10.9 
2.0 BLQ 14.1 25.7 
5.0 46.9 25.6 BLQ 
8.0 BLQ BLQ 12.5 
 
 
Table 4.4 Levels of Dadahol B in mice blood samples  
Time (hour) M1 (ng/ml) M2 (ng/ml) M3 (ng/ml) 
0.0 0 0 0 
0.5 BLQ BLQ 13.1 
1.0 31.3 11.0 9.26 
2.0 24.5 20.2 26.8 
5.0 BLQ BLQ BLQ 
8.0 BLQ BLQ BLQ 
BLQ = below limit of quantification 
 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
104 
 
Levels of the natural products in mice were too low for PK analysis and modeling. The 
relatively low levels of the compounds in the animal samples might be an indication 
that these compounds are metabolized rapidly in vivo. This is most likely due to non-
specific enzymatic cleavage of the p-coumaryl esters. The poor PK properties of 
Dadahols A and B explain their poor overall efficacy in a mouse model. 
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CHAPTER 5 
Analogues of DHCA and GGCE 
5.1 Biological Properties of DHCA and GGCE 
One-electron oxidation of the monolignol, E-coniferyl alcohol (37), results in “random” 
bimolecular radical coupling to afford initially dimeric products – the (±)-
dehydrodiconiferyl alcohols (DHCA) (38), (±)-pinoresinols (39), and (±)-
guaiacylglycerol 8-O-4'-coniferyl alcohol ethers (GGCE) (40) (Scheme 5.1).  
 
 
 
Scheme 5.1 Bimolecular phenoxy radical coupling products from E-coniferyl alcohol.  
 
GGCE and its analogues have not shown any significant bioactivity while analogues 
of the benzofuran DHCA have been reported to have antioxidant (Takara et al., 
2000), anti-cancer (Binns et al., 1987; Lee et al., 2007a; Lynn et al., 1987), 
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antiatherogenic (Rakotondramanana et al., 2007), antileishmanial (Miert et al., 2005) 
and anti-Helicobacter pylori (Hu and Jeong, 2006) activity. Analogues of DHCA which 
showed antiplasmodial activity include dehydrodiconiferyl dibenzoate (95) (Jensen et 
al., 2002), the gallate derivatized dihydrobenzofuran analogue (96) 
(Rakotondramanana et al., 2007), and dimerisation products of lipophylic esters of 
caffeic acid such as compound (97) (Miert et al., 2005) (Figure 5.1).  
 
DHCA (38) showed better initial antiplasmodial activity than GGCE (40) (Scheme 5.1) 
and was therefore considered as an alternative scaffold for derivatisation. The 
similarity between the core of DHCA and highly active antiprotozoal bisamidine 
analogues such as (98), which gave an IC50 of 6 nM against the chloroquine resistant 
K1 strain of P. falciparum (Bakunov et al., 2008), added t  its attractiveness as a 
scaffold for analogue generation.   
 
Figure 5.1 Antiplasmodial activities of benzofuran analogues 
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5.2 Approaches to Derivatisation of DHCA 
Based on literature precedent on antiplasmodial pharmacophores, synthetic and 
medicinal chemistry approaches, and making use of readily available organic 
reagents, a series of analogues based on DHCA (38) were considered with the aim of 
not only improving bioactivity but also to study and compare selected synthetic 
routes, derivatisation techniques and substitution effects.    
  
The two approaches selected for analogue generation were:  
 Optimisation of the ester moiety by preparing a range of esters from cinnamic acid 
derivatives (Kanaani and Ginsburg, 1992) and related bulky acids with known 
biological properties      
 
 
 
 
 Optimisation of the aromatic moiety using a range of readily available aromatic 
aldehydes with alternative substituents 
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5.3 Auto-oxidation Products of DHCA and GGCE  
Upon standing, the allylic alcohols of DHCA (38) and GGCE (40) were observed to 
gradually undergo spontaneous oxidation to their aldehyde forms, (99) and (100); 
respectively (Scheme 5.2). Although compound storage under nitrogen significantly 
reduced this conversion, it was still necessary to remove traces of the auto-oxidation 
products by column chromatography prior to major processes and reactions (viz. 
GGCE diastereomer separation). Traces of auto-oxidation products were also 
observed as by-products during preparation and synthesis of analogues of (38) and 
(40).  
 
 
 
Scheme 5.2 Auto-oxidation products of DHCA and GGCE 
 
Biological assaying of the auto-oxidation products revealed that the aldehydic form of 
DHCA (99) had reduced antiplasmodial efficacy (IC50 14.38 µg/ml) while that of 
GGCE (100) showed improved activity (IC50 12.97 µg/ml) relative to the parent 
compounds.  
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5.4 Alternative Preparation of DHCA 
In order to produce additional quantities of the benzofuran DHCA (38) for 
derivatisation, an alternative synthesis (Scheme 5.3) was adopted using more readily 
available reagents ferulic acid (101) as the starting material and silver(I) oxide as the 
oxidant. In dichloromethane, DHCA (38) was the only major product and the yield was 
increased to over 20% (as opposed to the 10 -15 % yield obtained using the 
expensive and condition-dependent peroxidase).  
 
 
 
Scheme 5.3 Alternative synthe is of DHCA  
 
 
In order to further improve on this yield, N,N-dimethylformamide (DMF) was 
investigated as an alternative solvent for the oxidative coupling reaction. However, in 
DMF the reaction yielded a mixture of products (Scheme 5.4), with compound (102) 
being a major product (8% yield). NMR analysis revealed that (102) was also a 
mixture of diastereomers and was closely related to GGCE, with a methoxy group in 
the 7-position. DMF promotes β-O-4 coupling and the β-O-4 quinone methide 
intermediate (Chapter 3; Scheme 3.5) most likely picked up a methoxy ion from 
impurities in the solvent. Trace quantities (1.4%) of the aldehyde (103) form of (102), 
were also recovered. Neither of these GGCE analogues showed any antiplasmodial 
activity. DHCA (38) and its aldehyde (99), were also isolated in comparable yields. 
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However, dichloromethane was reverted to as the solvent of choice for scale-up 
preparation of DHCA.      
 
 
 
Scheme 5.4 Silver(I) oxide dimerisation of coniferyl alcohol in DMF 
 
5.5 Acid Chloride Esterification of DHCA 
Reaction of DHCA with p-nitrobenzoyl chloride yielded the triester, (104) and the 
diester (105) (Scheme 5.5.). The high reactivity of the benzoyl chloride resulted in 
consumption of the acyl chloride and non-selective esterification at multiple sites. The 
p-nitrobenzoyl esters were fairly inactive relative to DHCA.   
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Scheme 5.5 Esterification of DHCA with p-nitrobenzoyl chloride 
 
 
To assess if this reactivity will be the same for any acyl chloride, the acid chloride of 
cinnamic acid was prepared by reaction with oxalyl chloride (106) and a catalytic 
amount of DMF. The resulting Vilsmeier-Haack reagent (107) reacts with the acid (51) 
to give cinnamoyl chloride (52) (Scheme 5.6).   
 
 
 
Scheme 5.6 Vilsmeier mechanism for cinnamoyl chloride formation 
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The reaction of one equivalent of cinnamoyl chloride (52) with DHCA (38) in the 
presence of triethylamine (Et3N) led to a single fair yielding product (108) (Scheme 
5.7.). NMR analysis revealed that there was no significant change in chemical shift of 
H-9 or H-9' in the proton NMR and no correlation was observed between the ester 
carbonyl and H-9 or H-9' in the HMBC. It was subsequently established that 
esterfication had occurred at the phenolic position. The deprotonation of the phenolic 
moiety of DHCA results in phenolate anions that are acylated in preference to the less 
acidic 9- and 9'-hydroxyls. This selectivity could not be altered by attempts to vary the 
reaction solvent, temperature or stoichiometry. Therefore the phenolic position would 
have to be protected in order to selectively esterify the other hydroxyls.   
 
 
 
Scheme 5.7 Reaction of DHCA with cinnamoyl chloride 
 
The 4-cinnamoyl analogue of DHCA (108) showed comparable antiplasmodial activity 
(IC50 3.96 µg/ml) to the parent compound (38) (IC50 5.97 µg/ml).   
 
5.6 Protection of the DHCA Phenol 
In order to circumvent the higher reactivity of the phenolic moiety of DHCA, it needed 
to be protected prior to reaction with the acid chloride. Silylation was considered as 
the preferred route due to the convenience of tetra-n-butylammonium fluoride (TBAF) 
deprotection and the sensitivity of the substrate to harsher deprotection methods, 
such as acid hydrolysis and hydrogenation.  
 
Reaction of DHCA with 1.1 equivalents of tert-butyldimethylsilyl chloride (TBS-Cl) 
resulted in silylation of the primary hydroxyl groups in preference to the phenol to 
yield the silyl ethers (109) and (110) (Scheme 5.8) in low yield. Bases such as 
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imidazole are expected to complex with the most acidic, less hindered phenols and 
alcohols but in this instance, it is the allylic alcohol which is the preferred site for 
silylation. This selectivity to silylation was confirmed with a selection of alternate 
bases (2,6-lutidine and Et3N) in the presence of a catalytic amount of 4-
(dimethylamino)-pyridine (DMAP) at 0 °C. An alternative protective group, the 
tetrahydropyranyl (THP) group was also found to react exclusively at the allylic 
alcohol position. 
   
 
Scheme 5.8 Silyl protection of DHCA 
   
A subsequent literature survey on the regioselective protection of hydroxylalkyl 
phenols confirmed that silyl and tetrahydropyranyl ethers are selectively formed at the 
hydroxyalkyl positions (Ballini et al., 1997; Sefkow and Kaatz, 1999). Perfluoroaryl 
derivatives, allyl bromide (van der Leij et al., 1981), t-butyoxycarbonyl (Boc) 
anhydride (Houlihan et al., 1985), acetylimidazole (Hagiwara et al., 1998) and trityl 
chloride (Sefkow and Kaatz, 1999) have all been used to selectively protect phenol 
groups. Most of these procedures required specialized reagents and conditions or 
harsh deprotection methods.  
 
An attempt to use trityl chloride to selectively protect the phenolic position of DHCA 
proved successful, yielding the trityl ether (111) in 55% yield (Scheme 5.9). However 
scale-up attempts resulted in a mixture of tri- and di-trityl ethers which were difficult to 
separate. Deprotection also proved challenging, with even the most facile methods 
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recommended for acid-sensitive compounds (Pathak et al., 2001), resulting in 
complex mixtures of decomposition and rearrangement products.   
 
 
 
Scheme 5.9 Trityl protection of DHCA   
 
5.7 Alternative Esterification Techniques  
With phenolic protection proving unsuccessful, the next approach was to consider 
alternative esterification techniques.  
 
The Mitsunobu esterification has been reported to be successfully applied to the 
chemoselective esterification of polyphenolic acids with polyphenolic alcohols 
(Appendino et al., 2002). However, no reaction was observed between DHCA (38) 
and gallic acid (112) under reported conditions (Scheme 5.10) and variations thereof 
(viz. longer reactions times, heating, and sonication).   
 
   
 
Scheme 5.10 Mitsunobu reaction between DHCA and gallic acid 
 
In assessing other typical condensing agents used in ester synthesis, trifluroacetic 
anhydride also proved unsuccessful, while dicyclohexylcarbodiimide (DCC) coupling 
(Stechlich esterification) between DHCA (38) and silylated p-coumaric acid (66) in the 
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presence of DMAP resulted in esterification primarily at the 9-OH and 4-OH positions 
(Scheme 5.11) to yield the monoesters (113) and (114).  
 
 
 
Scheme 5.11 DCC coupling between DHCA and protected p-coumaric acid 
 
As with GGCE (40) (cf Chapter 3), CDI coupling proved the most selective in yielding 
a range of different possible esters. The reaction between DHCA (38) and cinnamic 
acid (51), yielded the tricinnamoyl (115), the 9,9'- (116) and 4,9'- (117) dicinnamoyl 
and the 9- and 9'- cinnamoyl analogues [(118) and (119); respectively] (Scheme 
5.12). Here too, the reaction was slow with poor rates of recovery. However, the 
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products were separable and sufficient in yield for characterisation and bioassaying. 
Only the 9,9'-dicinnamoyl analogue (116) showed comparable activity to the parent 
compound, DHCA (38) (IC50 5.97 µg/ml).   
 
 
Scheme 5.12 CDI coupling between DHCA and cinnamic acid 
 
CDI coupling between DHCA (38) and silylated caffeic acid (120) resulted in just one 
product in low yield (Scheme 5.13). NMR analysis revealed that this was a mixture of 
the 9- and 9'-caffeoyl mono-esters (121) and that, as previously observed, the silyl 
groups had been removed during the course of the reaction. The mixture was 
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inseparable and the antiplasmodial activity of this mixture of caffeoyl esters was found 
to be equivalent to that of the parent compound, DHCA (38).  
 
 
 
Scheme 5.13 CDI coupling between DHCA and protected caffeic acid 
 
5.8 Alternative Routes to Esterification  
Alternative routes to esterification of DHCA (38) were also investigated to circumvent 
susceptibility of protective groups and low yields achieved from CDI coupling.  
 
5.8.1 Oxidative Coupling of Coniferyl Alcohol Esters 
Based on the approach of Miert et al. (2005), who synthesized a series of 
dihydrobenzofuran lignans by oxidative dimerisation of caffeic acid esters (122), the 
oxidative coupling of esters of coniferyl alcohol (123) was considered as an 
alternative route to preparing esters of DHCA (Scheme 5.14).  However, the selective 
esterification of the 4-OH (as opposed to the desired 9-OH)  position of coniferyl 
alcohol (37), as well as challenges associated with oxidative coupling of bulky 
hydroxylated (viz. coumaroyl) ester substituents, made this approach impractical.     
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Scheme 5.14 Alternative approach to DHCA esterification based o  oxidative 
coupling of caffeic acid esters 
 
5.8.2 Oxidative Coupling of Ethyl Ferulate 
A second approach was based on the oxidative coupling of the precursor ethyl 
ferulate (42) to yield the dimer (124), which could then be protected as the silyl ether 
(125), before reduction to the diol (126), and subsequent esterification to afford the 
three silyl esters [(127) – (129)], which could each then be deprotected to yield the 
desired 9,9'-dicoumaroyl analogue (130), the 9'-coumaroyl analogue (131) and the 9-
coumaroyl analogue (132) (Scheme 5.15).  
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Scheme 5.15 Esterification of DHCA via ethyl ferulate coupling 
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HO;ce 
~Co,EI 
(42) MeO 
"'" OEI 
OMe 
(124), 12.3% 
TBSO 
IC .. = 61.921lf1/ml (010) j 1.2 equiv. TBS-CI 2 equiv. Imidazole 0.05 equiv. OMAP OCM 
-."'OEI 0 O-~ 
OEI 
MeO OMe 
(125),95% 
!3.6 equiv. OIBAL-H -78'C OCM 
/OH 
~OH 
TBSO. Y b-Y 
MeO OMe 
(126),8% 
TBSO~COCI , EI,N, THF, rt 
o 0 
o.Jl.""'D OTBS [""'y0TBS OH OTBS o.Jl.""'<i OTBS ~~~~
TBSO· Y by 0 TBSO Y by 0 TBSO _y by '129' 
MeO OMe MeO OMe MeO OMe ( ) "~ "~ !3~ I 4 equiv. ~3 equiv. TBAFfTHF 
• TBAFfTHF TBAFfTHF 
o 0 :O~OH (y0H {OH (y0H :O~OH ~O~~O~~OH 
HO Y by 0 HO Y by 0 HO Y by 
MeO OMe MeO OMe MeO OM. 
(130),14% (132),1.6% 
IC
50 
= 19.30 IlfI/ml (010) (131),8% IC
50 
= 5.751lf1/ml (010) 
IC50 = 1.30 IlfI/ml (010) 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
120 
 
The DIBAL reduction step resulted in low yields (17%) of the 4-O-silyl ether of DHCA 
(126). The major products were found to be mixtures of rearrangement products such 
as the enol ether (133) (Scheme 5.16), which following deprotection to (134) was 
shown by NMR to lack the furan ring and contain an additional double bond.  
 
 
 
Scheme 5.16 Proposed ring opening mechanism leading to enol ether by-product 
 
Ethyl ferulate (42) has been successfully reduced to coniferyl alcohol (37) using 
DIBAL-H in yields as high as 90% (Hu and Jeong, 2006). Therefore, it is most likely 
the conformational changes in the benzofuran afforded by the silyl group of the 
protected ethyl ferulate dimer (125) and its reduction product (126), that exposes the 
furan moiety to ring opening side reactions. An electron withdrawing protective group 
(viz. tosylate) or a more inert reaction solvent (viz. toluene) might have helped 
improve yields; however the recovered product was sufficient to investigate the 
approach using at least two ester functionalities.   
 
The piperonylic esters (135) and (136) were subsequently also prepared (Scheme 
5.17) from the 4-O-silyl ether of DHCA (119). In this case it appears that some 
deprotection had occurred during the esterification process to afford the 4,9,9'-
tripiperonylic analogue (136).  
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Scheme 5.17 Piperonylic ester synthesis  
 
As the p-coumaric substituents of dadahol B was shown to contribute to the natural 
product‟s antiplasmodial properties, it was surprising to find that the corresponding 
9,9'-dicoumaroyl analogue of DHCA (130) was relatively inactive (IC50 19.30 µg/ml), 
even though DHCA (38) had better activity (IC50 5.97 µg/ml) than the dadahol B core 
structure, GGCE (40) (IC50 77.96 µg/ml). On the other hand, the 9-monoester (132) 
was equipotent (IC50 5.75 µg/ml) while the 9'-monoester (131) showed improved 
activity (IC50 1.30 µg/ml) relative to the parent compound, DHCA (38) (IC50 5.97 
µg/ml). Both the piperonylic esters, (135) and (136), lacked any antiplasmodial activity 
at the maximum concentration tested. 
 
5.9 DHCA and GGCE Ring Substitution 
Changing the substituents on the aromatic rings of DHCA (38) was targeted to assess 
how this would affect the antiplasmodial activity of the dimer. A range of substituted 
monolignols were synthesised from readily available benzaldehydes (as for coniferyl 
alcohol: Chapter 3; Figure 3.9). These were subsequently subjected to oxidative 
coupling using the HRP/H2O2 oxidant system to yield substituted DHCA and GGCE 
analogues (Scheme 5.18).   
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Reaction yields indicated that electronic and steric effects of substituents may 
influence the oxidative coupling as yields of the β-5 dimer were relatively high despite 
the reaction conditions favouring β-O-4 coupling. No real conclusions can be drawn 
on the electronic and steric effects of the substitutents on the rate of oxidative 
coupling as the reaction of the ring activating ethoxy-  (137) and electron withdrawing 
bromo- (139) substituted monolignols proceeded quickly to conclusion while, with the 
unsubstituted (138) and electron withdrawing nitro- (140) analogues, the reactions 
were slow and did not go to completion. A more detailed study using a broader range 
of substituents could be more useful in this respect but was beyond the scope of this 
study.     
 
 
Scheme 5.18 Oxidative coupling of mono-substituted coniferyl alcohol analogues 
 
With both ortho positions occupied, oxidative coupling of the dibromo-substituted 
monolignol (149) yielded only the threo (150i) and erythro (150ii) forms of the β-O-4 
dimer, which were easily separable by column chromatography (Scheme 5.19a). A 
probable explanation for the threo diastereomer (150i) forming in preference (64% 
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yield) to the erythro diastereomer (150ii) (8% yield), is that due to bulkiness of the 
bromo substituents and exerted conformational form of the β-O-4 dimer quinine 
intermediate (cf. Chapter 3, Schemes 3.5 and 3.6) the nucleophilic addition of water 
at C-8 occurs from the less hindered face. Similarly, due to the steric effects of the 
bulky methoxy substituents, the dimethoxy-substituted monolignol (151) yielded only 
the β-β coupling product, syringaresinol (152) (Scheme 5.19b).  
 
 
 
Scheme 5.19 Oxidative coupling of the disubstituted coniferyl alcohol analogues  
 
None of the substituted coniferyl alcohol, DHCA and GGCE analogues showed any 
significant antiplasmodial activity.   
 
 
5.10 Oxidative Cross-coupling 
An important extension of oxidative coupling is the coupling between two structurally 
different phenols (cross-coupling). The synthesis of dadahol A (8C), for instance, 
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would require the oxidative coupling of coniferyl alcohol (37) and sinapyl alcohol (151) 
to form the core 8-O-4 neolignan core.  
 
Oxidation of a mixture of two phenols can lead to a mixture of dimers of the individual 
phenols and cross-coupling products between the two phenols. When one phenol 
reacts faster than the other, for instance if it has a lower oxidation potential, 
dimerisation is favoured without formation of significant amounts of cross-coupling 
products (Syrjänen and Brunow, 2001).      
 
Using a relatively basic approach the more reactive phenol, sinapyl alcohol (151) 
(oxidation potential ~ 0.38) and the oxidant (H2O2) were added slowly to the reaction 
mixture containing excess of the less reactive phenol, coniferyl alcohol (37) (oxidation 
potential ~ 0.44) (Syrjanen and Brunow, 1998). This resulted in a mixture of low 
yielding products, including the sinapyl alcohol β-β coupled dimer (syringaresinol) 
(152), the β-5 cross-coupled product (153), the coniferyl alcohol coupled dimers, 
DHCA (38) and GGCE (40), and an inseparable mixture of the two cross- β-O-4-
coupled products (154) (Scheme 5.20).  
 
The yields of the cross-coupled products were low compared to the dimerization 
products, suggesting that slower modes of addition are required to promote cross-
coupling. One approach to suppressing dimerisation would be to diffuse the more 
reactive phenol through a dialysis membrane (Syrjänen and Brunow, 2001). However 
this study was limited to the demonstration of this cross-oxidative coupling process 
and the evaluation of the bioactivity of the major products. The β-5 cross-coupled 
analogue (153) was the only product which showed some level of antiplasmodial 
efficacy (IC50 8.27 µg/ml), in the same order of magnitude as that of DHCA (38) (IC50 
5.97 µg/ml).           
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Scheme 5.20 Oxidative cross-coupling between coniferyl alcohol and sinapyl alcohol 
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CHAPTER 6 
Conclusion 
 
Natural products and medicinal plants still remain an important starting point for drug 
discovery and the identification of novel template compounds. The historical success 
of natural products as antimalarials and the large number of structurally diverse plant-
derived compounds which have been shown to have antiplasmodial properties, 
provide justification for the continued effort in this area.   
 
The identification of neolignans with antiplasmodial properties from T. orientalis 
suggests that they may play a role in the medicinal properties of the plant. Although, 
the neolignans themselves were shown to have poor antimalarial properties in vivo, 
the extract as a whole demonstrated some ability to prolong survival despite high 
levels of parasitic infection, providing further evidence of the medicinal properties of 
the plant. An approach worth considering is the combination of the extract with 
effective antimalarial drugs (in vitro and in vivo) to see if any synergistic effect is 
observed with the combination treatment.  
 
The identification of dadahols A and B as the major compounds responsible for the 
observed antiplasmodial efficacy of the extract was confirmed by two bioassay-guided 
fractionation approaches using results from two independent screening laboratories 
(i.e. UCT‟s pLDH assay and Swiss TPH‟s 3H-hypoxanthine incorporation assay) as 
the biological indicator. The new accelerated “HPLC biogram” methodology allowed 
for early recognition of the active compounds in the complex plant extract, requiring 
considerably less time and material compared to the classical reiterative approach. 
However, the accelerated approach is more suited to the dereplication of known 
compounds with published accurate mass and UV maxima data and is dependent on 
access to regularly updated electronic databases.    
 
Although dadahols A and B are known compounds, this was the first report 
demonstrating any inherent biological activity. They were shown to have promising 
antiplasmodial activity (IC50 < 1 µg/ml) and selectivity (SI > 100) in vitro, but their lack 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
127 
 
of antimalarial activity in an animal model and their poor pharmacokinetic properties 
demonstrated in vivo, made them unsuitable for further development as potential 
antimalarial drug leads. The natural products did, however, provide opportunities to 
study different synthetic techniques and approaches as well as investigate various 
structure-activity relationships. Biomimetic oxidative coupling formed the basis of 
these studies, proving its usefulness in the exploitation and study of biologically active 
lignans and neolignans.  
 
The total diastereo-selective synthesis of dadahol B was demonstrated for the first 
time, allowing for the complete resolution of the proton NMR data of the threo and 
erythro forms. The 8-O-4´ neolignan core of dadahol B, i.e. GGCE, lacked 
antiplasmodial activity identifying the p-coumaroyl moieties (at the 9- and 9'-positions) 
as key pharmacophores of the natural product. The co-synthesis and bioassaying of 
the mono-esterified dadahol B analogues, revealed that the 9'-coumaroyl group 
contributed more to the bioactivity of the natural product than the ester at C-9.     
 
DHCA, a by-product of the oxidative coupling step, showed better initial activity than 
GGCE, and was subsequently also used as a scaffold for analogue generation. 
Despite the instability of DHCA and GGCE to basic derivatisation techniques and low 
reaction yields, a fair number of analogues with different ester and aromatic ring 
substituents were synthesized. CDI coupling was shown to be the most selective 
esterification technique, eliminating the need to selectively protect the phenol group of 
the substrate. A new approach based on the oxidative coupling of the ethyl ferulate 
precursor, was also shown to be useful in the synthesis of 9,9'-diesters of DHCA. The 
aromatic ring substituent was shown to affect the rate and regioselectivity of oxidative 
coupling, although a more detailed study using a broader pool of substituents will be 
required to draw more substantial conclusions on the substituent effects.    
 
None of the precursors, by-products or analogues synthesized in this study showed 
improved antiplasmodial activity relative to the natural products or chloroquine. 
However, opportunities exist to pursue with GGCE and DHCA as scaffolds for the 
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preparation of water-soluble derivatives (pro-drugs), which might result in more active 
and metabolically stable antimalarial lead compounds.    
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CHAPTER 7 
Experimental 
 
7.1 Plant Material  
T. orientalis plant material was first collected in October 2001 between Darnall and 
the Tugela River mouth on the KwaZulu-Natal North coast (GPS co-ordinates: 31 23 
307 E 29 14 66 S).  The collection was undertaken by an independent plant collector 
contracted by the CSIR. Voucher specimen (BP00908) of the aerial plant parts was 
identified as T. orientalis (Linn.) Blume and retained at the South African National 
Biodiversity Institute (SANBI) Herbarium in Pretoria.     
 
Permit applications were made to the KwaZulu-Natal Nature Conservation Board for 
subsequent recollections of T. orientalis twigs. Recollections were undertaken from 
the original collection site and surrounding areas by Jean Meyer, a SANBI botanist.   
 
7.2 Extract Preparation 
Plant material (152 g) was dried in an oven at 45 °C. Dried material was then ground 
to a coarse powder using a hammer mill. Powdered plant material was first extracted 
with de-ionized water and subsequently dried at 45 C before extraction with 1:1 
dichloromethane/methanol (DCM/MeOH). 
 
For each extraction procedure the plant material was steeped in sufficient solvent for 
4 - 5 h at room temperature, with occasional stirring. The solvent was subsequently 
drained. The aqueous extract was concentrated by freeze-drying (P05644C) and the 
organic extract (P05644B) was concentrated by rotary vacuum evaporation below 45 
ºC. Extracts were stored at -20 ºC and the yields of the extracts were recorded in 
terms of fresh plant material. 
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Table 7.1 Yield of extracts obtained from T. orientalis twigs  
Extract code Extract description Mass of extract (g) % Yield 
P05644B Dichloromethane/Methanol (1:1) 0.9 0.6 
P05644C Water 1.2 0.8 
 
 
7.3 General Fractionation Techniques 
7.3.1 Liquid/liquid partitioning 
Crude extract (1 g) was dissolved in methanol-water (9:1) (100 ml), and extracted 
with hexane (3 x 100 ml) (Figure 6.1). The combined hexane layers were evaporated 
under reduced pressure to yield the hexane-soluble fraction (A). The methanol from 
the methanol/water layer was evaporated off under reduced pressure. An additional 
30 ml of water was then added to the remaining water layer, which was subsequently 
extracted with dichloromethane (3 x 100 ml). The combined dichloromethane layers 
were evaporated under reduced pressure to yield the dichloromethane-soluble 
fraction (B). The water layer was freeze-dried to give the aqueous fraction (C).  
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Figure 7.1 Liquid/liquid partitioning method 
 
7.3.2 Column Chromatography 
Silica gel column chromatography was conducted on various size columns, ranging 
from 1.5 – 6 cm in diameter, depending on the quantity of sample and the purification 
stage. In general, a ratio of 1:100 (sample : silica gel; w/w) was used. Silica gel 60 
(0.063 - 0.2 mm) was sourced from Merck.  
 
Column was packed with starting eluent before addition of sample. If sample was 
insoluble in starting eluent, it was adsorbed onto silica gel before applying to column.  
 
Thin layer chromatography (TLC) was used to analyse and pool fractions.  TLC was 
carried out on 0.20 mm pre-coated (SIL-25 UV254) glass-backed plates. The plates 
were first viewed under UV, developed using a vanillin : conc. H2SO4 (1 g : 100 ml) 
spray reagent and then heated.  
Crude extract 
1) Dissolve in methanol-water (9:1) 
 
2)   Extract with hexane (x3) 
 
 
Evaporate off methanol 
Extract with dichloromethane (x3) 
90% methanol/10%water 
layer 
           (B) 
Dichloromethane 
soluble fraction 
            (C)    
Aqueous fraction 
Water layer 
(A) 
Hexane- soluble 
fraction 
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7.4 Classical Bioassay-guided Fractionation  
The fractionation process was guided by activity against the chloroquine-
sensitive D10 strain of P. falciparum in the pLDH assay.  
7.4.1 Bioassay-guided Fractionation of P05644B 
697 mg of P05644B was subjected to liquid/liquid partiioning to yield: 
1A (Hexane fraction); 354mg 
1B (Dichloromethane fraction); 264 mg 
1C (Aqueous fraction); 35 mg 
 
Fraction 1A was further fractionated by silica gel column chromatography using a 
gradient solvent of increasing polarity (5 % acetone/hexane - 30% acetone/hexane). 
The column was stripped with acetone.  A total of sixteen pooled fractions (2A – 2P) 
were generated.  
 
Fraction 1B was chromatographed on a silica gel column. Silica gel was eluted with 
2% MeOH/DCM. Polarity was gradually increased by addition of MeOH in 2% 
increments to 10% MeOH/DCM. Column was stripped with MeOH. Sixteen pooled 
fractions were generated (3A – 3P) (Figure 2.2).   
 
7.4.2 Bioassay-guided Fractionation of P05644B-5B 
A total of 102 kg of fresh twigs was recollected from Darnell in KwaZulu-Natal. The 
material was dried at 30°C and ground to yield 24 kg of material. This was extracted 
sequentially with de-ionized water (210 L) and DCM/MeOH (1:1) (170 L). The organic 
extract was concentrated down to 12.5 L and then subjected to liquid/liquid 
partitioning (i). The dichloromethane-soluble fraction was separated and evaporated 
in vacuo (60° C) to yield a total of 34.8 g of semi-purified extract (4B) (Figure 2.6). 
5 – 10 g batches of extract 4B were purified on 400 – 500 g of silica gel 60 (0.063 – 
0.2mm) under vacuum pressure, using 2.5% MeOH/DCM as eluant (ii). Fractions 
were pooled according to their behavior on TLC (8% MeOH/DCM).  
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
133 
 
Pooled fractions were submitted for in vitro bioassaying against P. falciparum D10. 
Active fractions (5D and 5E) were combined (8.6 g) and separated in 1 g batches on 
40 g of Sephadex LH20 in methanol (iii) and fractions were pooled by TLC (8% 
methanol/dichloromethane) and bioassayed.  
Further purification of the most active fraction (6D) was conducted in 200 – 300 mg 
batches on 10 g C-18 cartridges using a gradient eluent (10% acetonitrile/water to 
100% acetonitrile increasing in 10% increments). Fractions were pooled by TLC 
analysis (8% MeOH/DCM). 
A portion (240mg) of fraction 7D was further separated on an Agilent semi-
preparative HPLC system consisting of an auto sampler, high pressure mixing pump, 
column oven and DAD detector. Separation was achieved using an Eclipse XDB C-18 
column and an isocratic 46% acetonitrile/water system. Four major peaks detected at 
254.4 nm (Figure 7.2) were collected individually, pooled and evaporated (8A = 
11mg, 8B = 8mg, 8Ci = 7mg, 8Cii = 4mg).  
 
 
min 0 2 4 6 8 10 12 14 16 
mAU 
0 
500 
1000 
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2000 
2500 
 DAD1 B, Sig=254,4 Ref=off (C:\CHEM32\2\DATA\TREMIA\TREMIA POOL 2007-01-18 13-25-34\011-0101.D) 
 1. 
 
 2.234 55 2.317  . 80 2 402 
  
        
   
  
 
 .      
  
 
  
8A 
8B 
8Cii 
8Ci 
 
Figure 7.2 Chromatogram of semi-preparative HPLC purification  
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7.4.2.1 Structure of Compound 8Cii 
 
 
Common name: Dadahol A 
HRESI-MS (m/z): 698.2367 (calcd for C39H38O12  698.2364) 
Rf: 0.67 (8% MeOH/DCM) 
Optical rotation: [α]D
24 – 0.025°(c 0.1, MeOH); [lit. [α]D
20 + 20° (c 0.075, MeOH); (Su et 
al., 2002)] 
1H NMR (acetone-d6), δH : 3.79 (3H, s, 3-OMe); 3.86 (6H, s, 3'-OMe; 5'-OMe); 4.02 
(1H, dd, J = 4.8; 12.1 Hz, H-9b), 4.31 (1H, m, H-8), 4.44 (1H, dd, J = 3.11; 12.1 Hz, 
H-9a), 4.81 (2H, dd, J = 1.1; 6.2 Hz, H-9'), 4.99 (1H, d, J = 7.1  Hz, H-7), 6.25 (1H, d, 
J = 16.2 Hz, H-7''), 6.38 (1H, d, J = 15.9 Hz, H-7'''), 6.39 (1H, dt, J = 15.9; 6.2 Hz, H-
8'), 6.68 (1H, br d, J = 15.9 Hz, H-7'), 6.73 – 6.90  (7H, m, H-5; H-6, H-2; H-3''; H-5''; 
H-3'''; H-5'''), 7.06 (2H, br s, H-2', H-6'), 7.37 (1H, d, J = 16.2 Hz, H8''), 7.48 (2H, d, J 
= 8.8 Hz, H-2''; H-6''), 7.55 (2H, d, J = 8.8 Hz, H-2'''; H-6'''), 7.64 (1H, d, J = 15.9 Hz, 
H-8''') 
13C NMR (acetone-d6), δC : 56.1(3-OMe, q), 56.5 (3'-OMe; 5'-OMe, q), 65.0 (C-9', t), 
65.1 (C-9, t), 74.5 (C-7, d), 86.7 (C-8, d), 104.7 (C-2; C-6, d), 111.4 (C-2'; C-6', d), 
115.3 (C-7''; C-7''', d), 115.7 (C-5, d), 116.7 (C-3''; C-5''; C-3''', C-5''', d), 124.4 (C-8', 
d), 126.7 (C-1''; C-1''', s), 131.0 (C-2''; C-6''; C-2'''; C-6''', d), 133.3 (C-4', s), 133.7 (C-
1, d), 133.8 (C-1', s), 134.2 (C-7', d), 145.3 (C-8'', s), 145.7 (C-8''', d), 147.0 (C-4, s), 
148.0 (C-3, s), 153.9 (C-3'; C-5', s), 160.9 (C-4''; C-4''', s), 167.1 (C-9'', s), 167.3 (C-
9''', s)       
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7.4.2.2 Structure of Compound 8Ci 
 
 
Common name: Dadahol A 
HRESI-MS, m/z: 698.2384 (calcd for C39H38O12  698.2364) 
Rf: 0.64 (8% MeOH/DCM) 
Optical rotation: [α]D
24 – 0.029°(c 0.1, MeOH); [lit. [α]D
20 + 20° (c 0.075, MeOH); (Su 
et al., 2002)] 
1H NMR (acetone-d6), δH : 3.85 (3H, s, 3-OMe); 3.86 (6H, s, 3'-OMe; 5'-OMe); 4.32 
(1H, dd, J = 2.8; 11.8 Hz, H-9b), 4.46 (1H, dd, J = 7.6; 11.8 Hz, H-9a), 4.58 (1H, m, 
H-8), 4.81 (2H, dd, J = 0.9 ; J = 6.2 Hz, H-9'), 4.97 (1H, br m, H-7), 6.15 (1H, d, J = 
15.9 Hz, H-8''), 6.38 (1H, d, J = 15.9, H-8'''), 6.39 (1H, dt, J = 15.9; 6.2 Hz, H-8'), 
6.68 (1H, br d, J = 15.9 Hz, H-7'), 6.81 - 6.90 (7H, m, H-2, H-5, H-6, H-3''; H-5''; H-
3'''; H-5'''), 7.06 (2H, br s, H-2', H-6'), 7.29 (1H, d, J = 15.9 Hz, H7''), 7.43 (2H, d, J 
= 8.4 Hz, H-2''; H-6''), 7.54 (2H, d, J = 8.8 Hz, H-2'''; H-6'''), 7.64 (1H, d, J = 15.9 
Hz, H-7''') 
13C NMR (acetone-d6), δC : 56.2 (3-OMe, q), 56.5 (3'-OMe; 5'-OMe, q), 63.8 (C-9, 
t), 65.2 (C-9', t), , 73.2 (C-7, d), 84.7 (C-8, d), 104.7 (C-2; C-6, d), 110.6 (C-2', C-6', 
d), 115.4 (C-8'', d), 115.6 (C-8''', d), 115.7 (C-5, d), 116.7 (C-3''; C-5''; C-3''', C-5''', 
d), 119.7 (C-6, d), 124.3 (C-8', d), 126.7 (C-1''; C-1''', s), 131.0 (C-2''; C-6''; C-2'''; 
C-6''', d), 132.9 (C-1, s), 133.3 (C-1', s), 134.3 (C-7', d), 136.7 (C-4', s), 145.1 (C-
7'', s), 145.7 (C-7''', d), 146.5 (C-4, s), 148.1 (C-3, s), 154.3 (C-3'; C-5', s), 160.9 
(C-4''; C-4''', s), 166.0 (C-9'', s), 166.6 (C-9''', s)       
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7.4.2.3 Structure of Compound 8A 
 
 
 
Common name: Dadahol B 
HRESI-MS (m/z): 668.2276 (calcd for C38H36O11 668.2258) 
Rf: 0.58 (8% MeOH/DCM) 
Optical rotation: [α]D
24 – 0.006°(c 0.2, MeOH) 
1H and 13CNMR (cf. Section 7.15.9.2 and 7.15.9.3)  
 
7.5 Targeted Purification of Actives 
In order to isolate sufficient quantities of compounds 8A and 8C for in vivo studies a 
targeted purification was undertaken.  The remaining portion of fraction 7D (790 mg) 
was subjected to flash silica gel chromatography using 1.5% isopropanol/chloroform 
and fractions containing target compounds were combined based on TLC analysis. 
Repetitive silica gel column chromatography using 3 – 5 % isopropanol/chloroform led 
to the isolation of compounds 8A (80 mg; 0.38% w/w of dry plant material) and 8C (50 
mg; 0.25% w/w of dry plant material).        
 
7.6 Accelerated Bioassay-guided fractionation 
The dichloromethane fraction (4B; Figure 7.1) from liquid-liquid partitioning of the T. 
orientalis crude extract (P05644-5B) was fractionated into a 96-well microtiter plate.  
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Fractionation was conducted using an Agilent 1200 semi preparative HPLC system 
consisting of an auto sampler, high pressure mixing pump, column oven and DAD 
detector. 
HPLC conditions: SunfireTM prep C8 column (10 µm, 10 X 150 mm).  
 
Table 7.2 Semi-preparative HPLC Gradient Table 
Time  Acetonitrile Water    Methanol 
0  25  70    5 
3.00  25  70    5 
7.00  50  45    5 
15.00  100  0    0 
20.00  100  0    0 
23.00  25  70    5 
30.00        25  70    5 
Flow rate: 5 mL/min 
Injection volume: 500 µL 
Sample concentration: 16.7 mg/ml in CH3CN/MeOH 
No. of injections: 6 per plate 
DAD conditions: 190-700 nm 
Fraction type: time fractions with 0.2 min time slices  
 
Figure 7.3 HPLC chromatogram of semi-preparative purification of T. orientalis 
extract 
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Four identical plates, with 85 fractions each, were generated. Plates were evaporated 
on a GeneVac EZ-2 Plus evaporator at 40ºC using the pre-installed “HPLC fractions” 
vacuum settings.  
 
The semi-purified extract (4B) and one of the 96-well plates were submitted to the 
Swiss TPH for in vitro bioassaying against T.b. rhodesiense, T. cruzi, P. falciparum 
K1 and Leishmania donovani axenic amastigotes. The extract showed selectivity to 
the malaria parasite and the 96-well plate fractions were subsequently bioassayed 
against P.falciparum K1 at two concentrations, 4.8 and 0.8 µg/ml. IC50‟s were 
determined for those wells showing more than 50% inhibition at 0.8 µg/ml. The 
cytotoxicity of these fractions was also measured against an L6 (rat skeletal 
myoblast) cell line.  
 
The active wells of one of the duplicate plates was analysed on a Waters Acquity 
SDS UPLC coupled in tandem with a 200 – 500 nm Waters Acquity PDA and a 
Waters SYNAPT HDMS G1. Instrument parameters were as follows: 
MS Mode: ESI negative 
Centroid Threshold: 1 
Capillary: 2.5 kV 
Sampling cone: 40.0 
Extraction cone: 4.0 
Source Temperature: 120 ºC 
Desolvation Temperature: 400 ºC 
Cone Gas Flow: 50.0 L/hr 
Desolvation Gas Flow: 450 L/hr 
Scan Time: 0.100 s 
Start Mass: 100.0 
End Mass: 1000.0 
Start Time: 0.00 min 
End Time: 30.00 min 
Lock Mass: 554.2615 (Leucine enkephalin) 
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Solvent A: 0.1% Formic acid 
Solvent B: Acetonitrile 
 
Table 7.3 UPLC Gradient Table  
Time/min Flow rate % A % B Curve 
0.00 0.350 77 23 0 
3.00 0.350 77 23 6 
12.00 0.350 55 45 6 
17.00 0.350 55 45 6 
24.00 0.450 10 90 6 
26.00 0.450 10 90 6 
28.00 0.350 77 23 2 
30.00 0.350 77 23 6 
 
Sampling rate: 20 points/sec 
Range: 200 -  500 nm 
Resolution: 1.2 nm 
Target Column Temperature: 40 ºC 
Target Sample Temperature: 8.0 ºC 
 
The bioactivity was correlated to the chemical profiles of these wells. Accurate mass 
and UV maxima data were used to search for known compounds in the Dictionary of 
Natural Products database (Chapman & Hall, 2010).  
 
7.7 pLDH In Vitro Antiplasmodial Assay 
The pLDH assay was conducted at the University of Cape Town‟s Division of 
Pharmacology (UCT Pharmacology).  The chloroquine sensitive (D10) and 
chloroquine-resistant (K1) strains of Plasmodium falciparum were continuously 
cultured according to the methods described by Trager and Jensen (1976). The 
parasites were maintained at a 5% haematocrit with RPMI 1640 (Biowhittaker) 
medium supplemented with Albumax II (lipid rich bovine serum albumin) (GibcoBRL) 
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(25 g/L), hypoxanthine (44 mg/L), HEPES (N-[2-Hydroxyethyl]-piperazine-N‟-[2-
Ethansulphonic acid]) (Sigma-Aldrich) (6 g/L), sodium bicarbonate (Sigma-Aldrich) 
(2.1 g/L) and gentamycin (Sigma-Aldrich) (50 mg/L). The cultures were incubated at 
37 ºC in an atmosphere of 93% N2, 4% CO2 and 3% O2. 
 
Parasite viability was measured using parasite lactate dehydrogenase (pLDH) activity 
(Makler et al., 1993). This enzymatic assay differentiates between pLDH and host 
LDH activity by using 3-acetylpyridine adenine dinucleotide (APAD). The pLDH uses 
APAD as a coenzyme in the conversion of pyruvate to lactate and reduces it to 
APADH. The formation of APADH can be measured by the subsequent reduction of a 
yellow nitroblue tetrazolium (NBT) salt to a blue formazan product, the absorbance of 
which can be monitored on a microplate reader.  
 
The in vitro assays were performed as described by Clarkson et al (2003). 
Microtitration techniques were used to measure the activity of a large number of 
samples over a wide range of concentrations. The microtitre plates (Greiner) 
consisted of 96 wells arranged in a matrix of eight rows (A to H) and 12 coloumns (1 
to 12). Rows A to H in column 1 contained unparasitised RBC (blank), column 2 
served as a parasite control (parasitised RBC in the trophozoite stage, adjusted to a 
2% parasitaemia and 2% haemotocrit, and no drug) and columns 3 to 12 contained 
parasites and varying concentrations of the drug. A solution of chloroquine 
diphosphate (Sigma) in Millipore water served as a positive control in all experiments. 
The initial concentration of chloroquine was 1000 ng/ml. All tests were performed in 
duplicate and no attempt was made to determine 50% inhibitory concentration (IC50) 
values in excess of 100 µg/ml. 
 
Samples were stored at -20 ºC prior to testing and stock solutions were made up a 
day before the experiment and stored at -20 ºC. Crude extracts were first dissolved in 
methanol or DMSO, depending on their solubility, sonicated for 10 minutes and then 
diluted in Millipore water to give a 2 mg/ml solution. This was further diluted in RPMI 
1640 medium to give 200 µg/ml stock solutions. The highest concentration of solvent 
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that the parasites were exposed to was 0.5%, which was shown to have no 
measurable effect on parasite viability (Clarkson et al., 2004). Extracts were tested in 
nine serial twofold dilutions (final concentration range: 100 -0.2 µg/ml) in the 96-well 
microtitre plates. Fractions and pure compounds were dissolved in 10% methanol and 
were further diluted in complete medium on the day of the experiment. The starting 
concentration for a full dose-response was 100 µg/ml, which was diluted 2-fold in 
complete medium to give ten concentrations, with the lowest concentration being 
0.195 µg/ml. The microtiter test plates were placed in a desiccator cabinet, flushed 
with a gas mixture consisting of 93% N2, 4% CO2 and 3% O2, sealed and incubated at 
37 ºC for 48 h.   
 
The pLDH activity was measured using a 1.96 mM NBT (Sigma) and 0.24 mM 
phenazine ethosulphate (PES) (Sigma) solution in Millipore water, and the Malstat 
reagent containing triton (1ml/L), APAD (0.33 g/L) and TRIS buffer (3.3 g/L) in 
Millipore water. Malstat reagent (100 µl) and of NBT/PES (25µl) solution were added 
to all the wells of another 96-well microtiter plate. The test plate was removed from 
the desiccator after the 48 hour incubation period and the parasites were re-
suspended in each well and then transferred (15 µl) with a multi-channel dispenser to 
the corresponding wells in the plate containing the Malstat and NBT/PES solution. 
This plate was placed in a 7520 Microplate Reader (Cambridge Technology), blanked 
on the wells in column 1 and the absorbance of the blue formazan salt was measured 
at λ 620 nm. Since the amount of formazan produced is proportional to parasite 
viability, the percentage parasite survival in each well was calculated using the 
formula: 
 
% Parasite Viability =            Aλ620 test well (PRBC + drug)                    x 100 
                                       
                                     A λ620 parasite control well (PRBC + no drug)  
 
Dose response curves were constructed using non-linear dose-response curve fitting 
analyses with GraphPad Prism v.4.00 software. The concentration of the drug that 
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inhibits 50% of the parasites (IC50 values) was established from the dose response 
curves using GraphPad Prism.  
 
7.8 CHO In Vitro Cytotoxicity Assay 
Compounds were tested for in vitro cytotoxicity against a Chinese Hamster Ovarian 
(CHO) cell line using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay (Mosmann, 1983). This colorimetric assay is based on the ability of 
viable cells to metabolise a yellow water-soluble tetrazolium salt into a water-insoluble 
purple formazan product. The amount of formazan produced can be measured 
spectrophotometrically and is proportional to the metabolic activity and number of 
cells in the test plate. This assay was conducted at UCT Pharmacology. The CHO 
cells were cultured in Dulbecos Modified Eagles Medium (DMEM) : Hams F-12 
medium (1:1) supplemented with 10% heat inactivated fetal calf serum (FCS) and 
gentamycin (0.04 µg/ml). The medium reagents were obtained from Highveld 
Biological, South Africa.  
Samples were dissolved in methanol : water (1:9). Stock solutions (2 mg/ml) were 
prepared and were stored at -20 ºC until use. The highest concentration of methanol 
to which the cells were exposed to had no measurable effect on the cell viability. 
Emetine was used as the positive control in all cases. The initial concentration of 
emetine was 100 µg/ml, which was serially diluted in complete medium with 10-fold 
dilutions to give 6 concentrations, the lowest being 0.001 µg/ml. The same dilution 
technique was applied to all test samples with an initial concentration of 100 µg/ml to 
give 5 concentrations, with the lowest concentration being 0.01 µg/ml.  
In the initial stage of the experiments, the cells were adjusted to a concentration of 
105 / ml and 100 µl of this cell suspension were seeded in all wells except in column 1 
(blank) in a 96 well culture plate (Costar). The plates were incubated at 37 ºC for 24 h 
in a humidified 5% CO2-air atmosphere. After the incubation period, the medium was 
carefully aspirated out of the wells and 100 µl the different test substances (drug 
solutions) were added in quadruplicate to columns 3 through to 9. A further 100 µl of 
culture medium was then added to all of the wells containing cells and drugs 
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(columns 3 to 9), and 200 µl of medium was dispensed to the wells in column 1 
(blank) and column 2 (cells and no drug). The microplate was then incubated at 37 ºC 
for 48 h.   
After the 48 h incubation period, 25 µl of sterile MTT (5 mg/ml in PBS) was added to 
each well and incubation was continued for 4 h at 37 ºC. The plates were then 
centrifuged at 2050 rpm for 10 min and the supernatant was carefully aspirated from 
the wells, ensuring that the formazan crystals were not disturbed. The formazan 
crystals were dissolved in DMSO (100 µl) and the plate was gently shaken for 5 min 
on a microtitre plate shaker. The plate was blanked on the wells in column 1 and the 
absorbance of the crystals was measured at λ 540 nm on a Microtitre Plate Reader 
(Cambridge Technologies). The cell viability was calculated in each well using the 
formula:  
 
% Cell Viability =                  Aλ540 test well (cells + drug)               x 100 
                                       
                                     A λ540 cell control well (cells + no drug)  
 
The concentration of drug that inhibits 50% of the cells (IC50 values) for these 
samples were obtained from dose-response curves, using a non-linear dose-
response curve fitting analyses via GraphPad Prism v.2.01 software.   
 
 
7.9 Swiss Tropical and Public Health Institute’s In Vitro Assays 
Extracts/fractions are first tested in a medium throughput screening (MTS) assay at 
just one standard concentration against the following protozoan parasites: 
Trypanosoma brucei rhodesiense, T. cruzi, Leishmania donovani and Plasmodium 
falciparum. All extracts/fractions found to be active in the MTS assay are subjected to 
the serial dilution assay against the corresponding parasite to determine an IC50. At 
this stage a cytotoxicity assay with rat skeletal myoblasts (L-6 cells) is also be 
performed to obtain information on selectivity. Each assay is run in duplicate and 
repeated for compounds having reached the activity criteria. For each parasite a 
standard drug is run in parallel which acts as an internal control. If the IC50 for the 
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standard drug deviates from the established mean value by more than a factor 2x, the 
assay is discarded. In principle, all assays are 96-well plate based and run for 72 
hours at 37 °C. The endpoint is determined in a semi-automated way by reading the 
plates photometrically, fluorometrically or by scintillation counting. From the signal of 
each well a % inhibition vs. the untreated control is calculated, a sigmoidal inhibition 
curve is drawn and an IC50 value is determined.  
 
For T.b. rhodesiense bloodstream forms grown in MEM medium are used according 
to Baltz et al. (1985), supplemented with 15% heat-inactivated horse serum. Serial 3-
fold drug dilutions are prepared, trypanosomes are added and the plate is incubated 
for 72 hours. Then 10 µL of Alamar blue (resazurin) is added to each well and 
incubation continued for another 2-4 hours. The plates are then read in a microtiter 
fluorometer. Data is transferred to the graphic programme Softmax Pro (Molecular 
Devices) which calculates the IC50 value. 
 
For T. cruzi a parasite strain transfected with a reporter (β- galactosidase) gene is 
used. Rat skeletal myoblasts (L-6 cells) act as host cells. They are infected with 
trypomastigote forms from culture and 48 hours later a serial drug dilution is added. 
After 96 hours an enzymatic reaction is induced and the colour reaction is read 
photometrically at 540 nm. Data is transferred to the graphic programme Softmax Pro 
(Molecular Devices) which calculates the IC50 value.  
 
For Leishmania donovani axenically grown amastigote forms are used. Serial 3-fold 
drug dilutions are prepared, amastigotes are added and the plate incubated for 72 
hours. Then resazurin is added and the assay evaluated as described for the T.b. 
rhodesiense assay. 
 
For P. falciparum a modification of the 3H-hypoxanthine incorporation assay (Matile 
and Pink, 1990) is used. Infected human red blood cells are exposed to serial drug 
dilutions. After 48 hours of incubation, 0.5 µCi 3H-hypoxanthine is added to each well. 
Cultures are incubated for a further 24 h before they are harvested onto glass-fiber 
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filters. The radioactivity is counted in a liquid scintillation counter. IC50 values are 
calculated from the sigmoidal inhibition curves. 
 
Cytotoxicity is determined using rat skeletal myoblast (L-6 cells) in the Alamar blue 
assay as described for T.b.rhodesiense. A selectivity index is calculated by dividing 
IC50 values for L-6 cells/IC50 for P.falciparum. A high value (>100) indicates selective 
activity against the parasite. 
 
 
7.10 In Vivo Antiplasmodial Assay 
In vivo antimalarial activity was determined by a 4 day suppressive test with P. bergei 
infected mice. The assays were conducted at UCT Pharmacology. The strain of mice 
used for the experiment was C57 Black 6 (6-10 weeks old). There were five mice in 
the experimental groups and four mice in chloroquine control and negative control 
groups. 
 
The mice were infected with chloroquine sensitive Plasmodium bergei ANKA. Mice 
were infected interperitoneally with 200μl of 106 cells/ml parasite stock. Twenty -four 
hours post infection, the mice were treated once a day for 4 consecutive days. 
 
The route of administration was via subcutaneous injection. The test samples were 
delivered in 10% DMSO in water. Crude extracts were given at 500 mg/kg, and pure 
compounds at 100 mg/kg body weight. The chloroquine was delivered in water at a 
dose of 10mg/kg body weight. Parasitemia, body weight and survival were monitored 
regularly. Parasitemia was determined using Giemsa stained smears. 
  
The activity or percentage parasitemia reduction was calculated as follows: 
% Reduction = 100 – [mean parasitemia treated / mean parasitemia untreated x100] 
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7.11 In Vivo PK Evaluation 
The in vivo PK assay was conducted at UCT Pharmacology. The compounds were 
administered subcutaneously at a dose of 10 mg/kg to healthy mice and blood 
samples were collected at relevant time intervals. Test compounds were 
subsequently extracted and levels were determined by LC-MS/MS.  
Extraction: Spiked blank blood at a concentration of 1 µg/ml. Ten serial dilutions were 
prepared. 10µl of sample + 50 µl buffer (sodium carbonate, pH 10.8. 0.1M) + 250 µl 
ethyl acetate were vortexed, centrifuged, separated, dried, reconstituted with mobile 
phase and vortexed again. 5 µl of sample was injected for analysis.  
LC-MS/MS: Stock solutions of the compounds (1 mg/ml in acetonitrile) were 
prepared. Dilutions of 1000x were made up in mobile phase.  
 
Pump:  Agilent 1200 G1312A  
Column:  Phenomenex, Gemini C18, 5 µm, 5 cm x 2.0 mm 
Column Temperature: 30 ºC 
Mobile phase:  Acetonitrile: 0.1% formic acid (70:30) 
Flow-rate:  300 µl/min 
Sample Acquisition Duration: 1min 30sec 
 
 
Table 7.4 Agilent Gradient HPLC Table 
 
Step Total Time(min) Flow Rate(µl/min) A (%) B (%) 
0 0.00            300               32.0  68.0                                                                          
1 1.50            300               32.0 
 
Mass Spectrometer: Triple Quadrupole LC/MS/MS (API 3200) 
Source Type: Turbo Spray 
Source Temperature (at setpoint):  400.0 C 
Software: Analyst 1.4.2 
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7.12 Nuclear Magnetic Resonance (NMR) Spectroscopy  
NMR spectroscopy was carried out on a Varian 600 MHz Premium Shielded 
spectrometer. All the spectra were recorded at room temperature in deuteriated 
chloroform or acetone. The chemical shifts were all recorded in ppm relative to TMS. 
Proton data was acquired and analysed for all synthetic intermediates and products. 
Carbon and 2D NMR data were only acquired for products achieved in adequate yield 
and purity.   
  
7.13 Mass Spectrometry  
High resolution mass spectra were recorded on a SYNAPT G1 HDMS QTOF ESI-MS 
instrument, in the negative ES+ or ES- mode under the following conditions: 
Capillary (kV): 2.5 
Sampling cone: 45.0 
Extraction cone: 4.0 
Source Temp (ºC): 120 
Desolvation Temp (ºC): 400 
Scan Time (sec): 0.100 
Interscan Time (sec): 0.020 
Start mass: 100.00 
End mass: 1000.00 
 
 
7.14 Optical Rotations 
Optical rotations, on selective compounds, were measured in methanol at 20ºC on a 
Perkin-Elmer 343 polarimeter at 589 nm (Na D-line) using a 1 cm3 cell.  
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7.15 Synthesis and Analogue Generation 
All synthetic intermediates and products were confirmed by 1H NMR and HRESI-MS 
analysis. 13C and 2D NMR data were only acquired and analysed for final products, 
recovered in sufficient yield.   
 
7.15.1  Synthesis of Triphenylethoxycarbonylmethylphosphonium  
  bromide  
3.14 g (0.012 mol) of PPh3 was dissolved in 6 ml of THF in a 25 ml round bottom flask 
attached to a reflux condenser. A solution of 2.0 g (0.012 mol) of ethyl bromoacetate 
in 6 ml of THF was added drop-wise to the PPh3 solution through the top of the 
condenser. The mixture was stirred at room temperature for 45 min and then filtered. 
The white precipitate was washed with hexane and the filtrate and washings were 
saved and allowed to stand overnight to recover more salt (4.4g, 85% yield). This 
step was repeated five times to yield a total of 23.1 g of 
triphenylethoxycarbonylmethylphosphonium bromide (75% overall yield).  
 
HRESI-MS (m/z): 429.0388 (calcd for C22H22BrO2P 429.0397)  
1H NMR (CDCl3): δH 1.01 (3H, t, J = 7.1, O-CH2CH3)  3.98 (2H, q, J = 7.1, O-
CH2CH3), 5.50 (2H, d, J = 13.8, H-2), 7.88 - 7.59 (15H, m, P-(C6H5)3)  
 
7.15.2  Preparation of triphenylethoxycarbonylmethylphosphorane 
Phosphonium salt was dissolved in a minimum amount of water in 5-6 g batches; 
insolubles were filtered off. 2.5 M NaOH (1.2 mol equiv.) was added slowly with 
stirring at room temperature. Precipitate was filtered, dissolved in dichloromethane, 
dried over anhydrous sodium sulphate and evaporated to dryness to yield the Wittig 
reagent (46) (13.3 g, 71% yield).  
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HRESI-MS (m/z): 348.1267 (calcd for C22H21O2P 348.1278) 
1H NMR (CDCl3): δH 1.21 (3H, t, J = 7.1 Hz, O-CH2CH3),  4.08 (2H, q, J = 7.1 Hz, O-
CH2CH3), 6.81 (1H, s, H-2), 7.66 - 7.39 (15H, m, P-(C6H5)3)  
 
7.15.3  Wittig Reaction  
2.5 g of vanillin (0.0164mol) was dissolved in 50 ml of dry dichloromethane. 6.85 g 
(0.0197 mol, 1.2 equiv) of triphenylethoxycarbonylmethylphosphorane (46) was 
added and the reaction was stirred at room temperature under nitrogen for 24 h. 
Reaction mixture was refluxed at 60° C for 90 min but with no further depletion of 
vanillin. Recovered 650 mg (9.3%) of Z- isomer and 3g (43% yield) of E- ethyl ferulate 
(42) after repetitive flash silica gel column chromatography, using 15% 
EtOAc/Hexane. Repeated process on 2-4 g batches of substrate (49% overall yield).  
 
HRESI-MS (m/z): 222.0830 (calcd for C22H21O2P 222.0796) 
Rf: 0.54 (40% EtOAc/Hexane) 
1H NMR (CDCl3): δH 1.29 (3H, t, J = 7 Hz, 8-O-CH2CH3), 3.88 (3H, s, OCH3-3), 4.21 
(2H, q, J = 7 Hz, 8-O-CH2CH3), 6.25 (1H, d, J = 15.8 Hz, H-8), 6.99 (1H, d, J = 8.2 
Hz, H-5), 7.02 (1H, d, J = 2 Hz, H-2), 7.03 (1H, dd, J = 8.2, J = 2 Hz, H-6), 7.57 (1H, 
d, J = 15.8 Hz, H-7)  
 
7.15.4  DIBAL Reduction of Ethyl Ferulate 
11.1 g (0.05 mol) of E-ethyl ferulate was reduced with DIBAL (0.2 mol, 4 equiv. 36 ml) 
in anhydrous dichloromethane at -78°C under nitrogen. The DIBAL reaction was 
quenched with 500ml of saturated sodium sulphate. The mixture was filtered through 
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a 1 cm plug of celite and the filtrate was extracted with EtOAc (4 x 200 ml). Combined 
organic layers were dried over anhydrous Na2SO4, filtered and evaporated in vacuo. 
The residue was subjected to silica gel column chromatography using 0.5% 
isopropanol/dichloromethane. 3.2 g of unreacted starting material and 3.9 g (43 %) of 
coniferyl alcohol (37) was recovered.   
 
 
 
HRESI-MS (m/z): 180.0514 (calcd for C10H12O3 180.0522) 
Rf: 0.16 (1.5% MeOH/CH2Cl2) 
1H NMR (acetone-d6): δH 3.72 (1H, dd, J = 5.7, J = 5.7 Hz, 9-OH), 3.87 (3H, s, 3-
OCH3), 4.19 (2H, dd, J = 5.7, J = 5.0 Hz, H-9), 6.23 (1H, dt, J = 15.8 Hz, J = 5.0, H-8),  
6.50 (1H, d, J = 15.8 Hz, H-7), 6.77 (1H, d, J = 7.9 Hz, H-5), 6.86 (1H, dd, J = 7.9, J = 
1.3 Hz, H-6), 7.06 (1H, d, J = 1.3 Hz, H-2), 7.57 (1H, br s, 4-OH)  
 
7.15.5  Oxidative Coupling 
90 mg (0.5 mmol) of coniferyl alcohol (37) and 3 mg of HRP (250 Umg-1) were 
dissolved in dioxane-water (2/3, v/v, pH 4 – 4.5 adjusted with dil. H3PO4). 3% H2O2 
was added slowly; monitoring the disappearance of the substrate on TLC. After most 
of the substrate reacted, 100 ml of H2O was added to the reaction mixture, and this 
was then extracted with EtOAc (3 x 100 ml). EtOAc layers were combined, washed 
with H2O, dried over MgSO4 and then evaporated in vacuo. Residue was purified by 
silica gel column chromatography and prep TLC using 3% MeOH/DCM to yield the 
three major dimers, ( ) pinoresinol (39) (6.3 mg, 7%), ( ) dehydrodiconiferyl alcohol 
(38) (14.1 mg, 16%), and ( ) guaiacylglycerol-8-O-4'-coniferyl alcohol ether (40) (26.5 
mg, 29%).   
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HRESI-MS (m/z): 358.1416 (calcd for C20H22O6 358.1417) 
Rf: 0.45 (4% isopropanol/DCM) 
1H NMR (CDCl3): δH  3.05 (2H, dd, J = 4.3, J = 7.2 Hz, H-8, H-8'), 3.84 (2H, dd, J = 
9.1, J = 3.8 Hz, H-9b, H-9'b), 3.87 (6H, s, OCH3-3, OCH3-3'), 4.21 (2H, dd, J = 7.2, J 
= 9.1 Hz, H-9a, H-9'a), 4.70 (2H, d, J = 4.3 Hz, H-7,H-7'), 5.55 (2H, s, 4-OH, 4'-OH), 
6.78 (2H, dd, J = 8.2, J = 1.9 Hz, H-6, H-6'), 6.84 (2H, d, J = 8.2 Hz, H-5, H-5'), 6.86 
(2H, d, J = 1.9 Hz, H-2, H-2') 
 
 
 
HRESI-MS (m/z): 358.1452 (calcd for C20H22O6 358.1459) 
Rf: 0.24 (5% MeOH/DCM) 
[α]D
24: + 0.099°(c = 0.20, MeOH) [lit: [α]D
20 + 10.9°(c = 2.0, Acetone); (Yuen et al., 
1998)]  
1H NMR (acetone-d6): δH 3.54 (1H, ddd, J = 6.1, J = 6.3, J = 6.4 Hz, H-8), 3.74 (1H, t, 
J = 6.1 Hz, 9'-OH), 3.83 (3H, s, 3-OCH3), 3.87 (3H, s, 3'-OCH3), 3.92 – 3.83 (2H, m, 
H-9), 4.11(1H, t, J = 5.4 Hz, 9-OH), 4.20 (1H, dd, J = 5.6, J = 6.1 Hz, H-9'), 5.57 (1H, 
d, J = 6.4 Hz, H-7), 6.25 (1H, dt, J = 15.7, J = 5.6 Hz, H-8'), 6.53 (1H, br d, J = 15.6 
Hz, H-7'), 6.70 (1H, d, J = 8.1 Hz, H-5), 6.89 (1H, dd, J = 8.1, J = 1.4 Hz, H-6), 6.95 
(1H, br s, H-2'), 6.99 (1H, br s, H-6'), 7.04 (1H, br d, J = 1.4 Hz, H-2), 7.57 (1H, s, 4-
OH)  
13C NMR (acetone-d6): δC  53.9 (C-8, d), 55.4 (3-OMe, q), 55.5 (3'-OMe, q), 62.5 (C-
9', t), 63.7 (C-9, t), 87.6 (C-7, d), 109.6 (C-2, d), 110.8 (C-2', d), 114.8 (C-5, d), 115.2 
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(C-6', d), 118.7 (C-6, d), 127.5 (C-8', d), 129.5 (C-4', s) 129.6 (C-7', d), 131.0 (C-1', s) 
133.5 (C-1, s), 144.3 (C-3', s) 146.4 (C-4, s), 147.5 (C-3, s), 148.1 (C-5', s) 
 
GGCE (40): Refer to Section 17.15.8 
 
Scale-up: 3.2 g of coniferyl alcohol was subjected to oxidative coupling in ~ 1 g 
batches. The substrate and 30 mg of HRP (250 Umg-1) were dissolved in ~ 200 ml 
dioxane-water (2/3, v/v, pH 4 – 4.5 adjusted with dil. H3PO4). 3% H2O2 (~ 2ml) was 
added slowly; monitoring the disappearance of the substrate. 100 ml of water was 
added to the reaction mixture and this was then extracted with EtOAc (3 x 100 ml). 
EtOAc layers were combined, washed with H2O, dried over MgSO4 and then 
evaporated in vacuo. Residue was purified by silica gel column chromatography (1% 
MeOH/DCM to 3% MeOH/DCM), yielding the two major dimers, dehydrodiconiferyl 
alcohol (DHCA) (38) (280 mg, 9%), and ( ) guaiacylglycerol-8-O-4'-coniferyl alcohol 
ether (GGCE) (40) (878 mg, 26%).   
 
7.15.6  Acid Chloride Esterification of GGCE  
29.6 mg (0.2 mmol) of trans cinnamic acid was dissolved in 5 ml of dry 
dichloromethane. Added 2 drops of anhydrous DMF and then 44 µl (0.5 mmol, 2.5 
equiv.) of oxalyl chloride was added drop-wise at room temperature, under nitrogen. 
After addition the reaction mixture was refluxed at 50°C for 2.5 h. Solvent and excess 
oxalyl chloride was removed under vacuum pressure to yield pale yellow crystals of 
the acid chloride. Dissolved the acid chloride in 5 ml of dry dioxane and added to 
round bottom flask containing 30.0 mg (0.08 mmol) of DHCA in 0.5 ml THF. Added 13 
µl of Et3N (0.1 mmol, 1.2 equiv.) and stirred at room temperature under N2 overnight. 
The reaction mixture was diluted with 10 ml EtOAc and washed with 5% NaHCO3 and 
brine. The solution was dried over MgSO4, the solvent was evaporated under reduced 
pressure and residue was chromatographed on silica gel using 70% EtOAc/hexane to 
yield 4.3 mg (8.4%) of the erythro diester (53), and 11 mg (27.1%) of the monoester, 
(54).  
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HRESI-MS (m/z): 636.2527 (calcd for C38H36O9 636.2675) 
Rf: 0.32 (50% EtOAc/Hexane) 
1H NMR of erythro form (acetone-d6): δH 3.83 (3H, s, 3-OCH3), 3.85 (3H, s, 3'-OCH3), 
4.21 (2H, br d, J = 5.4 Hz, H-9'), 4.51 (2H, m, H-9), 4.75 (1H, br m, H-8), 4.85 (1H, br 
d, J = 3.5 Hz, 7-OH), 5.12 (1H, br dd, J= 3.5, J = 4.7 Hz, H-7),  6.30 (1H, dt, J = 16.1, 
J = 5.4 Hz, H-8'), 6.45 (1H, d, J = 15.8 Hz, H-8'''), 6.53 (1H, d, J = 16.1 Hz, H-7'), 6.77 
(1H, d, J = 15.8 Hz, H-8''), 6.92 (1H, br d, J = 8.2 Hz, H-6), 6.92 (1H, d, J = 8.2 Hz, H-
6), 7.01 (1H, d, J = 8.2 Hz, H-5'), 7.08 (1H, s, H-2'), 7.10 (1H, d, J = 8.2 Hz, H-5), 7.13 
(1H, br d, J = 8.2 Hz, H-6'), 7.34 (1H, br s, H-2), 7.43 (3H, m, H-3''', H-4''', H-5'''), 7.49 
(3H, m, H-3'', H-4'', H-5''), 7.49 (1H, d, J = 15.8 Hz, H-7'''), 7.62 (1H, br m, H-2''', H-
6'''), 7.78 (1H, br m, H-2'', H-6''), 7.84 (1H, d, J = 15.8 Hz, H-7'') 
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HRESI-MS (m/z): 506.2815 (calcd for C38H36O9 506.2802) 
Rf: 0.08 (50% EtOAc/Hexane) 
1H NMR of threo form (acetone-d6): δH 3.56 (1H, dd, J = 11.7, J = 5.9 Hz, H-9b), 3.76 
(1H, m, H-9a), 3.81 (3H, s, 3-OCH3), 3.90 (3H, s, 3'-OCH3), 4.21 (2H, br d, J = 5.1 Hz, 
H-9'), 4.29 (1H, br, m, H-8), 5.02 (1H, br d, J = 5.9 Hz, H-7), 6.30 (1H, br dt, J = 16.1, 
J = 5.1 Hz, H-8'), 6.41 (1H, d, J = 16.1 Hz, H-7'), 6.77 (1H, d, J = 16.1 Hz, H-8''), 6.89  
(1H, br d, J = 8.1 Hz, H-6), 6.93 (1H, J = 8.1 Hz, H-5'), 7.06 – 7.11 (3H, m, H-2', H-5, 
H-6'), 7.30 (1H,br s, H-2), 7.48 (3H, m, H-3'', H-4'', H-5''), 7.78 (2H, br m, d, H-2'', H-
6''), 7.85 (1H, d, J = 16.1 Hz, H-7'') 
 
7.15.7  CDI Coupling (GGCE with Cinnamic Acid) 
31.4 mg (0.21 mmol, 2 equiv.) of trans cinnamic acid was dissolved in 2 ml of 
anhydrous dichloromethane. 34.5 mg (0.21 mmol) of CDI was added and the mixture 
was stirred at room temperature for 4h under nitrogen. 40 mg (0.106 mmol) of GGCE 
in 2 ml of THF was added and the reaction mixture was stirred at room temperature 
for 48h, and then refluxed at 75 C for 6h with a catalytic amount of DMAP and 
Na2CO3. The reaction did not go to completion but was eventually cooled, diluted with 
EtOAc, washed quickly with cold 0.05N HCl and then brine. Organic layer was dried 
over MgSO4 and evaporated to dryness. Residue was purified over sílica gel using 
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20% EtOAc/hexane to yield 0.9 mg (1.3%) and 0.5 mg (0.7%) of the 9,9'-cinnamyl di-
esters, (56) and (57);  and 0.5 mg (0.9%) of the threo 4,9,9'-cinnamyl tri-ester, (55).                     
 
 
 
HRESI-MS (m/z): 766.3065 (calcd for C47H42O10 766.3034) 
Rf: 0.47 (40% EtOAc/Hexane) 
1H NMR (acetone-d6): δH 3.83 (3H, s, 3-OCH3), 3.88 (3H, s, 3'-OCH3), 4.24 (1H, dd, J 
= 6.5, J = 12.0 Hz, H-9b), 4.50 (1H, br dd, J = 12 Hz, H-9a), 4.77 (1H,br m, H-8), 4.83 
(2H, br d, J = 6.5 Hz, H-9'), 5.12 (1H, br d, J = 4.1 Hz, H-7), 6.35 (1H, dt, J = 15.9, J = 
6.5 Hz, H-8'), 6.48 (1H, d, J = 15.9 Hz, H-8''), 6.60 (1H, d, J = 15.9 Hz, H-7'), 6.71 
(1H, d, J = 15.9 Hz, H-8'''), 6.77 (1H, d, J = 15.6 Hz, H-8''''), 7.02 (1H, d, J = 7.6 Hz, 
H-5), 7.11 – 7.20 (4H, m, H-6, H-6', H-5', H-2'), 7.36 (1H, br s, H-2), 7.41 – 7.52 (11H, 
m, H-3'', H-3''', H-3'''', H-4'', H-4''', H-4'''', H-5'', H-5''', H-5'''', H-7''), 7.64 (2H, m, H-2'', 
H-6''), 7.71 (2H, m, H-2''', H-6'''), 7.73 (1H, d, J = 15.9, H-7'''), 7.78 (2H, m, H-2'''', H-
6''''), 7.85 (1H, d, J = 15.9 Hz, H-7'''') 
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HRESI-MS (m/z): 636.2375 (calcd for C38H36O9 636.2360) 
Rf: 0.38 (40% EtOAc/Hexane) 
1H NMR (acetone-d6): δH 3.83 (3H, s, 3-OCH3), 3.88 (3H, s, 3'-OCH3), 4.14 (1H, dd, J 
= 6.5, J = 12.0 Hz, H-9b), 4.38 (1H, dd, J = 12.0, J = 4.3 Hz, H-9a), 4.58 (1H, d, J = 
4.1 Hz, 7-OH), 4.65 (1H, br m, H-8), 4.84 (2H, br d, J = 6.5 Hz, H-9'), 4.98 (1H, br dd, 
J = 4.1 Hz, H-7), 6.36 (1H, dt, J = 15.8, J = 6.5 Hz, H-8'), 6.47 (1H, d, J = 15.8 Hz, H-
8''), 6.60 (1H, d, J = 15.8 Hz, H-7'), 6.71 (1H, d, J = 16.4, H-8'''), 6.81 (1H, d, J = 8.5 
Hz, H-5), 6.98 (1H, d, J = 7.9, H-6'), 7.01 (1H, br d, J = 8.5, H-6), 7.13 (1H, d, J = 7.9, 
H-5'), 7.16 (1H, s, H-2'), 7.18 (1H, br s, H-2),  7.41 – 7.49 (8H, m, H-3'', H-3''', H-5'', H-
5''', H-4'', H-4''', H-7'', 4-OH), 7.61 (2H, br d, J = 7.1, H-2'', H-6''), 7.71 (2H, br m, J = 
7.1, H-2''', H-6'''), 7.73 (1H, d, J = 16.4 Hz, H-7''') 
 
 
HRESI-MS (m/z): 636.2370 (calcd for C38H36O9 636.2360) 
Rf: 0.32 (40% EtOAc/Hexane) 
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1H NMR (acetone-d6): δH 3.84 (3H, s, 3-OCH3), 3.86 (3H, s, 3'-OCH3), 4.48 (2H, br m, 
H-9), 4. 61 (1H, d, J = 3.5 Hz, 7-OH), 4.73 (1H, br m, H-8), 4.82 (2H, br d, J = 6.5 Hz, 
H-9'), 5.00 (1H, br dd, J = 4.7, J = 3.5 Hz, H-7), 6.33 (1H, dt, J = 16.1, J = 6.5 Hz, H-
8'), 6.42 (1H, d, J = 16.1, H-8''),  6.60 (1H, d, J = 16.4 Hz, H-7'), 6.69 (1H, d, J = 15.9 
Hz, H-8'''), 6.79 (1H, d, J = 7.6 Hz, H-5), 6.96 (1H, d, J = 8.2 Hz, H-6'), 6.97 (1H, br d, 
J = 7.6 Hz, H-6), 7.03 (1H, d, J = 8.2 Hz, H-5'), 7.15 (1H, s, H-2'), 7.16 (1H, br s, H-2),  
7.40 – 7.45 (8H, m, H-3'', H-3''', H-5'', H-5''', H-4'', H-4''', H-7'', 4-OH), 7.59 (2H, br m, 
H-2'', H-6''), 7.71 (2H, br m, H-2''', H-6'''), 7.72 (1H, d, J = 15.9 Hz, H-7''')  
 
7.15.8  GGCE Diastereomer Separation 
An anion-exchange column (35 g QAE-Sephadex A-25; Pharmacia; column 
dimensions 3 x 35 cm) was packed and several hundred ml of the eluent (0.06 M 
K2B4O7 in EtOH-water (1:4)) was allowed to pass through the column. Mixture of 
threo and erythro forms of GGCE (40) (in 2 batches of 270 mg) was dissolved in a 
minimal amount of eluent and applied to the column. The eluent was collected in 2 ml 
fractions, which were pooled on the basis of an examination by TLC (toluene : 
dioxane: acetic acid (90:25:4)). The pooled fractions (volume, V ml) were extracted 
with EtOAc (0.75 ml + 2 x 0.25 V ml). The extracts were dried over Na2SO4 and 
solvent was removed in vacuo. Boric acid was removed by repeated addition and 
evaporation of MeOH. The pooled fractions were each purified on silica gel using 
1.25% isopropanol/chloroform to yield 139.8 mg of the threo form (40i) and 80.3 mg 
of the erythro (40ii) form, both as amorphous gums. The ethylated erythro GGCE by-
product (62) was also recovered (2.4 mg) and characterized.     
 
HRESI-MS (m/z): 376.1506 (calcd for C20H23O7 376.1523) 
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Rf: 0.20 (5% MeOH/Me2Cl2) 
[α]D
20
 : + 0.087°(c = 0.20, MeOH) 
1H NMR (acetone-d6): δH 3.50 (1H, ddd, J = 6.1, J = 11.5, J = 6.1 Hz, H-9b), 3.69 (1H, 
ddd, J = 6.1, J = 5.4, J = 11.5 Hz, H-9b) 3.78 (1H, t, J = 6.1, 9'-OH), 3.80 (1H, t, J = 
5.4, Hz, 9-OH), 3.81 (3H, s, OCH3-3), 3.91 (3H, s, OCH3-3'), 4.21 (3H, br m, H-9', H-
8), 4.39 (1H, d, J = 3.4 Hz, 7-OH), 4.88 (1H, dd, J = 3.4, J = 6.1 Hz, H-7), 6.31 (1H, 
dt, J = 5.4, J = 15.8 Hz, H-8'), 6.54 (1H, d, J = 15.8 Hz, H-7'), 6.78 (1H, d, J = 8.1 Hz, 
H-5), 6.91 (2H, br d, J = 8.1 Hz, H-5', H-6), 7.11 (1H, d, J = 8.1 Hz, H-6'), 7.12 (1H, br 
s, H-2'), 7.13 (1H, br s, H-2), 7.44 (1H, s, 4-OH),  
13C NMR (acetone-d6), δC : 55.3 (3-OMe, q), 55.4 (3'-OMe, q), 61.0 (C-9, t), 62.4 (C-
9', t), 73.0 (C-7, d), 87.6 (C-8, d), 110.0 (C-2', d), 110.5 (C-2, d), 114.3 (C-5, d), 118.8 
(C-6, d), 119.4 (C-5', d), 119.7 (C-6', d), 128.8 (C-8', d) 130.0 (C-7', d), 132.1 (C-1', s) 
132.9 (C-1, s), 146.0 (C-4, s) 147.1 (C-3, s), 148.3 (C-4', s), 150.9 (C-3', s) 
 
 
HRESI-MS (m/z): 376.1528 (calcd for C20H22O6 358.1523) 
Rf: 0.20 (5% MeOH/DCM) 
[α]D
20
 : - 0.022°(c= 0.20, MeOH) 
1H NMR (acetone-d6): δH 3.71 (2H,br m, H-9b, 9-OH), 3.79 (1H, ddd, J = 5.6, J = 5.7, 
J = 11.4 Hz, H-9b), 3.82 (3H, s, OCH3-3), 3.86 (3H, s, OCH3-3'), 4.20 (2H, dd, J = 5.7, 
J = 5.1 Hz, H-9'), 4.30 (1H, dd, J = 5.7, J = 3.8 Hz, H-8), 4.50 (1H, d, J = 5.1 Hz, 7-
OH), 4.90 (1H, dd, J = 4.4, J = 5.1 Hz, H-7), 6.28 (1H, dt, J = 5.7, J = 15.7 Hz, H-8'), 
6.52 (1H, d, J = 15.7 Hz, H-7'), 6.77 (1H, d, J = 7.9 Hz, H-5), 6.88 (2H, br dd, J = 8.1 
Hz, H-5', H-6'), 6.92 (1H, d, J = 7.9 Hz, H-6), 7.07 (1H, br s, H-2'), 7.11 (1H, br s, H-
2), 7.41 (1H, s, 4-OH),  
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13C NMR (acetone-d6), δC : 55.3 (3-OMe, q), 55.4 (3'-OMe, q), 61.0 (C-9, t), 62.4 (C-
9', t), 72.9 (C-7, d), 85.8 (C-8, d), 110.1 (C-2', d), 110.5 (C-2, d), 114.2 (C-5, d), 118.5 
(C-6, d), 119.4 (C-5', d), 119.6 (C-6', d), 128.7 (C-8', d) 129.0 (C-7', d), 132.0 (C-1', s) 
133.4 (C-1, s), 145.8 (C-4, s) 147.1 (C-3, s), 147.7 (C-4', s), 151.0 (C-3', s) 
 
 
HRESI-MS (m/z): 404.1791 (calcd for C22H28O7 404.1836) 
Rf: 0.30 (5% MeOH/Me2Cl2) 
1H NMR (acetone-d6): δH 1.58 (3H, t, J = 7.0 Hz, 9'-OCH2CH3), 3.50 (2H, q, J = 7.0 
Hz, 9'-OCH2CH3), 3.71 (2H, br m, H-9b, 9'-OH), 3.84 (1H, m, H-9a), 3.82 (3H, s, 3-
OCH3), 3.86 (3H, s, 3-OCH3), 4.06 (2H, d, J = 5.74 Hz, H-9'), 4.31 (1H, br m, H-8), 
4.51 (1H, br s, 7-OH), 4.89 (1H, br m, H-7), 6.23 (1H, dt, J = 6.0, J = 16.0 Hz, H-8'), 
6.53 (1H, d, 16.0 Hz, H-7'), 6.76 (1H, d, 8.0, J = 8.0 Hz, H-5), 6.88 (2H, d, J = 8.0 Hz, 
H-5', H-6'), 6.93 (1H, d, J = 8.0 Hz, H-6), 7.09 (1H, d, J = 1.5 Hz, H-2'), 7.11 (1H, s, H-
2), 7.41 (1H, s, 4-OH)     
13C NMR (acetone-d6): δC  14.7 (9'-OCH2CH3, q), (55.3 (3-OMe, q), 55.4 (3'-OMe, q), 
61.0 (C-9, t), 65.0 (9'-OCH2CH3, q), 70.7 (C-9', t), 72.9 (C-7, d), 85.8 (C-8, d), 110.1 
(C-2', d), 110.5 (C-2, d), 114.2 (C-5, d), 118.4 (C-6, d), 119.5 (C-5', d), 119.6 (C-6', d), 
125.3 (C-8', d) 131.0 (C-7', d), 131.6 (C-1', s), 133.4 (C-1, s), 145.8 (C-4, s) 147.1 (C-
3, s), 147.9 (C-4', s), 151.0 (C-3', s) 
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7.15.9  CDI Coupling (GGCE with silylated p-coumaric acid) 
7.15.9.1  Silylation of p-Coumaric Acid 
200 mg (1.32 mmol, 1.1 equiv.) of TBS-Cl was added to a solution of p-coumaric acid 
(200 mg, 1.2 mmol) and imidazole (163 mg, 2.4 mmol, 2 equiv.) in 2 ml DMF at 0°C. 
The mixture was stirred at room temperature overnight, then diluted with ethyl 
acetate, washed with 10% NaHCO3 and brine, dried over Na2SO4 and concentrated 
in vacuo. The residue was chromatographed on silica gel using 10% EtOAc/hexane 
to yield 218 mg (65%) of the white crystalline protected acid, (66).  
 
1H NMR (acetone-d6): δH 0.25 (6H, s, 4-O-Si(CH3)2), 1.00 (9H, s, 4-O-Si(CH3)3), 6.38 
(1H, d, J = 15.9 Hz, H-8), 6.94 (2H, d, J = 8.8 Hz, H-5, H-6), 7.60 (2H, J = 8.8 Hz, H-
2, H-3), 7.63 (1H, d, J = 15.9 Hz, H-7)  
 
7.15.9.2 CDI Coupling (threo GGCE) 
CDI (122.5 mg, 0.76 mmol, 3 equiv.) was added to solution of 70 mg (0.25 mmol, 2.1 
equiv.) of silyl protected p-coumaric acid (66) in 1 ml of anhydrous DMF and heated 
for 1 h at 45 ºC. Reaction mixture was cooled to room temperature before adding 
threo GGCE (40i) (45 mg, 0.12 mmol) in 1 ml DMF. Added catalytic amount of NaH, 
DMAP and Na2CO3; then heated to 70 ºC for 6 h. Added 1 ml of THF and 3 ml DCM 
and stirred at room temperature for 72 h. Diluted reaction mixture with EtOAc, 
washed with cold dilute (0.05N) HCL and brine. Organic layer was dried over MgSO4 
and evaporated to dryness. Residue was purified by sílica gel chromatography (2% 
MeOH/DCM), and prep TLC using 5% methanol/chloroform (x3) to yield 1.8 mg 
(2.2%) of threo Dadahol B 8Ai, 2.3 mg (3.6%) of the 9-mono ester (67) and 1.4 mg 
(2.2 %) of the 9'-mono ester (68). 
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HRESI-MS (m/z): 668.2248 (calcd for C38H36O11 668.2258) 
Rf: 0.58 (8% MeOH/CH2Cl2) 
1H NMR (acetone-d6): δH 3.83 (3H, s, 3-OCH3), 3.88 (3H, s, 3'-OCH3), 4.12 (1H, dd, J 
= 6.1, J = 11.8 Hz, H-9b), 4.35 (1H, dd, J = 11.8, J = 3.3 Hz, H-9a), 4.58 (1H,br s, 7-
OH), 4.63 (1H, br m, H-8), 4.81 (2H, br d, J = 6.4 Hz, H-9'), 4.98 (1H, br d, J = 3.3 Hz, 
H-7), 6.27 (1H, d, J = 16.0 Hz, H-8''), 6.34 (1H, dt, J = 16.0, J = 6.4 Hz, H-8'), 6.40 
(1H, d, J = 16.0 Hz, H-8'''), 6.69 (1H, d, J = 16.0 Hz, H-7'), 6.80 (1H, d, J = 8.0 Hz, H-
5), 6.89 (4H, d, J = 8.6 Hz, H-3'', H-3''', H-5'', H-5'''), 6.97 (1H, br d, J = 8.0 Hz, H-6), 
7.00 (1H, d, J = 8.3 Hz, H-6'), 7.13 (1H, d, J = 8.3 Hz, H-5'), 7.15 (1H, br s, H-2), 7.18 
(1H, br s, H-2'), 7.41 (1H, d, J = 16.0 Hz, H-7''), 7.48 (2H, d, J = 8.6 Hz, H-2'', H-6''), 
7.57 (2H, d, J = 8.6 Hz, H-2''', H-6'''), 7.65 (1H, d, J = 16.0 Hz, H-7''') 
13C NMR (acetone-d6): δC 55.3 (3-OMe, q), 55.4 (3'-OMe, q), 63.5 (C-9, t), 64.4 (C-9', 
t), 73.0 (C-7, d), 83.4 (C-8, d), 110.3 (C-2', d), 110.6 (C-2, d), 114.3 (C-8'', d), 114.5 
(C-8''', d), 114.6 (C-5, d), 115.8 (C-3'', C-3''', C-5'', C-5''', d), 118.0 (C-5', d), 119.7 (C-
6, d), 119.9 (C-6', d), 122.4 (C-8', d), 126.0 (C-1'', s), 126.1 (C-1''', s),  130.1 (C-2'', C-
2''', C-6'', C-6''', d), 131.2 (C-1', s), 132.3 (C-1, s), 133.4  (C-7', d), 144.7 (C-7'', C-7''', 
d), 146.2 (C-4, s) 147.2 (C-3, s), 148.7 (C-4', s), 150.9 (C-3', s), 159.7 (C-4'', s), 159.8 
(C-4''', s), 166.2 (C-9'', s), 166.3 (C-9''', s)  
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
162 
 
 
HRESI-MS (m/z): 522.1869 (calcd for C29H30O9 522.1891) 
1H NMR (acetone-d6): δH 3.83 (3H, s, 3-OCH3), 3.88 (3H, s, 3'-OCH3), 4.10 (1H, dd, J 
= 6.3, J = 12.0 Hz, H-9b), 4.21 (2H, br d, H-9'), 4.36 (1H, br dd, J = 12.0 Hz, J = 3.4 
Hz, H-9a), 4.58 (1H, br m, H-8), 4.97 (1H, br d, J = 3.4 Hz, H-7), 6.29 (1H, d, J = 16.0 
Hz, H-8''), 6.30 (1H, dt, J = 16.0, J = 5.2 Hz, H-8'), 6.54 (1H, d, J = 16.0 Hz, H-7'), 
6.80 (1H, d, J = 8.3 Hz, H-5), 6.89 (2H, d, J = 8.6 Hz, H-3'', H-5''), 6.93 (1H, br d, J = 
8.6 Hz, H-6'), 6.97 (1H, d, J = 8.3 Hz, H-6), 7.01 (1H, d, J = 8.6 Hz, H-5'), 7.11 (1H, br 
s, H-2'), 7.15 (1H, br s, H-2), 7.43 (1H, d, J = 16.0 Hz, H-7''), 7.49 (2H, d, J = 8.6 Hz, 
H-2'', H-6'') 
13C NMR (acetone-d6): δC 55.3 (3-OMe, q), 55.4 (3'-OMe, q), 62.4 (C-9', t), 63.5 (C-9, 
t), 73.0 (C-7, d), 83.6 (C-8, d), 110.2 (C-2', d), 110.6 (C-2, d), 114.3 (C-8'', d), 114.5 
(C-5, d), 115.8 (C-3'', C-5'', d), 118.3 (C-5', d), 119.3 (C-6', d), 119.7 (C-6, d), 126.0 
(C-1'', s), 128.9 (C-8', d), 129.0 (C-7'', d),  130.1 (C-2'', C-6'', d), 132.2 (C-1', s), 132.3 
(C-1, s), 144.7  (C-7'', d), 146.2 (C-4, s) 147.2 (C-3, s), 148.0 (C-4', s), 150.9 (C-3', s), 
159.8 (C-4'', s), 166.2 (C-9'', s) 
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HRESI-MS (m/z): 522.1894 (calcd for C29H30O9 522.1891) 
1H NMR (acetone-d6): δH 3.53 (1H, br m, H-9b), 3.70 (1H, br m, H-9a), 3.82 (3H, s, 3-
OCH3), 3.91 (3H, s, 3'-OCH3), 4.24 (1H, br m, H-8), 4.40 (1H, br d, 7-OH), 4.81 (2H, 
d, J = 6.46 Hz, H-9'), 4.18 (1H, br m, H-7), 6.34 (1H, dt, J = 6.5, J = 15.8 Hz, H-8'), 
6.39 (1H, d, J = 15.8 Hz, H-8''), 6.69 (1H, d, J = 15.8 Hz, H-7'), 6.77 (1H, d, J = 8.1 
Hz, H-5), 6.90 (3H, d, J = 8.6 Hz, H-3'', H-5'', H-6), 6.98 (1H, br d, J = 8.6 Hz, H-6'), 
7.10 (1H, br s, H-2), 7.14 (1H, d, J = 8.6 Hz, H-5'), 7.18 (1H, br s, H-2'), 7.50 (1H, br 
s, 4-OH), 7.57 (2H, d, H-2'', H-6''), 7.65 (1H, d, J = 15.8 Hz, H-7'') 
13C NMR (acetone-d6): δC 55.3 (3-OMe, q), 55.5 (3'-OMe, q), 61.0 (C-9, t), 64.4 (C-9', 
t), 73.0 (C-7, d), 87.3 (C-8, d), 110.1 (C-2', d), 110.5 (C-2, d), 114.3 (C-8'', d), 114.6 
(C-5, d), 115.8 (C-3'', C-5'', d), 118.4 (C-5', d), 119.6 (C-6, d), 120.0 (C-6', d), 122.4 
(C-8', d), 126.1 (C-1'', s), 130.1 (C-2'', C-6'', d), 131.1 (C-1', s), 132.9 (C-1, s), 133.4 
(C-7', d), 144.7  (C-7'', d), 146.0 (C-4, s) 147.1 (C-3, s), 148.9 (C-4', s), 150.9 (C-3', 
s), 159.8 (C-4'', s), 166.3 (C-9'', s) 
 
7.15.9.3 CDI Coupling (erythro GGCE) 
CDI (228.6 mg, 1.41 mmol, 3 equiv.) coupling of 130.9 mg (0.47 mmol, 2.5 equiv.) of 
silyl protected p-coumaric acid (66) with erythro GGCE (40ii) (70.8 mg, 0.19 mmol) 
was conducted as for threo GGCE (Section 7.15.9.2) to yield 2.0 mg (1.6%) of erythro 
Dadahol B 8Aii, 1.4 mg (1.4%) of the 9-mono ester (69) and 1.4 mg (1.1 %) of the 
4,9-diester (70). 
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HRESI-MS (m/z): 668.2234 (calcd for C38H36O11 668.2258) 
Rf: 0.58 (8% MeOH/CH2Cl2) 
1H NMR (acetone-d6): δH 3.84 (3H, s, 3-OCH3), 3.85 (3H, s, 3'-OCH3), 4.44 (2H, m, H-
9), 4.61 (1H,br s, 7-OH), 4.72 (1H, m, H-8), 4.80 (2H, d, J = 6.3, H-9'), 4.99 (1H, br d, 
J = 5.0 Hz, H-7), 6.23 (1H, d, J = 16.1 Hz, H-8''), 6.33 (1H, dt, J = 15.8, J = 6.3 Hz, H-
8'), 6.40 (1H, d, J = 15.8 Hz, H-8'''), 6.68 (1H, d, J = 15.8 Hz, H-7'), 6.79 (1H, d, J = 
7.6 Hz, H-5), 6.89 (4H, d, J = 8.2 Hz, H-3'', H-3''', H-5'', H-5'''), 6.95 (1H, br d, J = 7.6 
Hz, H-6), 6.96 (1H, d, J = 8.2, H-6'), 7.03 (1H, d, J = 8.2 Hz, H-5'), 7.14 (1H, br s, H-
2), 7.16 (1H, br s, H-2'), 7.38 (1H, d, J = 16.1 Hz, H-7''), 7.46 (2H, d, J = 8.2 Hz, H-2'', 
H-6''), 7.56 (2H, d, J = 8.6 Hz, H-2''', H-6'''), 7.65 (1H, d, J = 15.8 Hz, H-7''') 
13C NMR (acetone-d6): δC 55.3 (3-OMe, q), 55.4 (3'-OMe, q), 63.4 (C-9, t), 64.4 (C-9', 
t), 72.5 (C-7, d), 82.6 (C-8, d), 110.4 (C-2', C-2, d), 114.4 (C-5, s), 114.4 (C-8'', d), 
114.6 (C-8''', d), 115.8 (C-3'', C-3''', C-5'', C-5''', d), 118.3 (C-5', d), 119.5 (C-6, d), 
119.8 (C-6', d), 122.4 (C-8', d), 126.0 (C-1'', s), 126.1 (C-1''', s),  130.1 (C-2'', C-2''', C-
6'', C-6''', d), 131.2 (C-1', s), 132.3 (C-1, s), 133.4  (C-7', d), 144.6 (C-7'',d) 144.7 (C-
7''', d), 145.9 (C-4, s) 147.2 (C-3, s), 148.2 (C-4', s), 151.1 (C-3', s), 159.7 (C-4'', s), 
159.8 (C-4''', s), 166.3 (C-9'', C-9''', s)  
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HRESI-MS (m/z): 522.1887 (calcd for C29H30O9 522.1891) 
1H NMR (acetone-d6): δH 3.84 (6H, s, 3-OCH3, 3'-OCH3), 4.21 (2H, br d, J = 3.9 Hz, 
H-9'), 4.44 (2H, H-9), 4.68 (1H, br m, H-8), 4.99 (1H, d, J = 5.1 Hz, H-7), 6.24 (1H, d, 
J = 15.8 Hz, H-8''), 6.29 (1H, dt, J = 15.5, J = 5.1 Hz, H-8'), 6.52 (1H, d, J = 15.8 Hz, 
H-7'), 6.79 (1H, d, J = 7.8 Hz, H-5), 6.87 (2H, d, J = 8.4 Hz, H-3'', H-5''), 6.90 (1H, br 
d, J = 8.4 Hz, H-6'), 6.94 (1H, d, J = 7.8 Hz, H-6), 7.00 (1H, d, J = 8.4 Hz, H-5'), 7.07 
(1H, br s, H-2'), 7.16 (1H, br s, H-2), 7.39 (1H, d, J = 15.8 Hz, H-7''), 7.47 (2H, d, J = 
8.4 Hz, H-2'', H-6'') 
13C NMR (acetone-d6): δC 55.3 (3-OMe, q), 55.4 (3'-OMe, q), 62.4 (C-9', t), 63.3 (C-9, 
t), 73.5 (C-7, d), 82.7 (C-8, d), 110.2 (C-2', d), 110.3 (C-2, d), 114.4 (C-8'', d), 114.8 
(C-5, d), 115.8 (C-3'', C-5'', d), 118.6 (C-5', d), 119.4 (C-6', d), 119.5 (C-6, d), 126.0 
(C-1'', s), 128.8 (C-8', d), 128.9 (C-7', d),  130.1 (C-2'', C-6'', d), 132.2 (C-1', s), 132.8 
(C-1, s), 144.6  (C-7'', d), 145.9 (C-4, s) 147.2 (C-3, s), 147.6 (C-4', s), 151.1 (C-3', s), 
159.7 (C-4'', s), 166.3 (C-9'', s) 
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HRESI-MS (m/z): 668.2252 (calcd for C38H36O11 668.2258) 
1H NMR (acetone-d6): δH 3.85 (3H, s, 3-OCH3, 3'-OCH3), 4.21 (2H, d, J = 5.0 Hz, H-
9'), 4.47 (2H, m, H-9), 4.62 (1H,br s, 7-OH), 4.69 (1H, m, H-8), 5.00 (1H, br d, H-7), 
6.29 (1H, dt, J = 15.8, J = 5. Hz, H-8'), 6.42 (1H, d, J = 15.8 Hz, H-8''), 6.53 (1H, d, J 
= 15.8 Hz, H-7'), 6.57 (1H, d, J = 16.0 Hz, H-8'''), 6.80 (1H, d, J = 8.1 Hz, H-5), 6.93 
(4H, d, H-3'', H-5'', H-6, H-6'), 7.01 (1H, d, J = 8.1 Hz, H-5'), 7.08 (1H, br s, H-2'), 7.17 
(1H, br s, H-2), 7.25 (2H, d, J = 8.4 Hz, H-3''', H-5'''), H-8''), 7.46 (1H, d, J = 16.0 Hz, 
H-7''), 7.66 (2H, d, J = 8.4 Hz, H-2'', H-6''), 7.68 (2H, d, J = 8.4 Hz, H-2''', H-6'''), 7.82 
(1H, d, J = 16.0 Hz, H-7''') 
13C NMR (acetone-d6): δC 55.3 (3-OMe, q), 55.3 (3'-OMe, q), 62.4 (C-9', t), 63.6 (C-9, 
t), 72.5 (C-7, d), 82.7 (C-8, d), 110.3 (C-2', C-2, d), 113.3 (C-8''', d), 114.4 (C-5, s), 
115.9 (C-3'', C-5'', d), 117.9 (C-8'', d), 118.7 (C-5', d), 119.2 (C-6, d), 119.4 (C-6', d), 
122.4 (C-8', d), 122.4 (C-3''', C-5''', d), 128.9 (C-8', d), 129.3 (C-2'', C-6'', d), 130.5 (C-
7', d), 130.5 (C-2''', C-6''', d), 131.9 (C-1'', s), 132.3 (C-1', s), 132.8 (C-1, s), 133.2 (C-
1''', s), 143.5 (C-7'', C-7′′′, d), 145.9 (C-4, s) 147.2 (C-3, s), 147.5 (C-4', s) 151.2 (C-3', 
s), 153.7 (C-4'', s), 160.3 (C-4''', s), 165.2 (C-9'', s), 166.3 (C-9''', s)  
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7.15.10  Auto-oxidation Products 
7.15.10.1  DHCA 
DHCA (38) and its auto-oxidation product, balanophonin (99), were separated by 
silica gel column chromatography using 1% MeOH/DCM.  
 
Common name: Balanophonin (Lee et al., 2007b) 
HRESI-MS (m/z): 356.1269 (calcd for C20H20O6 356.1259) 
Rf: 0.59 (5% MeOH/DCM) 
1H NMR (acetone-d6): δH 3.63 (1H, br m, H-8) , 3.81 – 3.88 (2H, m, H-9), 3.83 (3H, s, 
3-OCH3), 3.92 (3H, s, 3‟-OCH3), 4.18 (1H, br m, 9-OH), 5.66 (1H, d, J = 6.5 Hz, H-7), 
6.67 (1H, dd, J = 7.9, J = 15.7 Hz, H-8'), 6.83 (1H, d, J = 8.3 Hz, H-5), 6.90 (1H, dd, J 
= 8.3, J = 1.9 H, H-6),  7.06 (1H, br d, J = 1.9 Hz, H-2), 7.31 (1H, s, H-2‟), 7.33 (1H, s, 
H-6′), 7.60 (1H, d, J = 15.7 Hz, H-7′), 7.64 (1H, s, 4-OH), 9.65 (1H, d, J = 7.9 Hz, H-9‟)  
 13C NMR (acetone-d6): δC  53.4 (C-8, d), 55.4 (3-OMe, q), 55.5 (3'-OMe, q), 63.4 (C-
9, t), 88.5 (C-7, d), 109.7 (C-2, d), 112.6 (C-2', d), 114.9 (C-5, d), 118.8 (C-6', d; C-6, 
d), 126.2 (C-8', d), 128.1 (C-1', s), 130.3 (C-4', s),  132.9 (C-1, s), 144.8 (C-3', s),  
146.6 (C-4, s), 146.6 (C-3, s), 151.5 (C-5', s), 153.2 (C-7', d), 190.0 (C-9', d) 
 
7.15.10.2  GGCE 
GGCE (40) and its auto-oxidation product (100) were separated by silica gel column 
chromatography using 5% MeOH/DCM. Typical yields were 3 – 5 %. 
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HRESI-MS (m/z): 374.1276 (calcd for C20H22O7 374.1366) 
Rf: 0.50 (5% MeOH/DCM) 
1H NMR of threo diastereomer (600 MHz, acetone-d6): δ 3.58 (1H, br m, H-9b), 3.76 
(1H, br m, H-9a), 3.82 (3H, s, 3-OCH3), 3.94 (3H, s, 3'-OCH3), 4.49 (1H, br m, H-8), 
4.56 (1H, d, J = 3.5 Hz, 7-OH), 4.92 (1H, br m, H-7), 6.68 (dd, J = 7.8, J = 15.8 Hz,  
H-8'), 6.77 (1H, d, J = 7.9 Hz, H-5), 6.92 (1H, br d, J = 7.9 Hz, H-6), 7.10 (1H, d, J = 
8.4 Hz, H-5'), 7.12 (1H, br s, H-2), 7.20 (1H, br d, J = 8.4 Hz, H-6'), 7.40 (1H, br s, H-
2'), 7.58 (1H, d, J = 15.8 Hz, H-7'), 9.66 (1H, d, J = 7.8 Hz, H-9') 
13C NMR (acetone-d6): δC 55.6 (3-OMe, q; 3'-OMe, q), 61.1 (C-9, t), 72.8 (C-7, d), 
86.2 (C-8, d), 110.5 (C-2, d), 112.8 (C-2', d), 114.3 (C-5, d), 116.5 (C-5', d), 119.6 (C-
6, d), 123.2 (C-6', d), 127.0 (C-8', d), 129.1 (C-1', s), 132.9 (C-1, s), 146.0 (C-4, s), 
147.2 (C-3, s), 150.6  (C-4', s), 151.8 (C-3', s), 152.6 (C-7', d), 193.0 (C-9', d) 
 
7.15.11  Alternative Preparation of DHCA 
7.15.11.1  Alternative Preparation via Ethyl Ferulate  
2 x 5 g batches of ferulic acid (101) were boiled in EtOH (30 cm3) containing H2SO4 
(1.2 cm3) for 4 h. The orange solution was concentrated to a gum, dissolved in ethyl 
acetate and extracted with H2O. After drying (MgSO4) and concentrating in vacuo, the 
combined organic fractions were chromatographed on a silica gel column using 10% 
ethyl acetate/hexane to give a total yield of 4.1 g (36 %) of ethyl ferulate (42). DIBAL 
reduction of ethyl ferulate (42) to coniferyl alcohol (37) was as reported before 
(Section 7.15.4). Silver (I) oxide (773 mg, 3.33 mmol) was added to a solution of 
coniferyl alcohol (37) (400 mg, 2.22 mmol) in anhydrous DCM (12 ml). After stirring at 
room temperature for ~ 24 h, the reaction mixture was filtered through a bed of celite, 
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and evaporated to dryness in vacuo. Column chromatography (1% MeOH/chloroform 
as eluent) afforded DHCA (38) as a beige solid (90 mg, 23%).  
 
7.15.11.2 Dimerisation of Coniferyl Alcohol in DMF 
Coniferyl alcohol (37) (150 mg, 0.83 mmol) was treated with silver (I) oxide (290 mg, 
1.25 mmol) in anhydrous DMF (2 ml) as in Section 7.15.11.1 to yield 2.5 mg of 
aldehyde (103) (1.6%), 12.6 mg of methylated GGCE analogue (102) (7.8%), 12 mg 
of DHCA (38) (8%) and 2 mg (1.4 %) of oxidation product (99).  
 
HRESI-MS (m/z): 390.1643 (calcd for C21H26O7 390.1679) 
Rf: 0.37 (5% MeOH/DCM) 
1H NMR of threo diastereomer (acetone-d6): δH 3.22 (3H, s, 7-OCH3), 3.41 (1H, br m, 
H-9b), 3.56 (1H, br m, H-9a), 3.81 (3H, s, 3-OCH3), 3.87 (3H, s, 3'-OCH3), 4.20 (2H, 
br d, J = 5.1 Hz, H-9'), 4.34 (1H, br m, H-8), 4.42 (1H, br m, H-7), 6.27 (1H, dt, J = 
5.1, J = 15.8 Hz, H-8'), 6.51 (1H, d, J = 15.8 Hz, H-7'), 6.79 – 6.89 (4H, m, H-5, H-6, 
H-5', H-6'), 7.02 (1H, s, H-2), 7.05 (1H, s, , H-2'), 7.52 (1H, br s, 4-OH)  
13C NMR (acetone-d6): δC 55.4 (3-OMe, q; 3'-OMe, q), 56.0 (7-Ome, q), 60.8 (C-9, t), 
62.4 (C-9', t), 82.5 (C-7, d), 84.5 (C-8, d), 110.1 (C-2', d), 111.3 (C-2, d), 114.3 (C-5, 
d), 117.8 (C-6', d), 119.3 (C-6, d), 121.0 (C-8, d), 128.5 (C-7', d), 130.0 (C-1', s), 
131.5 (C-1, s), 146.3 (C-3, s), 147.3 (C-4, s), 147.8 (C-4', s), 150.7 (C-3', s) 
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HRESI-MS (m/z): 388.1343 (calcd for C38H36O11 356.1675) 
Rf: 0.82 (5% MeOH/DCM) 
1H NMR of threo diastereomer (acetone-d6): δH 3.22 (3H, s, 7-OCH3), 3.52 (1H, br m, 
H-9b), 3.65 (1H, br m, H-9a), 3.82 (3H, s, 3-OCH3), 3.93 (3H, s, 3'-OCH3), 4.44 (1H, 
d, J = 8 Hz, H-7), 4.57 (1H, br m, H-8),  6.67 (1H, dt, J = 7.9, J = 15.9 Hz, H-8'), 6.77 
(1H, d, J = 7.9 Hz, H-5), 6.87 (1H, dd, J = 7.9 Hz, J = 1.5 Hz, H-6), 7.04 (1H, d, J = 
8.2 Hz, H-5'), 7.07 (1H, d, J = 1.5 Hz, H-2), 7.17 (1H, d, J = 8.2 Hz, H-6'), 7.31 (1H, s, 
H-2'), 7.55 (1H, d, J = 15.9 Hz, H-7'), 9.65 (1H, d, J = 7.9 Hz, H-9')  
 
 
7.15.12 p-Nitrobenzoyl Esterification of DHCA  
30mg (0.083 mmol) of DHCA was dissolved in 1 ml of dry THF. 23 mg (0.125 mmol, 
1.5 equiv.) of p-nitrobenzoyl chloride and 1 mg of DMAP was added. 14 µl (0.1 mmol, 
1.2 equiv.) of Et3N was added and the reaction mixture was stirred at room 
temperature overnight. The reaction was quenched by addition of 10 ml EtOAc which 
was then washed with 0.05 N HCl and water, dried over MgSO4 and evaporated 
under vacuum pressure. The residue was chromatographed over silica gel using 10% 
ethyl acetate/hexane. 9.7mg (29%) of the triester (104) and 3.4 mg (8.3%) of the 
diester (105) was recovered.  
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HRESI-MS (m/z): 805.2045 (calcd for C41H31N3O15 805.2011) 
Rf: 0.6 (50% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 3.65 (3H, s, 3-OCH3), 3.79 (3H, s, 3'-OCH3), 3.99 (1H, br 
ddd, J = 6.5, J = 7.6, J = 11.2 Hz, H-8), 4.61 (1H, dd, J = 5.3, J = 11.2 Hz, H-9b),  
4.78 (1H, dd, J = 6.5, J = 5.3 Hz, H-9a), 4.89 (2H, dd, J = 6.5, J = 1.2 Hz, H-9'), 5.72 
(1H, d, J = 7.6 Hz, H-7), 6.30 (1H, dt, J = 15.9, J = 7.0 Hz, H-8'), 6.70 (1H, d, J = 15.9 
Hz, H-7'), 7.01 (1H, br s, H-2'), 7.06 (1H, d, J = 8.2 Hz, H-5), 7.07 (1H, s, H-6'), 7.19 
(1H, dd, J = 8.2 Hz, H-6), 7.24 (1H, s, H-2),   8.01 – 8.33 (8H, 12 x dd, J = 8.8, J = 1.8 
Hz, H-2'''', H-6'''', H-2''', H-6''', H-2'', H-6'', H-3'''', H-5'''', H-3'', H-5'', H-3''', H-5''') 
 
 
HRESI-MS (m/z): 656.1905 (calcd for C34H28N2O12 656.1859) 
Rf: 0.25 (50% ethyl acetate/hexane) 
 1H NMR (acetone-d6): δH 3.49 (1H, br ddd, J = 6.5, J = 5.9, J = 12.9 Hz, H-8),  3.67 
(3H, s, 3-OCH3), 3.78 (3H, s, 3'-OCH3), 3. 76 (1H, m, H-9b), 3.84 (1H, dd, J = 5.3, J = 
12.9, H-9b), 4.12 (1H, t, J = 5.3 Hz, 9'-OH), 4.90 (2H, dd, J = 6.8, J = 5.3 Hz, H-9'), 
5.62 (1H, d, J = 5.9 Hz, H-7), 6.27 (1H, dt, J = 15.8, J = 6.8 Hz, H-8'), 6.68 (1H, d, J = 
15.8, H-7'), 6.96 (3H, m, H-2', H-6', H-6), 7.14 (1H, d, J = 8.2 Hz, H-5), 7.15 (1H, s, H-
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2), 8.17 – 8.32, 8 x dd, J = 8.8, J = 1.8 Hz, H-3'', H-5'', H-3''', H-5''', H-2''', H-6''', H-2'', 
H-6'')  
 
7.15.13 Acid Chloride Esterification of DHCA  
15.4 mg (0.104 mmol) of cinnamic acid (51) was dissolved in 5 ml of dry 
dichloromethane. 2 drops of anhydrous DMF were added and then 18 µl (0.208 
mmol, 2 equiv.) of oxalyl chloride was added drop-wise at room temperature, under 
nitrogen. After addition the reaction mixture was refluxed at 50°C for 2h. Solvent and 
excess oxalyl chloride was removed under vacuum pressure to yield pale yellow 
crystals of the cinnamoyl chloride (52) (17.3 mg, 100%, 1.1 equiv.). The acid chloride 
was dissolved in 5 ml of dry dichloromethane and added to round bottom flask 
containing 33.8 mg (0.094 mmol) of DHCA (38). Added a few drops of Et3N and 
stirred at room temperature under N2. Reaction was monitored on TLC and eventually 
refluxed at 50°C for 1h to force to completion. The reaction was then quenched with 
water and the organic layer was washed with 0.1M HCl and saturated NaHCO3. The 
solution was dried over MgSO4, the solvent was evaporated under reduced pressure 
and residue was chromatographed on silica gel using 2% MeOH/CHCl3 to yield 34 mg 
(74%) of the ester (108).  
  
 
HRESI-MS (m/z): 488.1834 (calcd for C29H28O7 488.1836) 
Rf: 0.35 (5% MeOH/Me2Cl2) 
1H NMR (acetone-d6): δH 3.58 (1H, br ddd, J = 6.5, J = 5.3, J = 5.9 Hz, H-8),  3.82 
(3H, s, 3-OCH3), 3.84 – 3.88 (1H, br m, H-9b), 3.88 (3H, s, 3'-OCH3), 3.96 (1H, br dd, 
J = 5.3, J = 10.6 Hz, H-9a), 4.20 (2H, br d, J = 5.3 Hz, H-9'), 5.71 (1H, d, J = 6.5 Hz, 
H-7), 6.26 (1H, dt, J = 16.1, J = 5.3 Hz, H-8'), 6.54 (1H, d, J = 16.1 Hz, H-7'),  6.78 
(1H, d, J = 15.8 Hz, H-8''), 6.97 (1H, s, H-2'), 6.98 (1H, s, H-6'), 7.05 (1H, br d, J = 8.2 
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Hz, H-6), 7.13 (1H, d, J = 8.2 Hz, H-5), 7.23 (1H, br s, H-2), 7.48 (3H, br m, H-3'', H-
4'', H-5''), 7.78 (2H, br m, H-2'', H-6''), 7.85 (1H, d, J = 15.8 Hz, H-7'')  
 
7.15.14 Silyl Protection of DHCA 
18 mg (0.12 mmol, 1.1eq) of tert-butyldimethylsilyl chloride, 14.4 mg of imidazole 
(0.21 mmol, 2 equiv.) and 0.6mg (0.005 mmol, 0.05 equiv.) of DMAP were added to a 
flask containing 38 mg (0.106 mmol) of DHCA (38) in 2 ml of THF at 0 ºC. The 
reaction mixture was stirred at room temperature overnight, then diluted with ethyl 
acetate, washed with 10% NaHCO3 and brine, dried over Na2SO4 and concentrated 
in vacuo. The residue was chromatographed on silica gel using 1% MeOH/DCM and 
1.8 mg (5%) of (109) and 23 mg (46%) of (110) were recovered.  
 
 
HRESI-MS (m/z): 586.3152 (calcd for C32H50O6Si2 586.3342) 
Rf: 0.88 (3% MeOH/DCM) 
1H NMR (acetone-d6): δH 0.03 (12H, s, 9'-O-Si(CH3)2, 9-O-Si(CH3)2), 0.83 (9H, s, 9-O-
Si-C(CH3)3), 0.86 (9H, s, 9'-O-Si-C(CH3)3), 3.49 (1H, br ddd, J = 7.0, J = 5.9, J = 10.0 
Hz, H-8), 3.75 (3H, s, 3-OCH3), 3.79 (3H, s, 3'-OCH3), 3.82 (1H, br dd, J = 7.0, J = 
10.0 Hz, H-9b), 3.91 (1H, dd, J = 5.9, J = 10.0 Hz, H-9a), 4.26 (1H, dd, J = 1.8, J = 
5.3, H-9'), 5.44 (1H, d, J = 5.9 Hz, H-7), 6.13 (1H, dt, J = 15.9, J = 5.3 Hz, H-8‟), 6.48 
(1H, br d, J = 15.9 Hz, H-7'), 6.74 (1H, d, J = 7.9 Hz, H-5), 6.80 (1H, dd, J = 7.9, J = 
1.8 Hz, H-6), 6.90 (1H, br s, H-2'), 6.93 (1H, d, J = 1.8 Hz, H-2), 6.94 (1H, br s, H-6'), 
7.52 (1H, s, 4-OH) 
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HRESI-MS (m/z): 472.2296 (calcd for C26H36O6Si 472.2265) 
Rf: 0.22 (3% MeOH/DCM) 
1H NMR (acetone-d6): δH 0.08 (6H, s, 9'-O-Si(CH3)2), 0.91 (9H, s, 9'-O-Si-C(CH3)3), 
3.52 (1H, m, H-8), 3.75 (3H, s, 3-OCH3), 3.79 (3H, s, 3'-OCH3), 3.91 – 3.80 (2H, m, H-
9), 4.32 (2H, dd, J = 1.2, J = 5.0 Hz, H-9'), 5.55 (1H, d, J = 6.5 Hz, H-7), 6.19 (1H, dt, 
J = 15.9, J = 5.0 Hz, H-8'), 6.53 (1H, br d, J = 15.9 Hz, H-7'), 6.79 (1H, d, J = 8.2 Hz, 
H-5), 6.86 (1H, dd, J = 8.2, J = 1.8 Hz, H-6), 6.94 (1H, br s, H-2'), 6.97 (1H, s, H-6'), 
7.02 (1H, d, J = 1.8 Hz, H-2), 7.56 (1H, s, 4-OH)  
 
7.15.15 Trityl Protection of DHCA 
16.4 mg (0.06 mmol, 1.1 equiv.) of trityl chloride, 11.7 µl (0.08 mmol, 1.5 equiv.) of 
triethylamine and 0.3 mg (0.003 mmol, 0.05 equiv.) of DMAP were added to a flask 
containing 20 mg (0.056 mmol) of DHCA (38) in 2 ml of dichloromethane at 0 ºC. The 
reaction mixture was allowed to reach room temperature stirring for at least 2 h, then 
was diluted with dichloromethane, washed with 10% NaHCO3 and brine, dried over 
Na2SO4 and concentrated in vacuo. The residue was chromatographed on silica gel 
using 1% MeOH/CH2Cl2 and 18.4 mg (55%) of the trityl ether (111) was recovered.  
 
1H NMR (acetone-d6): δH 3.39 (1H, m, H-8), 3.57 (3H, s, 3-OCH3), 3.71 – 3.80 (2H, m, 
H-9), 3.84 (3H, s, 3'-OCH3), 4.19 (2H, dd, J = 1.2, J = 5.3 Hz, H-9'), 5.48 (1H, d, J = 
6.5 Hz, H-7), 6.23 (1H, dt, J = 15.9, J = 5.3 Hz, H-8'), 6.51 (1H, br d, J = 15.9 Hz, H-
7'), 6.58 (1H, dd, J = 8.2, J = 1.8 Hz, H-6), 6.62 (1H, d, J = 8.2 Hz, H-5), 6.85 (1H, d, J 
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= 1.8 Hz, H-2), 6.92 (1H, s, H-2'), 6.94 (1H, d, H-2), 7.23 (3H, m, para Ph-H), 7.28 
(6H, m, meta Ph-H), 7.48 (6H, ortho Ph-H)  
 
7.15.16 DCC Coupling between DHCA and p-Coumaric Acid 
16.5 mg (0.05 mmol) of DHCA (38) and 25.6 mg (0.09 mmol 2 equiv.) silyl protected 
p-coumaric acid (66) were dissolved in 2 ml 1:1 dichloromethane/THF. The solution 
was cooled to 0 ºC. 20.9 mg (0.1 mmol, 2.1 equiv.) of DCC and 1.2 mg (0.01 mmol) of 
DMAP were added in portions to the solution, which was allowed to stirr at 0 ºC for 30 
min before warming to room temperature. The suspension as filtered through celite 
and the solvent removed in vacuo. Residue was purified on silica gel (0.5 % 
MeOH/dichloromethane eluent) to yield 3.6 mg (9%) of 9-monoester (113) and 2.1 mg 
(7.5%) of 4-monoester (114). Ester (113) was deprotected with 2.5 equiv. TBAF to 
yield the 9-coumaroyl ester (132) (cf. Section 7.15.19.4 for structural data)    
 
 
Rf: 0.46 (3% MeOH/DCM) 
 
 
Rf: 0.21 (3% MeOH/DCM) 
 
7.15.17 CDI Coupling between DHCA and Cinnamic Acid  
41.4 mg (0.28 mmol, 2 equiv.) of cinnamic acid (51) was dissolved in 2 ml of 
anhydrous dichloromethane. 45.4 mg of CDI (0.28 mmol) was added and the mixture 
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was stirred at room temperature for 4h at room temperature under nitrogen. 50 mg 
(0.14 mmol) of DHCA (38) in 2 ml of THF was added and the reaction mixture was 
stirred at room temperature for 48h, and then refluxed at 75 C for 7h with a catalytic 
amount of DMAP and Na2CO3. The reaction did not go to completion but was cooled, 
diluted with EtOAc, washed quickly with cold 0.05N HCl and then brine. Organic layer 
was dried over MgSO4 and evaporated to dryness. Residue was purified over sílica 
gel using 40% EtOAc/hexane to yield 1.3mg (1.9%)  of the 4,9,9'-tricinnamoyl 
analogue (115), 2.1mg (2.4%) 9,9'-cinnamoyl di-esters (116),  1.1 mg (1.3%)  of the 
4,9'- diester (117), 2.1mg (3.1%) of the 9-monoester and  3.2 mg (4.7%) of the 9'-
cinnamoyl mono-ester (118).                     
 
HRESI-MS (m/z): 748.3487 (calcd for C47H40O9 748.3356) 
Rf: 0.58 (40% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 3.81 (3H, s, 3-OCH3), 3.93 (3H, s, 3'-OCH3), 4.21 (1H, br m, 
H-8), 4.54 (1H, dd, J = 7.6, J = 11.2 Hz, H-9b), 4.66 (1H, dd, J = 5.3, J = 11.2 Hz, H-
9b), 4.83 (2H, d, J = 6.4 Hz, H-9'), 5.76 (1H, d, J = 7.1 Hz, H-7), 6.35 (1H, dt, J = 
15.9, J = 6.4 Hz, H-8'), 6.59 (1H, d, J = 15.9 Hz, H-7'), 6.59 (1H, d, J = 15.8, H-8''), 
6.74 (1H, d, J = 16.4 Hz, H-8'''), 6.78 (1H, d, J = 15.8 Hz, H-8''''), 7.11 (2H, br m, H-5, 
H-2'), 7.16 (2H, br m, H-6, H-6'), 7.28 (1H, s, H-2), 7.44 (6H, br m, H-3'', H-4'', H-5'', 
H-3'''', H-4'''', H-5''''), 7.48 (3H, br m, H-3''', H-4''', H-5'''), 7.67 (1H, d, J = 15.8, H-7''), 
7.69 (4H, br m, H-2'', H-6'', H-2'''', H-6''''), 7.72 (1H, br d, J = 15.8 Hz, H-7''''), 7.78 (2H, 
br m, H-2''', H-6'''), 7.85 (1H, d, J = 156.4 Hz, H-7''')  
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HRESI-MS (m/z): 618.2768 (calcd for C38H34O8 618.2847) 
Rf: 0.40 (40% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 3.82 (3H, s, 3-OCH3), 3.87 - 3.92 (1H, m, H-8), 3.90 (3H, s, 
3'-OCH3), 4.50 (1H, dd, J = 7.0, J = 11.2 Hz, H-9b), 4.61 (1H, dd, J = 5.3, J = 11.2 Hz, 
H-9a), 4.82 (2H, d, J = 6.5 Hz, H-9'), 5.61 (1H, d, J = 7.1 Hz, H-7), 6.34 (1H, dt, J = 
15.9, J = 6.5 Hz, H-8'), 6.53 (1H, d, J = 15.8 Hz, H-8''), 6.58 (1H, d, J = 15.8 Hz, H-
8'''), 6.73 (1H, br d, J = 15.9 Hz, H-7'), 6.84 (1H, d, J = 7.6 Hz, H-5), 6.94 (1H, br d, J 
= 7.6 Hz, H-6), 7.09 (2H, br s, H-2', H-6'), 7.14 (1H, s, H-2), 7.44 (6H, br m, H-3'', H-
4'', H-5'', H-3''', H-4''', H-5'''), 7.62 (1H, d, J = 15.8 Hz, H-7''), 7.66 (2H, br m, H-2'', H-
3''), 7.69 (2H, br m, H-2''', H-6'''), 7.72 (1H, d, J = 15.8 Hz, H-7''')  
13C NMR (acetone-d6): δC 50.4 (C-8, d), 55.4 (3-OMe, q), 55.5 ( 3'-OMe, q), 64.8 (C-
9', t), 65.3 (C-9, t), 88.4 (C-7, d), 109.7 (C-2', d), 111.4 (C-6', d), 114.9 (C-5, d), 115.5 
(C-2, d), 117.7 (C-8'', d), 118.1 (C-8''', d), 119.1 (C-6, d), 121.3 (C-8', d), 128.2 (C-7'', 
d, C-7''', d), 128.9 (C-3'', C-5'', C-3''', C-5''', d), 130.3 (C-7', d), 130.4 (C-4', s), 130.5 
(C-4'', s), 132.5 (C-4''', s), 134.1 (C-1, s, C-1', s), 134.4 (C-1'', s), 134.5 (C-1''', s), 
144.5 (C-3', s), 144.9 (C-2'', C-6'', C-2''', C-6''', d), 147.6 (C-4, s), 148.6 (C-3, s), 150.6  
(C-5', s), 165.9 (C-9'', s, C-9''', s) 
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HRESI-MS (m/z): 618.2469 (calcd for C38H34O8 618.2509) 
Rf: 0.21 (40% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 3.61 (1H, br m, H-8), 3.82 (1H, s, 3-OCH3), 3.90 (3H, s, 3'-
OCH3), 3.84 – 4.02 (2H, m, H-9), 4.83 (1H, d, J = 6.2 Hz, H-9'), 5.73 (1H, d, J = 5.9 
Hz, H-7), 6.31 (1H, dt, J = 15.8, J = 6.2 Hz, H-8'), 6.60 (1H, d, J = 15.8 Hz, H-8''), 6.72 
(1H, d, J = 15.8 Hz, H-7'),  6.78 (1H, d, J = 16.4, H-8'''), 7.08 (3H, br m, H-5, H-6', H-
2'), 7.13 (1H, d, J = 8.2 Hz, H-6), 7.23 (1H, s, H-2), 7.44 (3H, br m, H-3'', H-4'', H-5''), 
7.48 (3H, br m, H-3''', H-4''', H-5'''), 7.71 (2H, br m, H-2'', H-6''), 7.72 (1H, br d, J = 
15.8 Hz, H-7''), 7.78 (2H, br m, H-2''', H-6'''), 7.85 (1H, d, J = 16.4 Hz, H-7''')  
 
 
 HRESI-MS (m/z): 488.1784 (calcd for C29H28O7 488.1836) 
Rf: 0.07 (40% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 3.82 (3H, s, 3-OCH3), 3.85 (1H, br m, H-8), 3.88 (3H, s, 3'-
OCH3), 4.20 (2H, br d, J = 5.3 Hz, H-9'), 4.49 (1H, dd, J = 11.2, J = 7.6 Hz, H-9b), 
4.61 (1H, dd, J = 11.2, J = 5.3 Hz, H-9a), 5.59 (1H, d, J = 7.0 Hz, H-7), 6.28 (1H, dt, J 
= 15.9, J = 5.3 Hz, H-8'), 6.56 (2H, d, J = 15.9 Hz, H-7', H-8''), 6.84 (1H, d, J = 8.2 Hz, 
H-5), 6.95 (1H, br d, J = 8.2 Hz, H-6), 7.01 (1H, br s, H-2'), 7.05 (1H, br s, H-6'), 7.09 
(1H, s, H-2), 7.44 (3H, br m, H-3'', H-4'', H-5''), 7.62 (1H, d, J = 15.9 Hz, H-7''), 7.66 
(2H, br m, H-2'', H-6'') 
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HRESI-MS (m/z): 488.1789 (calcd for C29H28O7 488.1836) 
Rf: 0.10 (40% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 3.56 (1H, br m, H-8), 3.82 (3H, s, 3-OCH3), 3.88 (3H, s, 3'-
OCH3), 3.89 – 3.94 (1H, m, H-9b), 4.22 (1H, br m, H-9a), 4.83 (2H, d, J = 6.5 Hz, H-
9'), 5.58 (1H, d, J = 6.5 Hz, H-7), 6.30 (1H, dt, J = 15.9, J = 6.5 Hz, H-8'), 6.59 (1H, d, 
J = 15.9 Hz, H-8''), 6.71 (1H, br d, J = 15.9 Hz, H-7'), 6.81 (1H, d, J = 8.2 Hz, H-5), 
6.89 (1H, br d, J = 8.2 Hz, H-6), 7.04 (2H, br s, H-2', H-6'), 7.06 (1H, s, H-2), 7.44 (3H, 
br m, H-3', H-4'', H-5''), 7.59 (1H, s, 4-OH), 7.70 (2H, br m, H-2'', H-6''), 7.77 (1H, d, J 
= 15.9 Hz, H-7'') 
13C NMR (acetone-d6): δC 53.8 (C-8, d), 55.4 (3-OMe, q), 55.5 ( 3'-OMe, q), 63.7 (C-
9, t), 64.9 (C-9', t), 87.8 (C-7, d), 109.6 (C-2', d), 111.1 (C-6', d), 114.8 (C-5, d), 115.7 
(C-2, d), 118.1 (C-6, d), 118.7 (C-8'', d), 120.8 (C-7', d), 128.2 (C-7'', d, C-8', d), 128.9 
(C-3'', C-5'', C-3''', C-5''', d), 130.3 (C-4', d), 131.1 (C-4'', s), 134.4 (C-1, s, C-1', s), 
134.5 (C-1'', s), 134.5 (C-1''', s), 144.3 (C-3', s), 144.5 (C-2'', C-6'', d), 146.5 (C-4, s), 
147.8 (C-3, s), 149.6  (C-5', s), 165.9 (C-9'', s) 
  
7.15.18 CDI Coupling between DHCA and Caffeic Acid 
CDI (160.5 mg, 0.99 mmol, 3 equiv.) coupling between 132.7 mg (0.33 mmol) of silyl 
protected p-caffeic acid (120) and DHCA (38) (45 mg, 0.13 mmol) was conducted as 
in Section 7.15.17 to yield 2.1 mg (1.6%) of inseparable mixture (~ 2:1 ratio) of 9'- and 
9-caffeoyl esters (121). 
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HRESI-MS (m/z): 520.1725 (calcd for C29H28O9 520.1734) 
1H NMR (acetone-d6) of 9'-ester: δH 3.52 (1H, br m, H-8), 3.78 (3H, s, 3-OCH3), 3.79 – 
3.87 (2H, m, H-9), 3.84 (3H, s, 3'-OCH3), 4.75 (2H, d, J = 6.3 Hz, H-9'), 5.54 (1H, d, J 
= 5.7 Hz, H-7), 6.20 (1H, d, J = 15.5 Hz, H-8''), 6.24 (1H, dt, J = 16.0, J = 6.3 Hz, H-
8'), 6.65 (1H, d, J = 16.0 Hz, H-7'), 6.77 (1H, d, J = 8.2 Hz, H-5, H-5''), 6.81 – 7.09 (6 
H, m, H-2, H-6, H-2', H-6', H-6'', H-2''), 7.53 (1H, d, J = 15.5 Hz, H-7'')  
 
7.15.19 Alternative Route to DHCA Esterification via Ethyl Ferulate Dimer 
7.15.19.1  Dimerisation of Ethyl Ferulate 
Silver(i) oxide (3.75 g, 16.2 mmol) was added to a solution of ethyl ferulate (2.4 g, 
10.8 mmol, 1.5 equiv.) in anhydrous dichloromethane (20 ml). After stirring at room 
temperature for 4 h, the reaction mixture was filtered through celite and evaporated to 
dryness. The residue was chromatographed on silica gel using 25% ethyl 
acetae/hexane to yield 293 mg (12.3%) of the dimer (124). Repeated dimerisation 
reaction three times. 
 
 
 
HRESI-MS (m/z): 442.1627 (calcd for C24H26O8 442.1628) 
Rf: 0.56 (45% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 1.28 (3H, t, J = 7.1 Hz, 9-OCH2CH3), 1.31 (3H, t, J = 7.1 Hz, 
9'-OCH2CH3), 3.84 (3H, s, 3-OCH3), 3.93 (3H, s, 3'-OCH3), 4.20 (1H, q, J = 7.1 Hz, 9-
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OCH2CH3), 4.27 (1H, br q, J = 7.1 Hz, 9'-OCH2CH3), 4.44 (1H, d, J = 7.9 Hz, H-8), 
6.04 (1H, d, J = 7.9 Hz, H-7), 6.42 (1H, d, J = 15.8 Hz, H-8'), 6.85 (1H, d, J = 8.2 Hz, 
H-5), 6.92 (1H, dd, J = 8.2, J = 1.5 Hz, H-6), 7.10 (1H, d, J = 1.5 Hz, H-2), 7.29 (1H, 
br s, H-6'), 7.34 (1H, br s, H-2'), 7.63 (1H, d, J = 15.8 Hz, H-7'), 7.73 (1H, s, 4-OH)  
13C NMR (acetone-d6): δC  13.60 (9-OCH2CH3, q), 13.75 (9'-OCH2CH3, q), 55.2 (C-8, 
d), 55.4 (3-OMe, q), 55.6 (3'-OMe, q), 59.7 (9-OCH2CH3, t), 61.3 (9'-OCH2CH3, t), 
87.5 (C-7, d), 109.8 (C-2, d), 112.4 (C-2', d), 114.9 (C-5, d), 115.8 (C-8', d), 118.0 (C-
6', d), 119.3 (C-6, d), 126.5 (C-4', s), 128.6 (C-1', s) 131.2 (C-1, s), 144.3 (C-7', d),  
144.9 (C-3', s), 147.1 (C-4, s), 147.7 (C-3, s), 150.1 (C-5', s), 166.4 (C-9, s), 170.2 (C-
9', s)  
 
  
7.15.19.2  Silyl Protection of Ethyl Ferulate Dimer  
391.8 mg (2.6 mmol, 1.5 equiv.) of tert-butyldimethylsilyl chloride, 294 mg (4.3 mmol, 
2.5 equiv.) of imidazole and 11 mg (0.09 mmol) of DMAP were added to a flask 
containing 764 mg (1.73 mmol) of dimer (124) in 10 ml of dichloromethane at 0 °C. 
The reaction mixture was stirred at room temperature overnight, then diluted with 
ethyl acetate, washed with 10% NaHCO3 and brine, dried over Na2SO4 and 
concentrated in vacuo. The residue was chromatographed on silica gel using 30% 
EtOAc/hexane and 910 mg (95%) of silyl protected dimer (125) was recovered.  
 
 
HRESI-MS (m/z): 556.2497 (calcd for C30H40O8Si 556.2493) 
Rf: 0.86 (45% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 0.00 (6H, s, 4-O-Si(CH3)2), 0.84 (9H, s, 4-O-Si-C(CH3)3),  
1.12 (3H, t, J = 7.1 Hz, 9-OCH2CH3), 1.15 (3H, t, J = 7.1 Hz, 9'-OCH2CH3), 3.83 (3H, 
s, 3-OCH3), 3.94 (3H, s, 3'-OCH3), 4.19 (1H, q, J = 7.1 Hz, 9-OCH2CH3), 4.28 (1H, br 
q, J = 7.1 Hz, 9'-OCH2CH3), 4.44 (1H, d, J = 8.0 Hz, H-8), 6.07 (1H, d, J = 8.0 Hz, H-
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7), 6.42 (1H, br d, J = 16.2 Hz, H-8'), 6.90 (1H, d, J = 8.2 Hz, H-5), 6.93 (1H,br d, J = 
8.2 Hz, H-6), 7.12 (1H, br s, H-2), 7.30 (1H, br s, H-6'), 7.35 (1H, br s, H-2'), 7.63 (1H, 
d, J = 16.2 Hz, H-7') 
 
7.15.19.3 DIBAL reduction of Silyl Protected Ethyl Ferulate Dimer 
562 mg (1.0 mmol) of silyl dimer (125) dissolved in 20 ml anhydrous dichloromethane 
and 1 ml (6 mmol, 6 equiv.) of DIBAL-H in 5 ml of dichloromethane was added 
gradually to the reaction mixture at -78°C under nitrogen. The DIBAL reaction was 
quenched with 100ml of saturated sodium sulphate. The mixture was filtered through 
a 1cm plug of celite and the filtrate was extracted with EtOAc (4 x 100ml). Combined 
organic layers were dried over anhydrous Na2SO4, filtered and evaporated in vacuo. 
This reaction was repeated on 910 mg (1.67 mmol) of silyl dimer (125) and 1 ml (6 
mmol, 3.6 equiv.) of DIBAL-H. The combined reaction residues were subjected to 
silica gel column chromatography using 1.2% MeOH/DCM. A total of 96 mg (8%) of 
desired product (126) was recovered and 160 mg of by-product (133)  (13%) was 
recovered, a port. 25 mg of by-product (133) was treated with 30 µl of TBAF in THF to 
yield 2.4 mg (13%) of the enol ether (134).    
 
 
1H NMR (acetone-d6): δH 0.15 (6H, s, 4-O-Si(CH3)2), 0.99 (9H, s, 4-O-Si-C(CH3)3),  
3.54 (1H, m, H-8), 3.74 (2H, t, J = 5.3 Hz, 9'-OH), 3.81 (3H, s, 3-OCH3), 3.82 – 3.92 
(2H, m, H-9), 3.87 (3H, s, 3'-OCH3), 4.13 (1H, t, J = 5.0 Hz, 9-OH), 4.20 (1H, br dd, J 
= 5.3, J = 5.6 Hz, H-9'), 5.60 (1H, d, J = 5.9 Hz, H-7), 6.24 (1H, dt, J = 15.9, J = 5.6 
Hz, H-8'), 6.53 (1H, br d, J = 15.9 Hz, H-7'), 6.85 (1H, d, J = 8.2 Hz, H-5), 6.89 (1H, br 
d, J = 8.2 Hz, H-6), 6.95 (1H, br s, H-2'), 6.98 (1H, br s, H-6'), 7.06 (1H, br s, H-2)  
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HRESI-MS (m/z): 358.1396 (calcd for C20H22O6 358.1417) 
1H NMR (acetone-d6): δH 3.65 (3H, s, 3-OCH3), 3.81 (1H, t, J =  5.5 Hz, 9'-OH), 3.88 
(3H, s, 3'-OCH3), 4.11 (2H, br d, J = 5.5 Hz, H-9), 4.17 (2H, dd, J = 5.6, J = 5.5 Hz, H-
9'), 4.22 (1H, t, J = 5.5 Hz, 9-OH), 6.18 (1H, br m, H-8), 6.27 (1H, dt, J = 15.7, J = 5.5 
Hz, H-8'), 6.50 (1H, br d, J = 15.7 Hz, H-7'), 6.68 (1H, d, J = 8.2 Hz, H-5), 6.83 (1H, br 
d, J = 7.5 Hz, H-6'), 6.87 (1H, d, J = 8.2 Hz, H-5'), 6.95 (1H, br s, H-6'), 7.12 (1H, br s, 
H-2'), 7.27 (1H, br s, H-2), 7.57 (1H, s, 4-OH)  
13C NMR (acetone-d6): δC 54.9 (3-OMe, q), 55.3 (3'-OMe, q), 61.1 (C-9, t), 62.3 (C-9', 
t), 110.2 (C-2', d), 111.7 (C-6, d), 113.3 (C-8, d),114.6 (C-5, d), 115.7 (C-6', d), 119.1 
(C-5', d), 122.1 (C-8', d), 126.7 (C-1', s) 122.1 (C-7', d), 132.4 (C-1, s) 144.5 (C-4', s), 
145.7 (C-4, s) 147.0 (C-3', s), 150.0 (C-3, s), 150.2 (C-7, s) 
 
7.15.19.4  p-Coumaroyl Esterification of DHCA 
89 mg (0.30 mmol) of silyl protected p- coumaric acid (66) was dissolved in 2 ml of 
dry dichloromethane. 2 drops of anhydrous DMF were added and then 60 µl (0.38 
mmol) of oxalyl chloride was added drop-wise at room temperature, under nitrogen. 
After addition the reaction mixture was refluxed at 50°C for 2h. Solvent and excess 
oxalyl chloride was removed under vacuum pressure to yield the acid chloride, which 
was dissolved in 3 ml of dry dichloromethane and added to round bottom flask 
containing 70 mg (0.15 mmol) of silyl protected DHCA (126). 25 µl of Et3N and a 
catalytic amount of DMAP were added and the reaction mixture which was stirred at 
room temperature under N2. Reaction was monitored on TLC and then quenched with 
water and the organic layer was washed with 0.1M HCl and saturated NaHCO3. The 
solution was dried over MgSO4, the solvent was evaporated under reduced pressure 
and residue was chromatographed on silica gel using 30% ethyl acetate hexane to 
yield the three silyl esters, which were each subsequently deprotected with TBAF (3 – 
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4 equiv.) to yield 13.2 mg (14%) of the 9,9'-dicoumaroyl (130), 6.0 mg (8%) of the 9'-
coumaroyl (131) and 1.2 mg (1.6%) of the 9-coumaroyl (132) DHCA analogues.   
 
 
HRESI-MS (m/z): 650.2584 (calcd for C38H34O10 650.2153) 
Rf: 0.44 (45% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 3.81 (3H, s, 3-OCH3), 3.85 - 3.92 (1H, m, H-8), 3.90 (3H, s, 
3'-OCH3), 4.46 (1H, dd, J = 7.6, J = 10.5 Hz, H-9b), 4.59 (1H, dd, J = 5.2, J = 10.5 Hz, 
H-9a), 4.80 (2H, d, J = 6.7 Hz, H-9'), 5.60 (1H, d, J = 7.6 Hz, H-7), 6.32 (1H, dt, J = 
15.9, J = 6.7 Hz, H-8'), 6.34 (1H, d, J = 16.2 Hz, H-8''), 6.38 (1H, d, J = 15.7 Hz, H-
8'''), 6.71 (1H, br d, J = 15.6 Hz, H-7'), 6.84 (1H, d, J = 8.6 Hz, H-5), 6.90 (4H, d, J = 
8.6 Hz, H-3'', H-5'', H-3''', H-5'''), 6.94 (1H, br d, H-6), 7.08 (2H, br s, H-2', H-6'), 7.12 
(1H, br s, H-2), 7.53 (2H, br d, J = 8.6 Hz, H-2'', H-6''), 7.55 (1H, d, J = 16.2 Hz, H-7''), 
7.56 (2H, br d, J = 8.6 Hz, H-2''', H-6'''), 7.64 (1H, d, J = 15.7 Hz, H-7'''), 8.01 (1H, s, 
4-OH)  
13C NMR (acetone-d6): δC 50.5 (C-8, d), 55.4 (3-OMe, q), 55.5 ( 3'-OMe, q), 64.5 (C-
9', t), 65.0 (C-9, t), 88.4 (C-7, d), 109.8 (C-2', d), 111.3 (C-6', d), 114.2 (C-8'', d), 114.6 
(C-8''', d), 114.9 (C-5, d), 115.5 (C-2, d), 115.8 (C-3'', C-5'', C-3''', C-5''', d), 119.1 (C-
6, d), 121.5 (C-8', d), 126.0 (C-1'', s), 126.12 (C-1''', s), 128.4 (C-1', d), 130.1 (C-2'', C-
6'', d), 130.2  (C-2''', C-6''', d), 130.6 (C-4', s), 132.5 (C-4''', s), 134.1 (C-1, s), 133.9 
(C-7', d), 144.5 (C-3', s), 144.6 (C-7'', d), 145.0 (C-7''', d), 146.7 (C-3, s), 147.6 (C-4, 
s), 148.6 (C-5', s), 159.7  (C-4'', s), 159.8 (C-4'''), 166.3 (C-9'', s), 166.4 (C-9''', s) 
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HRESI-MS (m/z): 504.1788 (calcd for C29H28O8 504.1785) 
Rf: 0.23 (45% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 3.56 (1H, br m, H-8), 3.82 (3H, s, 3-OCH3), 3.85 – 3.89 (2H, 
m, H-9), 3.86 (3H, s, 3'-OCH3), 4.12 (1H, br s, 9-OH), 4.80 (2H, d, J = 6.5 Hz, H-9'), 
5.58 (1H, d, J = 6.5 Hz, H-7), 6.29 (1H, dt, J = 15.3, J = 6.5 Hz, H-8'), 6.39 (1H, d, J = 
15.7 Hz, H-8''), 6.69 (1H, br d, J = 15.3 Hz, H-7'), 6.81 (1H, d, J = 8.1 Hz, H-5), 6.88 
(1H, dd, J = 8.2, J = 1.6 Hz, H-6), 6.89 (2H, d, J = 8.1 Hz, H-3'', H-5''), 7.03 (1H, br s, 
H-2'), 7.04 (1H, d, J = 1.6 Hz, H-2), 7.05 (1H, br s, H-6',), 7.56 (2H, d, J = 8.1 Hz, H-
2'', H-6''), 7.65 (1H, d, J = 15.7 Hz, H-7'') 
13C NMR (acetone-d6): δC 53.8 (C-8, d), 55.4 (3-OMe, q), 55.5 ( 3'-OMe, q), 63.7 (C-
9, t), 64.6 (C-9', t), 87.8 (C-7, d), 109.6 (C-2', d), 111.1 (C-6', d), 114.7 (C-8'', d), 114.9  
(C-5, d), 115.6 (C-2, d), 115.8  (C-3'', C-5'', d), 118.8 (C-6, d), 121.1 (C-8', d), 126.2 
(C-1''), 129.8 (C-1', s), 130.2 (C-2'', C-6'', d), 133.5 (C-1, s), 134.2 (C-7', d), 144.4 (C-
3', s), 144.6 (C-7'', d), 146.5 (C-3, s), 147.6 (C-4, s), 148.8  (C-5', s), 159.7 (C-4'', s), 
166.4 (C-9'', s) 
 
HRESI-MS (m/z): 504.1800 (calcd for C29H28O8 504.1785) 
Rf: 0.14 (45% ethyl acetate/hexane) 
1H NMR (acetone-d6): δH 3.82 (3H, s, 3-OCH3), 3.85 - 3.92 (1H, m, H-8), 3.89 (3H, s, 
3'-OCH3), 4.20 (2H, br m, H-9'), 4.46 (1H, br m, H-9b), 4.57 (1H, dd, J = 11.2, J = 5.3 
Hz, H-9a), 5.58 (1H, d, J = 7.4 Hz, H-7), 6.32 (1H, dt, J = 15.9, J = 6.7 Hz, H-8'), 6.36 
(1H, d, J = 16.1 Hz, H-8''), 6.55 (1H, br d, J = 16.1 Hz, H-7'), 6.84 (1H, d, J = 7.9 Hz, 
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H-5), 6.90 (2H, d, J = 8.6 Hz, H-3'', H-5''), 6.94 (1H, br d, H-6), 7.00 (1H, br s, H-2'), 
7.05 (1H, br s, H-6'), 7.09 (1H, br s, H-2), 7.54 (2H, br d, J = 8.6 Hz, H-2'', H-6''), 7.61 
(1H, d, J = 16.1 Hz, H-7'')  
 
7.15.19.5  Piperonylic Esterification of DHCA 
18.8 mg (0.11 mmol) of piperonylic acid was dissolved in 1 ml of dry dichloromethane. 
1 drop of anhydrous DMF and 15 µl of oxalyl chloride were added. After addition the 
reaction mixture was refluxed at 50°C for 2h. Solvent and excess oxalyl chloride was 
removed under vacuum pressure to yield the acid chloride, which was dissolved in 2 
ml of dry dichloromethane and added to round bottom flask containing 26 mg (0.06 
mmol) of silyl protected DHCA (126). 20 µl of Et3N and a catalytic amount of DMAP 
were added and the reaction mixture which was stirred at room temperature under N2. 
Reaction was monitored on TLC and then quenched with water and the organic layer 
was washed with 0.1M HCl and saturated NaHCO3. The solution was dried over 
MgSO4, the solvent was evaporated under reduced pressure and residue was 
chromatographed on silica gel using 20% ethyl acetate/hexane to yield the two silyl 
esters, which were each subsequently deprotected with TBAF (3 – 4 equiv.) to give 
2.1 mg (5%) of the  9,9'-dipiperonylic (135) and 1.8 mg (3.7%) of the 4,9,9'-
tripiperonylic (136) ester analogues.   
 
HRESI-MS (m/z): 654.2103 (calcd for C36H30O12 654.2106) 
1H NMR (acetone-d6): δH 3.79 (3H, s, 3-OCH3), 3.89 (3H, s, 3'-OCH3), 3.96 (1H, m, H-
8), 4.56 (1H, dd, J = 7.6, J = 11.1 Hz, H-9b), 4.70 (1H, dd, J = 5.5, J = 11.1 Hz, H-9a), 
4.91 (2H, d, J = 5.9 Hz, H-9'), 5.66 (1H, d, J = 6.9 Hz, H-7), 6.11 (3''-O-CH2-O-4''), 
6.13 (3'''-O-CH2-O-4'''), 6.36 (1H, dt, J = 15.9, J = 5.9 Hz, H-8'), 6.75 (1H, d, J = 15.9 
Hz, H-7'), 6.83 (1H, d, J = 8.6 Hz, H-5), 6.93 (3H, m, H-5'', H-5''', H-6), 7.08 (1H, br s, 
H-2), 7.09 (1H, br s, H-6'), 7.15 (1H, br s, H-2'), 7.33 (1H, d, J = 1.4 Hz, H-2''), 7.44 
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(1H, d, J = 1.4 Hz, H-2'''), 7.55 (1H, dd, J = 8.3, J = 1.4 Hz, H-6''), 7.64 (1H, s, 4-OH), 
7.67 (1H, dd, J = 8.3, J = 1.4 Hz, H-6''') 
13C NMR (acetone-d6): δC 50.4 (C-8, d), 55.3 (3-OMe, q), 55.5 ( 3'-OMe, q), 65.3 (C-
9', t), 65.8 (C-9, t), 88.6 (C-7, d), 102.1 ([3''-O-CH2-O-4''], t), 102.2 ([3'''-O-CH2-O-4'''], 
t), 107.9 (C-5'', C-5''', d), 108.8 (C-2'', C-2''', d), 109.8 (C-2', d), 111.5 (C-6', d), 114.9 
(C-5, d), 115.5 (C-2, d), 119.1 (C-6, d), 121.2 (C-8', d), 123.9 (C-1'', s), 124.3 (C-1''', 
s), 125.1 (C-6'', d), 125.2 (C-6''', d), 128.3 (C-4, s), 130.5 (C-1', d), 132.5 (C-1), 134.1 
(C-7', d), 144.5 (C-3', s), 146.8 (C-3, s), 147.6 (C-4, s), 148.0 (C-4'', C-4'''), 148.7 (C-
5', s), 151.8  (C-3'', s), 151.9 (C-3'''), 165.0 (C-9'', C-9''', s) 
 
 
HRESI-MS (m/z): 802.1790 (calcd for C44H34O15 802.1812) 
1H NMR (acetone-d6): δH 3.76 (3H, s, 3-OCH3), 3.92 (3H, s, 3'-OCH3), 4.01 (1H, m, H-
8), 4.61 (1H, dd, J = 8.3, J = 11.1 Hz, H-9b), 4.75 (1H, dd, J = 5.5, J = 11.1 Hz, H-9a), 
4.91 (2H, d, J = 6.9 Hz, H-9'), 5.81 (1H, d, J = 6.9 Hz, H-7), 6.12 (3''-O-CH2-O-4''), 
6.13 (3'''-O-CH2-O-4'''), 6.17 (3''''-O-CH2-O-4''''), 6.38 (1H, dt, J = 15.2, J = 6.9 Hz, H-
8'), 6.76 (1H, d, J = 15.2 Hz, H-7'), 6.94 (2H, d, J = 8.3 Hz, H-5'', H-5'''), 7.02 (1H, d, J 
= 8.3 Hz, H-5''''), 7.11 (1H, d, J  = 6.9 Hz, H-5), 7.12 (1H, br s, H-6'), 7.17 (1H, br s, H-
2), 7.20 (1H, d, J = 6.9 Hz), 7.28 (1H, br s, H-2'), 7.38 (1H, br s, H-2''), 7.44 (1H, br s, 
H-2'''), 7.54 (1H, br s, H-2''''), 7.56 (1H, br d, J = 8.3 Hz, H-6''), 7.67 (1H, br d, J = 8.3 
Hz, H-6'''), 7.80 (1H, br d, J = 8.3 Hz, H-6'''') 
 
7.15.20 DHCA and GGCE Ring Substitution 
7.15.20.1 Monolignol synthesis 
4.9 g (0.027 mol) of syringaldehyde was dissolved in 100 ml of dry dichloromethane. 
11.3 g (0.0325 mol,1.2 equiv.) of triphenylcarbethoxymethylphosphorane (46) was 
added and the reaction was stirred at room temperature under nitrogen for 48 h. The 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
188 
 
reaction residue was purified by silica gel column chromatography, using 12% 
EtOAc/Hexane. Recovered 3.7 g (0.015 mol, 54% overall yield) of E- isomer, ethyl 
sinapate, which was reduced with DIBAL (0.06 mol, 4 equiv. 10.5 ml) in 
dichloromethane at -78°C under nitrogen. The reaction was worked up as previously 
and the residue was subjected to silica gel column chromatography using 1.5% 
isopropanol/dichloromethane. Recovered 1.2 g of unreacted starting material and 1.3 
g (43 %) of sinapyl alcohol (151). 
 
 
HRESI-MS (m/z): 210.0871 (calcd for C11H14O4 210.0893) 
Rf: 0.32 (2% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 3.84 (6H, s, 3-OCH3, 5-OCH3), 4.19 (2H, d, J = 5.0 Hz, H-9), 
6.25 (1H, dt, J = 15.9, J = 5.0 Hz, H-8),  6.48 (1H, d, J = 15.9 Hz, H-7), 6.73 (2H, s, H-
2, H-6) 
  
Similarly, the following monolignols were prepared:  
 
 
HRESI-MS (m/z): 194.0875 (calcd for C11H14O3 194.0866) 
Rf: 0.45 (6% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 1.38 (3H, t, J = 7.0 Hz, 3-O-CH2CH3), 3.71 (1H, t, J = 5.5 
Hz, 9-OH), 4.12 (2H, q, J = 7.0 Hz, 3-O-CH2CH3), 4.19 (2H, dd, J = 5.3, J = 5.5 Hz, H-
9), 6.22 (1H, dt, J = 16.0, J = 5.5 Hz, H-8),  6.49 (1H, d, J = 16.0 Hz, H-7), 6.77 (1H, 
d, J = 8.2 Hz, H-5), 6.86 (1H, dd, J = 8.2, J = 1.5 Hz, H-6), 7.04 (1H, d J = 1.5 Hz, H-
2) 
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13C NMR (acetone-d6): δC 14.2 (3-O-CH2CH3), 62.5 (C-9, t), 64.1 (3-O-CH2CH3, t), 
110.2 (C-2, d), 114.9 (C-5, d), 119.7 (C-6, d), 127.2 (C-8, d), 129.4 (C-1, s), 129.5 (C-
7, d), 146.5 (C-3, s), 146.7 (C-4, s) 
 
 
HRESI-MS (m/z): 150.0349 (calcd for C9H10O2 150.0270) 
Rf: 0.40 (8% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 3.71 (1H, t, J = 5.3 Hz, 9-OH), 4.19 (2H, dd, J = 5.3, J = 5.9 
Hz, H-9), 6.20 (1H, dt, J = 15.9, J = 5.9 Hz, H-8),  6.50 (1H, d, J = 15.9 Hz, H-7), 6.80 
(2H, d, J = 8.5 Hz, H-3, H-5), 7.27 (2H, d, J = 8.5 Hz, H-2, H-6) 
13C NMR (acetone-d6): δC 62.5 (C-9, t), 115.3 (C-3, C-5, d), 127.0 (C-8, d), 127.5 (C-
2, C-6, d), 128.9 (C-1, s), 129.2 (C-7, d), 156.9 (C-4, s) 
 
 
HRESI-MS (m/z): 229.9775 (calcd for C9H9BrO2 229.9763) 
Rf: 0.49 (6% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 4.20 (2H, br d, J = 5.3 Hz, H-9), 6.27 (1H, dt, J = 15.9, J = 
5.3 Hz, H-8),  6.50 (1H, d, J = 15.9 Hz, H-7), 6.96 (1H, d, J = 8.5 Hz, H-5), 7.28 (1H, 
dd, J = 8.5, J = 1.8 Hz, H-6), 7.57 (1H, d, J = 1.8 Hz, H-2) 
13C NMR (acetone-d6): δC 62.3 (C-9, t), 109.7 (C-3, s), 116.4 (C-5, d), 126.6 (C-6, d), 
127.5 (C-7, d), 129.0 (C-8, d), 130.6 (C-2, d), 131.0 (C-1, s), 153.2 (C-4, s)  
 
 
HRESI-MS (m/z): 195.0513 (calcd for C9H8NO4 195.0532) 
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Rf: 0.54 (5% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 4.25 (2H, br d, J = 5.2 Hz, H-9), 6.45 (1H, dt, J = 15.8, J = 
5.2 Hz, H-8),  6.65 (1H, d, J = 15.8 Hz, H-7), 7.17 (1H, d, J = 8.8 Hz, H-5), 7.83 (1H, 
dd, J = 8.8, J = 1.9 Hz, H-6), 8.08 (1H, d, J = 1.9 Hz, H-2) 
13C NMR (acetone-d6): δC 62.0 (C-9, t), 120.1 (C-5, d), 122.1 (C-2, d), 126.53 (C-7, 
d), 130.3 (C-1, s), 131.4 (C-8, d), 134.6 (C-6, d), 137.7 (C-3, s), 153.6 (C-4, s)  
 
 
HRESI-MS (m/z): 307.8869 (calcd for C9H8BrO2 307.8853) 
Rf: 0.50 (6% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 4.22 (2H, d, J = 4.9 Hz, H-9), 6.37 (1H, dt, J = 4.9, J = 15.8 
Hz, H-8),  6.50 (1H, d, J = 15.8 Hz, H-7), 7.61 (2H, s, H-2, H-6) 
13C NMR (acetone-d6): δC 62.3 (C-9, t), 109.7 (C-3, s), 116.4 (C-5, d), 126.6 (C-6, d), 
127.5 (C-7, d), 129.0 (C-8, d), 130.6 (C-2, d), 131.0 (C-1, s), 153.2 (C-4, s), 8.01 (1H, 
s, 4-OH)  
 
 
7.15.20.2 Oxidative Coupling of Coniferyl Alcohol Analogues 
Oxidative coupling of each monolignol was conducted as for coniferyl alcohol (Section 
7.15.5) in dioxane-water 92/3, v/v, pH 4 – 4.5 adjusted with dil. H3PO4) with HRP (120 
U/10ml) and 0.5 – 1.5 equiv. H2O2 as the oxidant. 
i) Oxidative coupling of 345 mg (1.78 mmol) of monolignol (137) yielded 162 mg 
(47%) of β-5 dimer (141) and 44 mg (12%) of the β-O-4 dimer (145).  
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HRESI-MS (m/z): 386.1783 (calcd for C22H26O6 386.1772) 
Rf: 0.17 (6% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 1.35 (6H, t, J = 7.2 Hz, 3-O-CH2CH3, 3'-O-CH2CH3), 3.53 
(1H, m, H-8), 3.74 (1H, t, J = 5.6 Hz, 9'-OH), 3.82 (1H, br m, H-9b), 3.88 (1H, m, H-
9a), 4.08 (2H, q, J = 7.2 Hz, 3-O-CH2CH3), 4.16 (2H, q, J = 7.2 Hz, 3'-O-CH2CH3), 
4.20 (2H, br dd, J = 5.6, J = 5.7 Hz, H-9'), 5.55 (1H, d, J = 6.2 Hz, H-7), 6.23 (1H, dt, J 
= 15.7, J = 5.7 Hz, H-8'), 6.51 (1H, br d, J = 15.7 Hz, H-7'), 6.81 (1H, d, J = 8.3 Hz, H-
5), 6.88 (1H, br d, J = 8.3 Hz, H-6), 6.93 (1H, br s, H-2'), 6.98 (1H, br s, H-6'), 7.02 
(1H, br s, H-2), 7.57 (1H, s, 4-OH)  
13C NMR (acetone-d6): δC  14.2 (3-O-CH2CH3, q), 14.4 (3'-O-CH2CH3, q), 53.9 (C-8, 
d), 62.5 (C-9', t), 63.8 (C-9, t), 64.2 (3-O-CH2CH3, t), 64.3 (3'-O-CH2CH3, t), 87.6 (C-7, 
d), 110.6 (C-2, d), 112.4 (C-2', d), 114.8 (C-5, d), 115.2 (C-6', d), 118.7 (C-6, d), 127.4 
(C-8', d), 129.6 (C-7', d), 129.7 (C-4', s), 131.0 (C-1', s) 133.5 (C-1, s), 143.4 (C-3', s), 
146.5 (C-4, s), 146.6 (C-3, s), 148.3 (C-5', s) 
 
HRESI-MS (m/z): 404.1830 (calcd for C22H28O7 404.1836) 
Rf: 0.15 (6% methanol/dichloromethane) 
1H NMR (acetone-d6) of erythro diastereomer: δH 1.35 (3H, t, J = 7.2 Hz, 3-O-
CH2CH3), 1.41 (3H, t, J= 7.2 Hz, 3'-O-CH2CH3), 3.81 (2H, m, H-9), 4.06 (2H, q, J = 7.2 
Hz, 3-O-CH2CH3), 4.09 (2H, q, J = 7.2 Hz, 3'-O-CH2CH3), 4.21 (2H, br d, J = 5.2 Hz, 
H-9'), 4.24 (1H, m, H-8), 4.51 (1H, d, J = 4.1 Hz, 7-OH), 4.87 (1H, dd, J = 4.8, J = 4.1 
Hz, H-7), 6.29 (1H, dt, J = 15.5, J = 5.2 Hz, H-8'), 6.51 (1H, br d, J = 15.5 Hz, H-7'), 
6.78 (1H, d, J = 8.3 Hz, H-5), 6.87 (1H, dd, J = 8.3, J = 2.0 Hz, H-6), 6.91 (1H, br d, J 
= 8.3 Hz, H-6'), 6.93 (2H, br s, H-2, H-2'), 7.16 (1H, d, J = 8.3 Hz, H-5'), 7.41 (1H, s, 
4-OH)  
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13C NMR (acetone-d6): δC  14.2 (3-O-CH2CH3, q), 14.3 (3'-O-CH2CH3, q), 61.0 (C-9, 
t), 62.4 (C-9', t), 64.2 (3-O-CH2CH3, t), 64.3 (3'-O-CH2CH3, t), 73.0 (C-7, d), 86.6 (C-8, 
d), 111.6 (C-2, C-2', d), 114.3 (C-6, d), 119.4 (C-6', d), 119.6 (C-5', d), 119.8 (C-5, d), 
128.9 (C-8', d), 129.0 (C-7', d), 132.4 (C-1', s), 133.3 (C-1, s), 146.0 (C-3', s), 146.2 
(C-3, s), 148.4 (C-4, s), 150.5 (C-4', s) 
 
ii) Oxidative coupling of 82.4 mg (0.55 mmol) of monolignol (138) yielded 15.2 mg 
(19%) of the β-5 dimer (142) and 7.7 mg (9%) of the β-O-4 dimer (146).  
 
 
HRESI-MS (m/z): 298.1257 (calcd for C18H18O4 298.1248) 
Rf: 0.23 (8% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 3.49 (1H, m, H-8), 3.74 (1H, br s, 9'-OH), 3.83 (1H, br m, H-
9b), 3.88 (1H, br m, H-9a), 4.1(1H, br s, 9-OH), 4.20 (2H, br m, H-9'), 5.56 (1H, d, J = 
6.2 Hz, H-7), 6.23 (1H, dt, J = 15.8, J = 5.8 Hz, H-8'), 6.54 (1H, br d, J = 15.8 Hz, H-
7'), 6.75 (1H, d, J = 8.2 Hz, H-3'), 6.83 (2H, d, J = 8.4 Hz, H-5, H-3), 7.22 (1H, dd, J = 
8.2, J = 1.6 Hz, H-2'), 7.24 (1H, d,  J = 8.4 Hz, H-2, H-6), 7.40 (1H, s, H-6') 
13C NMR (acetone-d6): δC  53.6 (C-8, d), 62.6 (C-9', t), 63.9 (C-9, t), 87.2 (C-7, d), 
108.8 (C-3', d), 115.2 (C-5, C-3, d), 122.6 (C-6', d), 127.2 (C-2', C-2, C-6, d), 127.3 
(C-8', d), 128.6 (C-4', s), 129.4 (C-7', d), 130.2 (C-1', s), 133.2 (C-1, s), 157.2 (C-4, s), 
159.7 (C-5', s) 
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HRESI-MS (m/z): 316.1293 (calcd for C18H20O5 316.1354) 
Rf: 0.10 (8% methanol/dichloromethane) 
1H NMR (acetone-d6) of the erythro diastereomer: δH 3.76 (2H, br m, H-9), 4.20 (2H, 
br d, J = 5.5 Hz, H-9'), 4.44 (1H, m. H-8), 4.95 (1H, br m, H-7), 6.25 (1H, dt, J = 16.0, 
J = 5.5 Hz, H-8'), 6.53 (1H, br d, J = 16.0 Hz, H-7'), 6.78 (2H, d, J = 8.8 Hz, H-3, H-5), 
6.97 (2H, d, J = 8.8 Hz, H-5', H-3'), 7.29 (4H, m, H-2, H-2', H-6, H-6') 
13C NMR (acetone-d6): δC  60.8 (C-9, t), 62.5 (C-9', t), 72.4 (C-7, d), 83.6 (C-8, d), 
114.6 (C-3, C-5, d), 116.4 (C-5', C-3', d), 127.2 (C-6, C-2, C-6', C-2', d), 128.0 (C-8', 
d), 128.9 (C-7', d), 130.2 (C-1', s), 133.7 (C-1, s), 156.7 (C-4, s), 158.8 (C-4', s) 
 
iii) Oxidative coupling of 462 mg (2.02 mmol) of monolignol (139) yielded 67 mg 
(15%) of the β-5 dimer (143) and 88.7 mg (19%) of the β-O-4 dimer (147).  
 
HRESI-MS (m/z): 456.9420 (calcd for C18H16Br2O4 456.9516) 
Rf: 0.28 (6% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 3.64 (1H, m, H-8), 3.88 (1H, dd, J = 7.6 Hz, 11.4 Hz, H-9b), 
3.94 (1H, dd, J = 6.3, 11.4 Hz, H-9a), 4.21 (2H, d, J = 4.4 Hz, H-9'), 5.69 (1H, d, J = 
6.3 Hz, H-7), 6.30 (1H, dt, J = 15.8, J = 4.4 Hz, H-8'), 6.53 (1H, br d, J = 15.7 Hz, H-
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7'), 7.02 (1H, d, J = 8.8 Hz, H-5), 7.27 (1H, dd, J = 8.8, J = 2.5 Hz, H-6), 7.40 (2H, br 
d, J = 8.8 Hz, H-2', H-6'), 7.58 (1H, br s, H-2)  
13C NMR (acetone-d6): δC  54.4 (C-8, d), 62.2 (C-9', t), 63.5 (C-9, t), 86.7 (C-7, d), 
101.7 (C-3', s), 109.5 (C-3, s), 116.5 (C-5, d), 121.8 (C-2', d), 126.4 (C-7', d), 127.7 
(C-8', d), 129.2 (C-6, d), 129.7 (C-6', d), 129.9 (C-4', s), 130.5 (C-2, d), 132.5 (C-1', s), 
134.4 (C-1, s), 153.9 (C-4, s), 156.2 (C-5', s) 
 
 
 
HRESI-MS (m/z): 474.9497 (calcd for C18H18Br2O5 474.9418) 
Rf: 0.20 (6% methanol/dichloromethane) 
1H NMR (acetone-d6) of the erythro diastereomer: δH 3.83 (2H, br m, H-9), 4.20 (2H, 
br d, J = 4.7 Hz, H-9'), 4.56 (1H, br m, H-8), 5.01 (1H, d, J = 4.8 Hz, H-7), 6.29 (1H, 
dt, J = 15.5, J = 4.7 Hz, H-8'), 6.51 (1H, br d, J = 15.5 Hz, H-7'), 6.95 (1H, d, J = 8.1 
Hz, H-5), 7.17 (1H, d, J = 8.8, H-5'), 7.32 (2H, m, H-6, H-6'), 7.60 (1H, br s, H-2'), 7.70 
(1H, br s, H-2)  
13C NMR (acetone-d6): δC  60.9 (C-9, t), 62.2 (C-9', t), 71.7 (C-7, d), 83.6 (C-8, d), 
109.0 (C-3, s), 112.6 (C-3', s), 115.6 (C-5, d), 126.3 (C-7', d), 127.2 (C-6, d), 127.7 
(C-8', d), 129.7 (C-5', d), 130.6 (C-2, d), 131.6 (C-2', d), 132.1 (C-6', d), 134.4 (C-1', 
s), 134.6 (C-1, s), 153.2 (C-4', s), 154.7 (C-4, s) 
 
iv) Oxidative coupling of 333 mg (1.7 mmol) of monolignol (140) yielded 4.3 mg 
(1.3%) of the β-5 dimer (144), 4.5 mg (1.3%) of the threo form of the β-O-4 dimer 
(148i) and 24.4 mg (7.1%) of the erythro β-O-4 dimer (148ii).  
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HRESI-MS (m/z): 388.0890 (calcd for C18H16N2O8 388.0907) 
Rf: 0.28 (5% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 3.75 (1H, m, H-8), 4.00 (1H, dd, J = 6.6 Hz, 10.4 Hz, H-9b), 
3.94 (1H, dd, J = 5.1, 10.4 Hz, H-9a), 4.26 (2H, d, J = 4.4 Hz, H-9'), 6.02 (1H, d, J = 
5.9 Hz, H-7), 6.45 (1H, dt, J = 15.9, J = 4.4 Hz, H-8'), 6.67 (1H, br d, J = 15.9 Hz, H-
7'), 7.26 (1H, d, J = 8.8 Hz, H-5), 7.83 (2H, br m, H-6, H-2'), 7.95 (1H, br s, H-6'), 8.24 
(1H, br s, H-2)  
13C NMR (acetone-d6): δC  52.5 (C-8, d), 62.0 (C-9', t), 63.2 (C-9, t), 88.5 (C-7, d), 
120.5 (C-5, d), 121.8 (C-2, d), 122.5 (C-2', d), 126.7 (C-7', d), 128.2 (C-6', d), 131.2 
(C-8', d), 131.5 (C-4', s), 129.9 (C-4', s), 132.5 (C-1, s), 133.2 (C-3, s), 133.5 (C-3', s), 
134.0 (C-1', s), 134.9 (C-6, d), 153.4 (C-5', s), 154.3 (C-4, s) 
 
 
HRESI-MS (m/z): 406.1013 (calcd for C18H18N2O9 406.1013) 
Rf: 0.22 (5% methanol/dichloromethane) 
1H NMR (acetone-d6) of the threo diastereomer: δH 3.67 (1H, dd, J = 5.9, 11.8 Hz, H-
9b), 3.87 (1H, m, H-9a), 4.23 (2H, br d, J = 4.8 Hz, H-9'), 4.78 (1H, br m, H-8), 4.94 
(1H, d, J = 4.3 Hz, H-7), 6.42 (1H, dt, J = 16.1, J = 4.8 Hz, H-8'), 6.60 (1H, br d, J = 
16.1 Hz, H-7'), 7.16 (1H, d, J = 8.8 Hz, H-5), 7.42 (1H, d, J = 8.8 Hz, H-5'), 7.61 (1H, 
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dd, J = 8.8, J = 1.6 Hz, H-6'), 7.79 (1H, br s, H-2'), 7.82 (1H, dd, J = 8.8, J = 1.6 Hz, 
H-6), 8.24 (1H, br d, J = 1.6 Hz, H-2)  
13C NMR (acetone-d6): δC  60.9 (C-9, t), 62.0 (C-9', t), 71.5 (C-7, d), 85.3 (C-8, d), 
117.3 (C-5', d), 119.5 (C-5, d), 122.1 (C-2', d), 123.2 (C-2, d), 126.3 (C-7', d), 131.0 
(C-6', d), 131.4 (C-8', d), 133.8 (C-1, s), 136.0 (C-6, d), 141.0 (C-1', s), 150.9 (C-4, C-
4', s), 153.8 (C-3, C-3', s) 
 
 
HRESI-MS (m/z): 406.1002 (calcd for C18H18N2O9 406.1013) 
Rf: 0.15 (5% methanol/dichloromethane) 
1H NMR (acetone-d6) of the threo diastereomer: δH 3.88 (1H, dd, J = 5.7, 11.5 Hz, H-
9b), 3.93 (1H, dd, J = 3.8 , J = 11.5 Hz, H-9a), 4.22 (2H, br d, J = 4.2 Hz, H-9'), 4.77 
(1H, br m, H-8), 5.07 (1H, d, J = 6.1 Hz, H-7), 6.40 (1H, dt, J = 16.0, J = 4.2 Hz, H-8'), 
6.58 (1H, br d, J = 16.0 Hz, H-7'), 7.11 (1H, d, J = 8.8 Hz, H-5), 7.39 (1H, d, J = 8.8 
Hz, H-5'), 7.58 (1H, dd, J = 8.8, J = 1.5 Hz, H-6'), 7.74 (1H, d, J = 1.5 Hz, H-2'), 7.78 
(1H, dd, J = 8.8, J = 2.2 Hz, H-6), 8.19 (1H, br d, J = 2.2 Hz, H-2)  
13C NMR (acetone-d6): δC  60.9 (C-9, t), 62.0 (C-9', t), 71.2 (C-7, d), 84.2 (C-8, d), 
116.9 (C-5', d), 119.3 (C-5, d), 122.0 (C-2', d), 123.5 (C-2, d), 126.2 (C-7', d), 130.9 
(C-6', d), 131.3 (C-8', d), 134.1 (C-1, s), 136.3 (C-6, d), 140.9 (C-1', s), 150.4 (C-4, C-
4', s), 153.8 (C-3, C-3', s) 
 
v) Oxidative coupling of 374 mg (1.22 mmol) of monolignol (149) yielded 246 mg 
(64%) of the threo β-O-4 dimer (150i) and 32 mg (8%) of the erythro β-O-4 dimer 
(150ii).  
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HRESI-MS (m/z): 631.7663 (calcd for C18H16Br4O5 631.7584) 
Rf: 0.29 (6% methanol/dichloromethane) 
1H NMR (acetone-d6) of the threo diastereomer: δH 3.87 (1H, dd, J = 4.2, J = 12.0 Hz, 
H-9b), 3.93 (1H, dd, J = 5.4, J = 12.0 Hz, H-9a), 4.24 (2H, br d, J = 4.2 Hz, H-9'), 4.81 
(1H, br ddd, J = 4.2, J = 5.4, J = 5.4 Hz, H-8), 5.12 (1H, d, J = 5.4 Hz, H-7), 6.44 (1H, 
dt, J = 15.9, J = 4.2 Hz, H-8'), 6.53 (1H, br d, J = 15.9 Hz, H-7'), 7.61 (2H, s, H-2', H-
6'), 7.67 (2H, s, H-2, H-6), 7.70 (1H, s, 4-OH)  
13C NMR (acetone-d6): δC  60.9 (C-9, t), 61.9 (C-9', t), 72.3 (C-7, d), 85.9 (C-8, d), 
110.1 (C-3, C-5, s), 118.0 (C-3', C-5', d), 125.4 (C-7', d), 130.4 (C-2', C-6', d), 131.0 
(C-2, C-6, d), 132.8 (C-8', d), 135.9 (C-1', s), 136.3 (C-1, s), 149.8 (C-4, s), 150.7 (C-
4', s) 
 
HRESI-MS (m/z): 631.7505 (calcd for C18H16Br4O5 631.7584) 
Rf: 0.23 (6% methanol/dichloromethane) 
1H NMR (acetone-d6) of the erythro diastereomer: δH 3.87 (2H, m, H-9), 4.23 (1H, br 
d, J = 4.6 Hz, H-9'), 4.80 (1H, br m, H-8), 5.13 (1H, br m, H-7), 6.43 (1H, dt, J = 15.9, 
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J = 4.6 Hz, H-8'), 6.52 (1H, br d, J = 15.9 Hz, H-7'), 7.61 (2H, s, H-2', H-6'), 7.69 (2H, 
s, H-2, H-6) 
13C NMR (acetone-d6): δC  60.8 (C-9, t), 61.9 (C-9', t), 72.1 (C-7, d), 85.7 (C-8, d), 
110.2 (C-3, C-5, s), 117.2 (C-3', C-5', d), 125.5 (C-7', d), 130.4 (C-2', C-6', d), 131.0 
(C-2, C-6, d), 132.8 (C-8', d), 135.9 (C-1', C-1, s), 150.7 (C-4, C-4', s) 
 
vi) Oxidative coupling of 366.5 mg (1.75 mmol) of the dimethoxy-substituted 
monolignol (151) yielded 222 mg (61%) of the β-β coupling product, syringaresinol 
(152). 
 
HRESI-MS (m/z): 418.1627 (calcd for C22H26O8 418.1628) 
Rf: 0.50 (6% methanol/dichloromethane) 
1H NMR (CDCl3): δH  3.10 (2H, br d, J = 1.8 Hz, H-8, H-8'), 3.82 (12H, s, 3-OCH3, 3'-
OCH3, 5-OCH3, 5'-OCH3), 3.84 (H, m, H-9b, H-9'b), 4.23 (2H, dd, J = 6.8, J = 1.8 Hz, 
H-9a,H-9'a), 4.67 (2H, d, J = 3.6 Hz, H-7,H-7'), 6.69 (4H, br s, H-2, H-2', H-6,H-6') 
13C NMR (acetone-d6): δC 54.4 (C-8, C-8', d), 55.7 (3-OMe, 3'-OMe, 5-OMe, 5'-Ome, 
q), 71.5 (C-9, C-9', t), 85.9 (C-7, C-7', d), 103.6 (C-2, C-6, C-2', C-6', d), 132.3 (C-1, 
C-1', s), 135.3 (C-4, C-4', s), 147.8 (C-3, C-3', C-5, C-5', s)  
 
7.15.21 Oxidative Cross-coupling  
59 mg (0.28 mmol, 0.5 equiv.) of sinapyl alcohol (152) and ~ 1 ml of 3% H2O2 were 
added slowly to 100mg (0.56 mmol) of coniferyl alcohol, dissolved in ~ 60 ml dioxane-
water (2/3, v/v, pH 4 – 4.5 adjusted with dil. H3PO4) containing 6 mg of HRP (250 
Umg-1). TLC was used to monitor  the disappearance of the substrates.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
40 ml of water was added to the reaction mixture and this was then extracted with 
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EtOAc (3 x 50 ml). EtOAc layers were combined, washed with H2O, dried over 
MgSO4 and then evaporated in vacuo. Residue was purified by silica gel column 
chromatography and prep TLC using 0.5 – 1.5% MeOH/DCM to yield 10.6 mg (18%) 
of syringaresinol (152), 13.4 mg (12%) of the β-5 cross-coupled benzofuran analogue 
(153), 11.3 mg (11%) of DHCA (38), 7.6 mg (7.2%) of GGCE (40) and 15 mg (13%) 
of an inseparable mixture of the β-O-4 cross coupled products (154).  
 
 
 
HRESI-MS (m/z): 388.1530 (calcd for C21H24O7 388.1523) 
Rf: 0.12 (5% methanol/dichloromethane) 
1H NMR (acetone-d6): δH 3.55 (1H, br ddd, J = 6.5, J = 7.1, J = 5.3, H-8), 3.73 (1H, t, 
J = 5.3 Hz, 9'-OH), 3.80 (6H, s, 3-OCH3, 5-O H3), 3.82 – 3.94 (2H, m, H-9), 3.87 (3H, 
s, 3'-OCH3), 4.11 (1H, t, J = 5. Hz, 9-OH), 4.20 (2H, br dd, J = 5.3, J = 5.9 Hz, H-9'), 
5.55 (1H, d, J = 7.0, H-7), 6.25 (1H, dt, J = 15.9, J = 5.3 Hz, H-8'), 6.53 (1H, , J = 15.9 
Hz, H-7'), 6.75 (2H, br s, H-2, H-6), 6.95 (1H, br s, H-2'), 6.98 (1H, br s, H-6'), 7.21 
(1H, s, 4-OH) 
13C NMR (acetone-d6): δC  53.9 (C-8, d), 55.5 (3-OMe, 5-OMe, q), 55.8 (3'-OMe, q), 
62.5 (C-9', t), 63.6 (C-9, t), 87.9 (C-7, d), 103.7 (C-2, C-6, d), 110.9 (C-2', d), 115.2 
(C-6', d), 127.5 (C-8', d), 129.5 (C-4', s) 129.6 (C-7', d), 131.1 (C-1', s) 132.4 (C-1, s), 
135.8 (C-4, s) 144.3 (C-3', s), 147.9 (C-3, C-5, s), 148.1 (C-5', s) 
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APPENDIX I 
Figure A1 BPI and UV chromatograms of semi-purified extract P05644-4B 
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APPENDIX I I 
Raw data of in vivo evaluation of extract P0544-4B 
 
Table A1 The parasitemia percentages from three mice/per group , on given number  
of days after infection with Plasmodium berghei 
 
Days Control Chloroquine P05644-4B 
 
 
A1 
 
A2 
 
A2 
 
A1 
 
A2 
 
A3 
 
A1 
 
A2 A3 
0 0 0 0 0 0 0 0 0 0 
3 5.2 5.5 5.3 1.54 0.91 0.60 0.93 0.92 1.55 
4 13.7   0.94 0.8 0.78 5.5 8.9 10.9 
5 25.2   0.57 0.2 0.89 14.1 28.1 31.1 
6 28.4   0.71 0.46 0.97 16.4 26.8 35.1 
7    1.6 0.46 0.55 22.3 36.4 43.4 
9    1.65 1.4 0.62 19.2 24.7 26.7 
10    2.6 3.13 0.67 17.3 28 19.6 
13    4.7 4.8 0.8 48.5 18.9 17.6 
15       60 49.3  
 
 
 
Table A2 The average parasitimia percentages in each group, on a given number of 
days after infection with Plasmodium berghei 
 
No of days post 
infection 
Average     
Control Average Chloroquine 
Average 
P05644-4B 
0 0 0 0 
3 5.3 1.02 1.15 
4 13.7 0.84 8.4 
5 25.2 0.55 24.4 
6 28.4 0.71 26.1 
7  0.87 23.5 
9  0.89 21.6 
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No of days post 
infection 
Average     
Control Average Chloroquine 
Average 
P05644-4B 
10  2.13 28.3 
13  3.43 47.3 
15  5.66  
 
 
 
 
Table A3 Weight loss over time post infection 
 
No of days Control CQ PO5644-4B 
1 23.4 29.9 24.96 
4 24.7 29.3 24.82 
5 24.1 29.4 23.24 
6 23.1 29.2 22.4 
7 22.3 29.2 20.9 
8  29.7 20.44 
9  29 20 
10  28.7 20.09 
11  28.73 19.56 
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APPENDIX I I I 
Table A4 Swiss TPH Bioassay data for 96 well plate fractions of T.orientalis extract  
 
Well 
Activity vs P. falciparum K1 Cytotoxicity Selectivity 
Conc1 
(ug/ml) 
% 
Growth 
Inhibition 
(Conc1) 
Conc2 
(ug/ml) 
% 
Growth 
Inhibition 
(Conc2) 
K1 
IC50 
(ug/ml) 
L6 IC50  
(ug/ml) SI 
a1 4.8 99.8 0.8 98.4 0.459 5.19 11.3 
a2 4.8 99.4 0.8 85.8 0.544 7.8 14.3 
a3 4.8 98.3 0.8 80.0 0.877 17.8 20.3 
a4 4.8 90.5 0.8 55.1 2.44 >20   
a5 4.8 29.5 0.8 16.4       
a6 4.8 1.2 0.8 45.3       
a7 4.8 33.3 0.8 5.4       
a8 4.8 38.0 0.8 19.3       
a9 4.8 33.5 0.8 0.0       
a10 4.8 44.5 0.8 10.6       
a11 4.8 50.1 0.8 6.7       
a12 4.8 71.4 0.8 0.0       
b1 4.8 45.3 0.8 18.7       
b2 4.8 48.2 0.8 22.9       
b3 4.8 44.1 0.8 4.0       
b4 4.8 47.5 0.8 17.7       
b5 4.8 52.1 0.8 26.0       
b6 4.8 54.8 0.8 22.3       
b7 4.8 71.4 0.8 23.1       
b8 4.8 39.5 0.8 15.1       
b9 4.8 43.4 0.8 0.0       
b10 4.8 77.8 0.8 36.9       
b11 4.8 53.8 0.8 18.1       
b12 4.8 52.1 0.8 0.0       
c1 4.8 68.4 0.8 23.8       
c2 4.8 63.4 0.8 26.8       
c3 4.8 72.8 0.8 28.6       
c4 4.8 84.2 0.8 35.8       
c5 4.8 90.5 0.8 39.5       
c6 4.8 96.2 0.8 55.8 2.01 19.1 9.5 
c7 4.8 97.4 0.8 55.1 1.68 >20   
c8 4.8 97.4 0.8 68.6 >10 >20   
c9 4.8 98.8 0.8 62.8 0.983 14.1 14.3 
c10 4.8 99.4 0.8 76.6 0.507 7.2 14.2 
c11 4.8 99.8 0.8 94.9 0.729 9.3 12.8 
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Well 
Activity vs P. falciparum K1 Cytotoxicity Selectivity 
Conc1 
(ug/ml) 
% 
Growth 
Inhibition 
(Conc1) 
Conc2 
(ug/ml) 
% 
Growth 
Inhibition 
(Conc2) 
K1 
IC50 
(ug/ml) 
L6 IC50  
(ug/ml) SI 
c12 4.8 100.0 0.8 92.8 0.771 11.4 14.8 
d1 4.8 99.3 0.8 79.3 0.945 12.4 13.1 
d2 4.8 100.0 0.8 92.2 0.601 5.56 9.3 
d3 4.8 100.0 0.8 96.6 0.501 5.8 11.6 
d4 4.8 100.0 0.8 97.4 0.403 4.83 12.0 
d5 4.8 100.0 0.8 98.6 0.502 3.2 6.4 
d6 4.8 100.0 0.8 98.6 0.324 3.32 10.2 
d7 4.8 100.0 0.8 98.0 0.374 9.1 24.3 
d8 4.8 100.0 0.8 98.4 1.54 >20   
d9 4.8 100.0 0.8 98.2 0.296 10.7 36.1 
d10 4.8 100.0 0.8 98.5 0.381 8.9 23.4 
d11 4.8 100.0 0.8 99.6 0.286 9.1 31.8 
d12 4.8 100.0 0.8 98.4 0.652 13.7 21.0 
e1 4.8 99.7 0.8 94.4 0.521 14.8 28.4 
e2 4.8 99.6 0.8 70.9 1.13 >20   
e3 4.8 98.2 0.8 57.6 0.647 6.4 9.9 
e4 4.8 98.1 0.8 52.2 1.88 >20   
e5 4.8 96.1 0.8 45.0       
e6 4.8 91.8 0.8 49.7 1.93 >20   
e7 4.8 73.6 0.8 24.0       
e8 4.8 73.1 0.8 18.3       
e9 4.8 66.6 0.8 22.0       
e10 4.8 64.2 0.8 22.8       
e11 4.8 70.7 0.8 15.3       
e12 4.8 55.6 0.8 44.0       
f1 4.8 63.9 0.8 26.7       
f2 4.8 66.5 0.8 15.0       
f3 4.8 68.4 0.8 20.6       
f4 4.8 78.8 0.8 32.0       
f5 4.8 68.9 0.8 23.2       
f6 4.8 66.9 0.8 28.7       
f7 4.8 78.5 0.8 18.2       
f8 4.8 77.4 0.8 13.3       
f9 4.8 78.6 0.8 13.5       
f10 4.8 83.5 0.8 25.8       
f11 4.8 78.5 0.8 29.3       
f12 4.8 67.6 0.8 6.9       
g1 4.8 83.2 0.8 30.8       
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Well 
Activity vs P. falciparum K1 Cytotoxicity Selectivity 
Conc1 
(ug/ml) 
% 
Growth 
Inhibition 
(Conc1) 
Conc2 
(ug/ml) 
% 
Growth 
Inhibition 
(Conc2) 
K1 
IC50 
(ug/ml) 
L6 IC50  
(ug/ml) SI 
g2 4.8 83.0 0.8 37.3       
g3 4.8 95.4 0.8 25.6       
g4 4.8 73.4 0.8 16.3       
g5 4.8 73.3 0.8 40.0       
g6 4.8 92.1 0.8 42.2       
g7 4.8 100.0 0.8 69.6 0.256 8.5 33.2 
g8 4.8 97.3 0.8 41.9       
g9 4.8 86.1 0.8 11.8       
g10 4.8 91.5 0.8 41.9       
g11 4.8 73.0 0.8 25.3       
g12 4.8 69.1 0.8 13.7       
h1 4.8 39.1 0.8 20.4       
h2 4.8 64.1 0.8 15.0       
h3   95.7   25.1 
   Chloro-
quine 
    
0.085 
  Podo-
phyllo-
toxin 
    
   0.004   
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APPENDIX IV 
Figure A2 BPI and UV chromatograms of representative wells from each active region 
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APPENDIX V 
Figure A2 ES- BPI chromatograms of representative active wells 
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Table A5 Summary of spectroscopic data, DNP search criteria and results for major compounds in active fractions 
 
Peak 
No. 
 Rt 
 (min) 
Present 
in Wells 
M - H 
Accurate 
mass 
UV 
max 
DNP Search 
parameters 
No. 
of 
hits 
in 
DNP 
Possible structure/s 
Accurate 
mass 
UV 
Max 
1 2.93 A1 328.1166 329.12454 
220, 
318 
329.12 -
329.14 
215-
225; 
315-
322 
1 
 
2 6.42 A1 312.1201 313.12804 
219, 
318 
313.12 – 
313.14 
215-
225; 
315-
322 
2 
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Peak 
No. 
 Rt 
 (min) 
Present 
in Wells 
M - H 
Accurate 
mass 
UV 
max 
DNP Search 
parameters 
No. 
of 
hits 
in 
DNP 
Possible structure/s 
Accurate 
mass 
UV 
Max 
3 12.73 
A1, D4, 
D6, D7 
727.2421 728.25004 
220, 
317 
728.24 – 
728.26 
218-
230; 
315-
322 
0 
 
4 16.74 
A1, D4, 
D6, D7, 
D9, 
D10, 
D11 
667.2184 668.22634 
222, 
310 
668.22 – 
668.24 
218-
225; 
300-
320 
1 
 
5 17.38 
A1, D4, 
D6, D7, 
D9, 
D10, 
D11 
653.2396 654.24754 
227, 
311 
654.23 – 
654.26 
218-
230; 
315-
322 
0 
 
6 17.89 
A1, D4, 
D6, D7, 
D9, 
D10, 
D11 
697.2315 698.23944 
222, 
310 
698.22 – 
698.24 
218-
225; 
300-
320 
1 
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Peak 
No. 
 Rt 
 (min) 
Present 
in Wells 
M - H 
Accurate 
mass 
UV 
max 
DNP Search 
parameters 
No. 
of 
hits 
in 
DNP 
Possible structure/s 
Accurate 
mass 
UV 
Max 
7 18.16 
A1, D4, 
D6, D7, 
D9, 
D10, 
D11 
697.2305 698.23844 
223, 
310 
698.22 – 
698.24 
218-
225; 
300-
320 
1 
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APPENDIX VI 
1H NMR spectra (with selected resonances labelled) of Dadahol B and its two diastereomers 
9ab 
 
1
H Erythro Dadahol 
B 
1
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H Natural product (~1:1 diastereomeric ratio) 
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APPENDIX VII 
Raw data of in vivo evaluation of extract P0544-4B 
 
 
Weight and % Parasitemia of individual mice measured on days 4 and 6 post 
infection (PI) of in vivo study:   
 
 
 
Table A6 Chloroquine group 
No of 
days PI 
Measure- 
ment M1(g) / % M2(g) / % M3(g) / % M4(g) / % 
Average  
(g) / % 
0 Weight 26.11 21.72 19.60 25.22 23.16 
4 Weight 
Parasitemia 
26.04 21.8 19.68 25.25 23.19 
3.88 3.83 3.14 4.10 3.7 
6 Weight 
Parasitemia 
26.19 21.04 19.36 24.65 22.81 
8.57 6.2 2.86 2.8 5.1 
8 Weight 27.18 21.22 25.54 19.83 23.44 
 
 
 
 
 
Table A7 Negative control group 
No of 
days PI 
Measure- 
ment M1(g) / % ) M2 (g / % M3(g) / % M4(g) / % 
Average  
(g) / % 
0 Weight 24.32 19.64 27.25 21.98 23.30 
4 Weight 
Parasitemia 
22.22 18.05 25.08 19.6 21.23 
11.49 10.24 11.83 5 8.78 
6 Weight 
Parasitemia 
20.26 16.77 22.27 17.98 19.32 
25.65 29.67 23.84 23.19 25.59 
8 Weight 19.66 15.24 20.16  18.35 
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Table A8 Dadahol A group 
 
 
 
Table A9 Dadahol B group 
 
 
* = Dead or sacrificed on that day 
 
 
 
No of 
days PI 
Measure- 
ment 
M1(g) / 
% 
M2 (g) 
/ % 
M3(g) / % M4(g) / 
% 
M5(g) / 
% 
Average  
(g) / %  
0 0 25.02 23.77 20.63 24.69 22.02 23.23 
4 Weight 
Parasite
mia 
23.35 21.37 18.92 24.20 19.45 21.52 
4.4 3.3 3.2 0.8 4.5 3.85 
6 Weight 
Parasite
mia 
20.79 19.98 16.86 24.16 17.70 19.90 
24.1 22.68 20.3 0.75 27.1 23.55 
8 Weight 19.30 19.34 * 16.5* * 18.38 
No of 
days PI 
Measure- 
ment 
M1(g) / 
% 
M2 (g) 
/ % 
M3(g) / % M4(g) / 
% 
M5(g) / 
% 
Average  
(g) / %  
 0 17.09 22.94 24.34 24.14 25.86 22.90 
4 Weight 
Parasite
mia 
16.12 20.86 22.90 23.68 23.5 21.41 
6.0 3.3 6.0 6.1 3.5 5.0 
6 Weight 
Parasite
mia 
13.88 19.15 20.05 20.20 21.15 18.89 
16.7 19 17.6 16.5  17.5 
 8 13.6* 18.10 * 19.2 * 16.97 
